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Chapter  1
General introduction

General introduction 11
Recent developments in next-generation sequencing technologies have led to extensive 
transcriptome analysis of many human tissues and cell lines at an unprecedented scale. 
These data display that nearly the entire human genome has been transcribed, however, 
only a very small proportion (2%) of the transcripts are translated into protein products 
[1]. The rest of the transcripts that do not possess any protein-coding capacity are anno-
tated as non-coding RNAs (ncRNAs). Over the past few years, it has become increasingly 
evident that ncRNAs act as important players in the epigenetic, post-transcriptional and 
translational coordination of gene expression in developmental processes and human 
diseases [2]. The ncRNAs can be roughly categorized, based on their transcript size, into 
two main classes: small ncRNAs (< 200 nucleotides) and long ncRNAs (> 200 nucleotides) 
[2, 3]. By far the best-characterized ncRNAs are microRNAs (miRNAs), which are the main 
focus of this thesis.
MIcRoRNAs (MIRNAs)
MiRNAs are a conserved class of small ncRNAs, spanning 20-24 nucleotides, that post-
transcriptionally regulate gene expression at both messenger RNA (mRNA) and protein 
levels [4]. MiRNAs were discovered in C.elegans in the early 1990s, when Ambros and col-
leagues observed that small RNA products from the heterochronic lin-4 gene regulated 
lin-14 gene expression by means of an RNA-RNA antisense pairing [5, 6]. However, not 
having homologs in other species, this RNA-based regulatory mechanism was thought 
to be unique to C.elegans until the second miRNA, let-7, was discovered with homo-
logs in humans and Drosophila melanogaster [7, 8]. Since then, miRNAs have gained 
extensive attention as important modulators in diverse biological pathways, including 
stem cell differentiation, cell proliferation, apoptosis, and organ development, as well as 
being associated with a number of human diseases ranging from cancer to cardiovas-
cular disease [9, 10].  The total number of confidently identified human miRNAs is now 
approximately 1,500 according to miRBase database (build 21), and around two-third of 
all coding genes in our genome are predicted to have at least one miRNA-binding site in 
their 3’UTR [11-14]. It was initially thought that human miRNAs are transcribed from ge-
nomic regions quite distant from previously annotated genes, suggesting that they are 
generated as independent transcriptional units. However, later analyses of miRNA gene 
positions demonstrated that approximately 50% of human miRNAs are hosted within 
and co-transcribed with a protein-coding mRNA transcription unit. Thus, the expression 
of intronic miRNAs largely coincides with the transcription of the host gene [15]. Nearly 
50% of miRNAs are clustered with one or more other miRNAs and are believed to be 
co-transcribed as a single polycistron by RNA Pol II enzyme in the nucleus [15].
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MIRNA bIogeNesIs
In the canonical biogenesis pathway, miRNA genes are initially transcribed in the nucleus 
by the normal cellular machinery to yield a large RNA transcript, approximately 1000 
nucleotides, containing an extended stem-loop structure called a primary miRNA (pri-
miRNA) [16]. Two subsequent processing events lead to the functional, mature miRNA 
in animals. First, the RNase-III endonuclease enzyme, Drosha, coupled with the dsRNA-
binding protein DiGeorge Syndrome critical region 8 (DGCR8), cleaves the pri-miRNA 
transcript into a smaller, ~70 nucleotides, hairpin precursor miRNA (pre-miRNA) [17, 18]. 
The pre-miRNA is then shuttled out of the nucleus through the Exportin 5 (XPO5) nuclear 
transport receptor in cooperation with a Ran GTPase cofactor [19]. After being transported 
to the cytoplasm, a second RNase-III enzyme (Dicer) cleaves the loop structure of the 
pre-miRNA, resulting in an approximately 22bp double-stranded miRNA [20]. The duplex 
miRNA is then dissociated and the passenger strand is degraded. Subsequently, the strand 
with the less thermodynamically stable 5’ end (guide strand) gets incorporated into the 
RNA-induced silencing complex (RISC) [21]. This active RISC complex, consisting of the 
mature miRNA and Argonaute (Ago) proteins, interacts with the 3’-untranslated region 
(3’UTR) of target mRNA. This results in either translational repression or site-specific cleav-
age of target mRNAs, depending on the degree of complementarity to its target [14, 22]. 
An overall schematic of miRNA biogenesis and function is shown in Figure 1.
MIRNA-TARgeT RecogNITIoN AND RegulAToRy FuNcTIoN
The core of a mature miRNA, called the “seed” sequence, includes nucleotides 2-7 
(sometimes 2-8) from the 5’ end. This region of the miRNA is the most conserved among 
species and plays a critical role in target recognition and interaction [21]. The 3’-end of a 
miRNA modifies binding of the miRNA to its target genes and may compensate for seed 
mismatches [23]. Most miRNAs in animals are thought to control mRNA stability and trans-
lation through imperfect base-pairing to the 3’UTR of target mRNAs [16, 21]. The most 
common mechanism through which a miRNA regulates its target gene expression is the 
binding of the miRNA seed sequence to the 3’UTR sequence of the target mRNA (Figure 2) 
[13, 21]. Other less common mechanisms that have been described include non-canonical 
sites, which display good base-pairing at both the 5’ and 3’ ends, and 3’ compensatory 
sites, which show weak 5’ base-pairing and depend on a strong pairing at the 3’ end [24].
The biological role of individual miRNAs is dictated by regulating their target 
mRNAs expression [21]. Given that miRNAs need only minimum binding by a short 
seed sequence, it is not surprising that a single miRNA targets multiple genes [13]. As 
a consequence, the accurate prediction of the miRNA target genes has been a great 
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challenge. In recent years much effort has been put toward devising a genome-wide 
computational search that captures most of the regulatory targets without bringing 
in too many false-positive predictions [25]. Computational algorithms have been the 
major driving force in predicting miRNA targets [13, 25]. Current prediction methods 
are diverse, however a general agreement that has emerged on two important criteria 
includes: 1) Assessing the thermodynamic features of the miRNA:mRNA duplex by cal-
Figure 1. The biogenesis of miRNAs is a multistep coordinated process. After transcription, the Drosha 
enzyme processes the long primary transcripts (pri-miRNA), yielding a hairpin precursors (pre-miRNA) con-
sisting of approximately 70 nucleotides. The pre-miRNA hairpins are exported by Exportin 5 (XPO5) to the 
cytoplasm where they are further processed into unstable, 19-25 nucleotides miRNA duplex structures by 
the Dicer enzyme. The 5’ end of the miRNA (guide strand) is incorporated into a multiple-protein nuclease 
complex, the RNA-induced silencing complex (RISC), which regulates gene expression by transcript desta-
bilization, inhibition of protein translation and translational repression.
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culating the free energy of the putative interaction, where a lower free energy indicating 
the binding of the miRNA to mRNA is stronger, and 2) Conservation of the miRNA target 
site among different species [13]. Several prediction programs are currently available 
that follow these major criteria, including TargetScan [13], miRTarBase [26], PicTar [27] 
and miRecords [28]. However, perfect seed pairing is not a generally reliable predictor 
for miRNA-target interactions, which may explain why some putative miRNA target 
sites were shown to be nonfunctional [29]. Therefore, in addition to the bioinformatic 
analysis of predicting an accessible miRNA-binding site, the functional significance of 
the predicted miRNA-mRNA interaction needs to be validated experimentally.
geNeTIc vARIANTs IN MIRNA geNes AND TheIR bINDINg sITes
MiRNA transcripts need to fulfill structural and sequences prerequisites in order to result 
in expression of the right mature miRNAs [16, 30]. In addition, the expression level of a 
miRNA is critical for its activity on the target mRNA. Genetic polymorphisms in miRNA 
genes can affect the expression level as well as the functionality of miRNAs (Figure 3) 
[31-33]. In this context, variants located in pri- or pre-miRNA sequences can change the 
binding affinity of the miRNA hairpin to biogenesis enzymes (Drosha and Dicer) or ac-
cessory proteins [34, 35]. These variants can lead to changed processing accuracy, alter 
frequencies of alternative cleavage sites of the biogenesis enzymes or change miRNA 
strand loading bias into the RISC complex [31]. These changes in maturation can all 
result in altered expression of the miRNA, resulting in deregulation of target genes [32]. 
Variants in the miRNA seed sequence can further affect the miRNA-target gene interac-
tion [36]. In addition to variants in miRNA-encoding sequences, variants within miRNA 
promoter regions, and other regulatory regions, may result in an altered transcription 
rate of the pri-miRNA [37]. Given the potentially significant effect of genetic variants on 
the tightly regulated miRNA repertoire and the importance of miRNA-mediated gene 
regulation, it is not surprising that variants in miRNA genes have been found to be as-
sociated with human diseases [31, 36, 38, 39].
 
Figure 2. The miRNA seed sequence (nucleotides 2-7/8 from the 5’ end) binds to its complementary se-
quence in the 3’UTR of target mRNA.
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In addition to variants in miRNA genes, genetic polymorphisms located in miRNA-
binding sites within the 3’UTRs of target genes can lead to impaired miRNA regulation 
(Figure 4) [40]. Polymorphisms in miRNA-binding sites are likely to have a smaller 
impact than variants in miRNA genes, because only the targeting of one gene by one 
miRNA would be disrupted in case the target gene does not contain multiple binding 
sites for that miRNA. Nevertheless, the loss of a miRNA-binding site can have important 
biological implications. Previous computational and experimental studies have shown 
that miRNA-binding site variants can modulate the risk for disease [38, 41, 42].
  
 
miRNA regulatory region  
miRNA seed   
Pre-miRNA  
Pri-miRNA  
Figure 3. Genetic variants in miRNA regulatory regions, pri- and pre-miRNA sequences may affect the 
miRNA expression level. Variants in the miRNA seed sequences can further affect the interaction between 
miRNAs and their target mRNAs.
 
 
 
 
 
A. Disruption of a miRNA-binding site within a gene 3’UTR 
B. Creation of a new miRNA-binding site within a gene 3’UTR 
Figure 4. Genetic variants within gene 3’UTRs can disrupt an existing miRNA-binding site or create new 
binding sites for miRNAs.
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geNeTIcs oF coMPlex DIsoRDeRs
The human genome is thought to consist of approximately 20,000 protein-coding 
genes [43]. The general positions of these genes within the genome are referred to as 
loci (singular, locus). Each locus is surrounded by or embedded with DNA sequences 
dictating when, where and how each gene should be expressed per its interaction with 
DNA-regulatory factors. The human variation comes in many forms and is influenced 
by multiple factors including evolutionary forces. The origin of this variation is likely to 
consist of errors in DNA replication, DNA recombination and the insertion or deletion 
of mobile transposon elements [44]. The most common form of human variation is the 
single-nucleotide polymorphism (SNP), which includes variation at a single base posi-
tion [45]. It has been estimated that SNPs occur at a frequency of 1/1000 base pairs, on 
average, and constitute approximately 90% of the isolated variations in the human ge-
nome [46]. The number of SNPs in human identified currently exceeds 50 million [47, 48]. 
SNPs in protein coding sequences can result in an amino acid change, which may modify 
the peptide or the entire protein, and play a role in disease pathophysiology. SNPs in 
non-coding regions of the genome could change the gene expression through different 
mechanisms, for example by affecting binding sites of transcription factors or miRNAs 
[49, 50]. Genetic studies have traditionally used candidate gene studies and family-based 
linkage studies to identify novel genes for human disease. Candidate gene studies rely 
on our partial understanding of genes with known biological function regulating the 
developmental processes of the investigated traits [51]. The practicability of candidate 
gene approach is largely limited by its reliance on the current knowledge about the 
known or presumed biology of the trait under study [51]. Family-based linkage analysis 
has been a traditional means for identifying regions of the genome that contribute to 
a disease which will guide the search for the causative gene (Mendelian disease) [52]. 
However, this approach has only achieved little success in identifying genes for complex 
disorders because of low power and lack of replication [53].
Genome-wide association study (GWAS) is a hypothesis-free approach that investi-
gates the genetic component of common diseases without relying on prior knowledge 
[54]. In the recent decade, with the development of high-throughput genotyping and 
next-generation sequencing platforms, GWAS have been successfully conducted to 
identify genetic variants associated with many complex traits and diseases [55-60]. 
The completion of the Human Genome project and the International HapMap project 
provided the possibility to select a set of genetic variants that are representative of all 
human haplotypes, groups of alleles that are co-inherited based on linkage disequi-
librium (LD) maps [60, 61]. This allowed researchers to investigate the genetic variants 
that nearly cover the entire genome variation by genotyping hundreds of thousands to 
one million SNPs using SNP array technologies. GWAS survey individual human genetic 
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variations in thousands of individuals and test for association between those variants 
and a given trait or condition (Figure 5) [62, 63]. For GWAS to be successful, there must 
be multiple common loci (>1% of the population) that influence a trait or disease risk, by 
which each locus contributes a small proportion of the overall trait variance or disease 
susceptibility [64]. Although large-scale GWAS have led us to the discovery of a large 
number of genetic variants at multiple loci associated with complex disorders, majority 
of associated variants (~90%) map to non-coding regions of the genome. These include 
variants in non-coding RNAs and gene 3’UTRs that are responsible for fine-tuning gene 
expression regulation. Investigation of the functional consequences of non-coding vari-
ants and elucidating the biological mechanisms by which these variants and related 
genes act is a major challenge facing the biological sciences today.
sTuDyINg MIRNAs INvolveD IN huMAN DIseAses
MiRNAs have become a source of great excitement as regulators of complex diseases 
because they provide new insights into disease mechanisms and could potentially be 
therapeutically targeted. Elucidating the associations between miRNAs and diseases 
in a systematic approach will extend our understanding of the molecular mechanisms 
underlying human diseases. To study whether miRNAs are involved in the pathogenesis 
of human diseases, researchers usually perform miRNA expression profiling to conduct 
a genome-wide analysis of miRNA expression in normal and diseased samples, or to 
 
Figure 5. Manhattan plot showing the statistical association between SNPs and a trait of interest, each dot 
on this plot signifies a SNP. Genomic coordinates (Chr 1-22) are displayed along the X-axis and the nega-
tive logarithm of the association p-value for each SNP displayed on the Y-axis. Dash line shows significance 
threshold.
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distinguish miRNA expression signatures associated with diagnosis and therapeutic 
interventions (Figure 6). The expression of miRNAs can be tested by different technolo-
gies such as microarray based methods or RNA sequencing. Microarray technology is a 
powerful high-throughput tool capable of monitoring the expression of hundreds of 
miRNAs at once processed in parallel in a single experiment [65]. The miRNA expression 
profiles are compared between the normal and diseased samples in order to determine 
differentially expressed miRNAs. The next step would be to identify the target genes and 
pathways that are regulated by the identified miRNAs. To determine deregulated target 
genes of miRNAs, gene expression profiling should be done in the same samples. The 
interactions between deregulated miRNAs and their putative target genes need to be 
experimentally verified. One possible experiment is to clone the 3’UTR of the target gene 
immediately downstream of the luciferase (or Renilla) or green fluorescent protein (GFP) 
open reading frame sequence contained in the reporter plasmid [66]. The recombinant 
plasmid and the miRNA are then transiently transfected into a host cell, preferably one 
that does not endogenously express the miRNA under study, and luciferase activity or 
fluorescence is measured 48 hours after transfection [66]. Alternatively, just the reporter 
construct can be transfected into cells which express the relevant miRNAs, along with 
vectors which express mutant versions of the miRNA-binding sites. In this experimental 
system, the wild-type reporters should have less activity than their respective mutants 
[67]. To fully understand how the miRNA contributes to the pathology of disease, further 
experimental studies are needed to be done such as inhibition and overexpression of 
miRNAs in the right cellular context or animal models [67, 68].
Genome-wide miRNA expression profiling can provide a global insight in which 
miRNAs may play a role in a disease by generating disease-specific miRNA expression 
signatures, however, it has some limitations. The main limitation is that differential 
expression of miRNAs in itself does not provide an indication of causality because the 
altered expression can be a causal factor, a consequence, or could even be unrelated 
to the disease pathogenesis [37]. Expression profiling studies are therefore subject to 
confounding bias or reverse causation. Another constraint is that the affected tissue 
has to be accessible which is especially problematic in the study of neurodegenerative 
diseases such as Alzheimer’s and Parkinson’s diseases. In addition, these type of stud-
ies are mainly based on differentially expressed miRNAs in a small number of samples, 
which makes it difficult to extrapolate the results to the general population. Expression 
profiling of miRNAs in large cohort studies with validated clinical data is also costly, 
time-consuming and labor intensive.
The availability of high-throughput omics data (e.g. genomics and transcriptomics) 
provide a valuable resource for genetic epidemiologic studies. These data encourage 
researchers to develop novel integration approaches to understand the complexity of 
the genomic mechanisms behind complex diseases. In this thesis we intended to use 
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a new method to identify miRNAs associated with age-related disorders using genetic 
evidence. In this approach, the starting point is an association analysis between genetic 
variants in miRNA-related sequences and the trait of interest. When a genetic variant 
in a miRNA or in a miRNA-binding site is associated with the trait, functional validation 
studies can be initiated to investigate the effect of the variant on the miRNA-mediated 
gene regulation. The genetic approach has some advantages in comparison with miRNA 
expression profiling approach. The main advantage is that when a miRNA variant is as-
sociated with the disease risk, it supports the idea that the miRNA may play a role in the 
disease pathomechanism. In addition, since genetic information is constant over the life 
course, reverse causation and confounding bias, two matters of using miRNA expression 
profiling approach, are refuted. Another advantage is that diseases with no accessible 
affected tissue (e.g. Alzheimer’s disease) can still be studied because genomic DNA can 
be isolated from easy-accessible patient tissues such as blood.
AIM oF ThIs ThesIs
The overall objective of this thesis was to identify miRNAs involved in age-related disor-
ders (including cardiovascular risk factors and disease, and a number of common neu-
rodegenerative and ophthalmic diseases). The second aim was to ascertain target genes 
of the identified miRNAs that may mediate the miRNA downstream effects in relation to 
 
 
Figure 6. A schematic of studying miRNAs involved in human disease using miRNA profiling approach.
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the associated traits and diseases. To accomplish these aims, we used a new approach 
in which we investigated the association of miRNAs with these complex disorders using 
genetic data followed by various in silico and in vitro validation studies.
ouTlINe oF ThIs ThesIs
chapter 2 of this thesis is devoted to the association of genetic variants in non-coding 
RNAs (miRNAs and lncRNAs) with cardiovascular risk factors and disease. In chapter 
2.1 we make a dataset of genetic variants located in miRNA-encoding sequences. We 
examine the association between variants in miRNA seed sequences with cardiometa-
bolic disorders using data from the largest available GWAS. We perform in silico and in 
vitro analyses to examine the functionality of a miRNA seed sequence variant associated 
with cardiovascular traits. In chapter 2.2 we scan for the association between variants 
located in miRNA-encoding sequences, beyond the seed sequence, and cardiovascular 
risk factors and disease followed by experimental validation studies. In chapter 2.3 we 
make a comprehensive dataset of variants located in miRNA-binding sites and investi-
gate their associations with different cardiometabolic traits and diseases. We apply a 
prioritization method based on a set of predefined criteria to highlight the most likely 
functional candidate variants for functional studies. We experimentally test whether 
the candidate variants affect miRNA-mediated regulation of their genes. In chapter 2.4 
we investigate the association of genetic variants in lncRNAs with ten cardiometabolic 
disorders using the publicly available GWAS data. We further examine the association of 
expression and DNA methylation of hosting lncRNAs with cardiometabolic disorders us-
ing the Rotterdam Study data. We underline a number of potentially functional variants 
associated with cardiometabolic disorders that may act through lncRNAs. We further 
highlight a number of loci for which the role of lncRNAs may have been overlooked in 
the current literature.
chapter 3 focuses on the association between non-coding RNAs (miRNAs and ln-
cRNAs) and neurodegenerative diseases. In chapter 3.1 we investigate the association 
of genetic variants in miRNAs as well as miRNA-binding sites with Alzheimer’s disease 
(AD) using the largest available GWAS. Subsequently, we perform several computational 
and experimental studies to determine the impact of a candidate miRNA variant as-
sociated with AD. In chapter 3.2 we scan for the association of miRNA-related variants 
with Parkinson’s disease (PD). Performing subsequent in silico and in vitro studies, we 
test whether the associated variants in miRNAs and their target sites may affect miRNA-
mediated regulation of PD genes. In chapter 3.3 we examine the association between 
genetic variants in lncRNAs and AD. We perform various in silico and in vitro analyses to 
provide evidence for the functionality of a non-coding variant  associated with AD.
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chapter 4 focuses on the association between miRNA-related variants and ophthal-
mic diseases. In chapter 4.1 we perform a genome-wide scan for miRNAs contributing 
to Age-related macular degeneration (AMD). We demonstrate that three variants in miR-
NAs and a number of variants in miRNA-binding sites may affect miRNA-mediated regu-
lation of genes involved in AMD. Finally, in chapter 4.2 we investigate the association of 
miRNA-related variants with Primary Open-Angle Glaucoma (POAG) endophenotypes, 
aiming to identify miRNAs and target genes that may play a role in the pathogenesis of 
POAG.
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AbsTRAcT
Background. MicroRNAs (miRNA) play a crucial role in the regulation of diverse biologi-
cal processes by post-transcriptional modulation of gene expression. Genetic polymor-
phisms in miRNA genes can potentially contribute to a wide range of phenotypes. The 
effect of such variants on cardiometabolic diseases has not yet been defined.
Methods and Results. We systematically investigated the association of genetic variants 
in the seed region of miRNAs with cardiometabolic phenotypes, using data from the 
available genome wide association studies (GWAS) on 17 cardiometabolic traits and 
diseases. We found that rs2168518:G>A, in the seed region of miR-4513, associates 
with fasting glucose, LDL-cholesterol and total cholesterol, systolic and diastolic blood 
pressure and risk of coronary artery disease. We experimentally showed that miR-4513 
expression is significantly reduced in presence of the rs2168518 minor allele. We sought 
to identify miR-4513 target genes that may mediate these associations and revealed 
five genes (PCSK1, BNC2, MTMR3, ANK3 and GOSR2) through which these effects might 
be taking place. Using luciferase reporter assays we validated GOSR2 as a target of miR-
4513 and demonstrated that the miRNA mediated regulation of this gene is reduced by 
rs2168518.
Conclusion. Our findings suggest a pleiotropic role of miR-4513 in cardiometabolic 
traits and disease, which may improve our understanding of the pathophysiology of 
cardiovascular disease.
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INTRoDucTIoN
MicroRNAs (miRNAs) are a class of small non-coding RNAs, spanning 20-24 nucleotides, 
function as crucial regulators in a broad range of biological processes [1]. Since the first 
miRNA was discovered in the early 1990s, over 1500 miRNAs have been identified with 
confidence in humans [2, 3]. This number of miRNAs together are predicted to regulate 
expression levels of approximately 60% of all protein-coding genes [4]. In recent years, 
miRNAs have been widely studied as potential diagnostic biomarkers and therapeutic 
targets in complex disorders [5]. Furthermore, miRNAs have gained attention as impor-
tant modulators of cardiovascular diseases such as myocardial infarction [6, 7], cardiac 
hypertrophy [8] and heart failure [9], as well as various metabolic processes such as in-
sulin production [10], glucose homeostasis [11], lipid metabolism [12] and obesity [13].
MiRNAs are post-transcriptional regulators of gene expression by interacting with the 
3’ untranslated region (3’UTR) of target mRNAs [1]. Thereby they repress translation and 
to a lesser extent accelerate the decay of target transcripts [14]. Given the central role 
of miRNAs in gene expression, genetic polymorphisms in the corresponding sequences 
of a miRNA may contribute to a phenotypic variation and disease susceptibility [15, 
16]. The core of a mature miRNA, called the “seed region”, includes nucleotides 2-7/8 
from the 5’ end, and plays a critical role in target gene recognition and interaction [17]. 
Genetic variation within this critical region of miRNA may both disrupt the interaction 
of a miRNA with target transcripts and create illegitimate miRNA targets [18, 19]. There-
fore, miRNA seed polymorphisms are expected to alter the expression profile of target 
genes and subsequently affect corresponding phenotypes. However, so far only very 
few pathogenic variants in miRNAs have been evidenced in cardiovascular disease and 
metabolic syndrome.
In the present study, we aimed to systematically investigate the association between 
miRNA seed variants and cardiometabolic disorders. In addition, we sought to deter-
mine whether any of the target genes of the identified miRNAs may mediate the miRNA 
effects in the associated phenotypes.
MATeRIAl AND MeThoDs
Identification of miRNA seed polymorphisms
A flow chart of our approach to retrieve single nucleotide polymorphisms (SNPs) in 
miRNA seed regions is shown in Figure 1. We systematically screened all known hu-
man miRNAs to identify variants in their seed regions, by reviewing the literature and 
searching the following online databases: microSNiPer [20], PolymiRTS [21], Patrocles 
[22] and miRvar [23]. We included variants with minor allele frequency (MAF) > 0.01. 
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Since previous GWAS meta-analysis on cardiometabolic traits and diseases have been 
performed using HapMap imputed data, we focused on SNPs that were present in the 
international HapMap project (release 22) (http://www.hapmap.org/) [24]. For SNPs that 
were not present in the HapMap, we used the SNAP web tool to find proxy SNPs in high 
Linkage Disequilibrium (LD) (R2 > 0.8 and distance < 200 kb) (http://www.broadinstitute.
org/mpg/snap/id) [25].
Association of miRNA seed variants with cardiometabolic phenotypes
We examined the association of miRNA seed SNPs with cardiometabolic phenotypes 
using data from the available GWAS meta-analyses on 17 cardiometabolic traits and 
diseases. Table 1 shows a description of the studied phenotypes and consortia that we 
used in this study.
Data on glycemic traits have been contributed by the Meta-Analyses of Glucose 
and Insulin-related traits Consortium (MAGIC) investigators, including fasting glucose, 
serum glucose after 2hr, fasting insulin, fasting pro-insulin, HbA1c, HOMA-B, and HOMA-
IR from up to 133,000 individuals (http://www.magicinvestigators.org) [26-30]. The 
DIAbetes Genetics Replication and Meta-analysis (DIAGRAMv3) consortium has done a 
GWAS meta-analysis in 12,171 type 2 diabetes (T2D) cases and 56,862 controls [31]. The 
Global Lipid Genetics Consortium (GLGC) has carried out GWAS on plasma concentra-
tions of total cholesterol, low-density lipoprotein cholesterol (LDL), high-density lipo-
protein cholesterol (HDL) and triglyceride for approximately 100,000 individuals [32]. 
The Genetic Investigation of ANthropometric Traits (GIANT) consortium has performed 
Creating a dataset of SNPs in miRNA corresponding sequences 
(literature review and searching on the online databases) 
Focusing on SNPs present in the HapMap 
(n= 7) 
Retrieval SNPs in miRNA seed regions  
(n= 275) 
Including SNPs with MAF > 0.01 
(n= 26) 
Association of seven SNPs with cardiometabolic traits 
and diseases using the publicly available GWAS data 
Figure 1. This flow chart describes our method to retrieve SNPs in miRNA seed sequences.
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GWAS on anthropometric traits including body mass index (BMI) of over 120,000 and 
waist/hip ratio (WHR) adjusted for BMI of 77,000 individuals [33, 34]. The Global BPgen 
consortium has done GWAS on systolic and diastolic blood pressure in over 71,000 indi-
viduals. Individuals under treatment for hypertension were imputed to have 15 mm Hg 
higher systolic blood pressure and 10 mm Hg higher diastolic blood pressure than the 
observed measurements [35]. The CARDIoGRAMplusC4D consortium conducted GWAS 
in 63,746 coronary artery disease (CAD) cases and 130,681 controls. In this study, they 
have assessed 79,138 important related SNPs with CAD on the Metabochip [36].
effect of miRNA seed variant on the miRNA secondary structure and expression
When a miRNA seed variant was associated with cardiometabolic phenotypes, we used 
the Vienna RNAfold algorithm to predict the effect of variant on the secondary structure 
of the primary miRNA sequence [37]. Furthermore, we examined whether the SNP af-
fect mature miRNA expression. We cloned the pre-miRNA sequence containing either 
major (wild-type) or minor (mutant) allele behind the gene encoding green fluorescent 
Table 1. Description of 17 cardiometabolic phenotypes and publicly available GWAS data used in this study
Phenotype consortium sharing
gwAs data
gwAs sample size Reference
glycemic indices      
  Fasting glucose MAGIC 133010 26
  Fasting insulin MAGIC 108557 26
  Glucose after2h MAGIC 42854 27
  Pro-insulin MAGIC 10701 28
  HbA1c MAGIC 46368 29
  HOMA-B MAGIC 46186 30
  HOMA-IR MAGIC 46186 30
Type 2 diabetes DIAGRAM 12,171 cases/ 56,862 controls 31
lipid traits      
  Total Cholesterol GLGC 100184 32
  Tri -Glyceride GLGC 96598 32
  HDL Cholesterol GLGC 99900 32
  LDL Cholesterol GLGC 95454 32
Anthropometric measures
  BMI GIANT 123764 33
  WHR GIANT 77105 34
blood pressure      
  Systolic BP Global BPGen 71225 35
  Diastolic BP Global BPGen 71225 35
coronary artery disease CARDIoGRAMplusC4D 63,746 cases/ 130,681 controls 36
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protein (GFP) in the expression plasmid MSCV-BC [38], resulting in GFP-miRNA fusion 
transcripts. We thus had two separate expression vectors containing either pre-miRNA 
(Wt) or pre-miRNA (Mut). HEK293 cell transfection, total RNA isolation and quantitative 
PCRs were performed as previously described [38]. Mature miRNA levels in cells trans-
fected with pre-miRNA (Wt) compared with cells transfected with pre-miRNA (Mut).
Association of miRNA target genes with cardiometabolic phenotypes
To explore the putative mediatory role of the target genes of a miRNA associated with 
cardiometabolic phenotypes, we investigated the association of genetic variants in 
these target genes with the associated phenotypes. The significance threshold for this 
analysis was set by using a Bonferroni correction based on the number of independent 
SNPs. We calculated the number of independent SNPs using of Linkage disequilibrium 
based SNP pruning in PLINK with R2 > 0.5 (http://pngu.mgh.harvard.edu/purcell/plink/). 
The TargetScan database was used to identify target gene information, including their 
context score, and evolutionary conserved sites of miRNAs (release 6.2) (http://www.
TargetScan.org/).
expression Quantitative Trait loci (eQTl)
We examined the association of miRNA seed variant with expression levels of the miRNA 
target genes using whole blood trans-eQTL, and on the host genes expression using cis-
eQTL data from the Rotterdam Study (n=762). We further replicated the eQTL analyses 
in two other cohorts; SHIP-TREND (n=963) and InCHIANTI (n=611). The designs of these 
cohorts have been described in detail elsewhere [39-41]. Association of SNPs or their 
proxies, based on an R2 > 0.7, were assessed with gene expression levels in whole blood 
cells. Whole-blood cells were collected in PAXgene-tubes (Becton Dickinson, Breda, the 
Netherlands). Total RNA was isolated using PAXgene Blood RNA kits (Qiagen, Benelux 
BV, Venlo, the Netherlands), and to ensure a constant high quality of the RNA prepara-
tions, all RNA samples were analyzed using the Labchip GX (Calliper) according to the 
manufacturer’s instructions. Samples with an RNA Quality Score>=7 were amplified and 
labelled (Ambion Total Prep RNA, Life Technologies, Bleiswijk, the Netherlands), and 
hybridized to the Illumina Whole-Genome Expression Beadchips (HumanHT-12 v4). Pro-
cessing of the samples was performed at the Genetic Laboratory of Internal Medicine, 
Erasmus University Medical Center Rotterdam. The RS-III expression dataset is available 
at GEO (Gene Expression Omnibus) public repository under the accession GSE 33828. For 
normalization, raw intensity data generated with the expression arrays were exported 
from Illumina’s Genome Studio V 2010.1 Gene Expression Module to the R environment 
and quantile normalized and log2-transformed, as well as probe-centered, and sample-
standardized. We used the eQTL mapping pipeline called MegaQTL. eQTLs were deemed 
cis when the distance between the SNP chromosomal position and the probe midpoint 
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was less than 250 kb; eQTLs were deemed trans when the distance between the SNP 
chromosomal position and the probe midpoint position was larger than 5 Mbp. eQTLs 
were mapped using Spearman’s rank correlation, using the imputation dosage values 
as genotypes. Resultant correlations were then converted to p-values and respective 
z-scores weighted with the square root of the sample size. The model was adjusted for 
40 principal components [42].
luciferase reporter assay
Luciferase reporter assay system was used to validate the interaction of a miRNA 
with its identified target genes and also to determine the functional consequence of 
miRNA seed SNP on the binding of the miRNA to its target genes. To amplify the mature 
miR-4513 sequence, we used a forward primer containing XhoI restriction site (AACTC-
GAGAGGATGTGGTCTTTGCATCTTC) and a reverse primer containing EcoRI restriction site 
(AAGAATTCCCTCCAGTCTCCCCACCTAG). The miRNA sequences with major or minor al-
leles were cloned in the MSCV-BC vector. In addition, 3’UTR sequence of GOSR2 was am-
plified with the forward primer (AATCTAGAGTGATCCCAGCGACTCTTCA) containing the 
restriction enzyme site XbaI and the reverse primer (AAGGGCCCCCGTAGAGATGGCAG 
GGACT) containing an ApaI restriction site. The 3’UTR fragment of GOSR2, containing the 
putative target site of miR-4513, was cloned in the pGL3 Luciferase reporter vector [31]. 
All constructs were confirmed by Sanger sequencing. HEK293 cells were plated into 12-
well plates and co-transfected with MSCV-wild type miR-4513 (contain major allele) or 
MSCV-mutant miR-4513 (contain minor allele) and pGL3 containing the 3’UTR fragment 
of GOSR2. Luciferase activity was measured with the Dual-Glo Luciferase Assay System 
according to manufacturer’s protocol (Promega, Madison, Wisconsin). Renilla luciferase 
activity was normalize to the corresponding firefly luciferase activity and plotted as a 
percentage of the control. The experiments were performed in triplicate.
Pathway analysis for the identified miRNA target genes
To explore the pathways and networks in which the identified miRNA’s target genes may 
play a role, we performed Ingenuity Pathway Analysis (IPA). IPA is a knowledge database 
generated from peer-reviewed scientific publications that enables the discovery of 
highly represented biological mechanisms, pathways or functions most relevant to the 
genes of interest from large, quantitative datasets (http://www.ingenuity.com/prod-
ucts/ipa/). We uploaded list of the miRNA target genes associated with cardiometabolic 
phenotypes, and performed a core analysis with the default settings in IPA. We mapped 
these target genes to biological functions or canonical pathways. We looked at each 
gene separately to identify the associated pathways and biological networks. We further 
sought to determine whether the highlighted target genes of a miRNA that were found 
to be associated with cardiometabolic phenotypes are correlated together.
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ResulTs
genetic variants in miRNA seed regions
We retrieved all possible SNPs in miRNA corresponding sequences, of which a total num-
ber of 275 SNPs were located in the miRNA seed regions (Table s1). We included SNPs 
with MAF > 0.01 (n=26) and focused on the SNPs present in the HapMap project. Using 
the SNAP web tool, we found 2 proxy SNPs in high LD (R2 > 0.8 and distance < 200 kb) 
with 2 further miRNA seed variants that were not present in HapMap (Figure 1). In total, 
we examined 7 SNPs pertaining to 7 different miRNAs, including miR-146a-3p, miR-548a, 
miR-1178-5p, miR-1269b, miR-4513, miR-4741, and miR-6499-5p (Table 2).
A miR-4513 seed variant associates with multiple cardiometabolic phenotypes
The genetic association analysis of 7 miRNA seed SNPs with 17 cardiometabolic traits/
diseases are shown in Table s2. We used a Bonferroni correction to compensate for 
119 tests (7×17= 119), resulting in a p-value of 4.2×10-4 as a threshold of study-wide 
significance. We found rs1378942:G>T, a proxy in full LD (R2= 1.0) with rs2168518:C>T 
in the seed region of miR-4513 (Figure s1), to be significantly associated with multiple 
cardiometabolic phenotypes. Among glycemic traits, rs1378942 was significantly as-
sociated with increased levels of fasting glucose (effective allele: A, p-value= 2.5×10-4, 
β= 1.2×10-2). For lipid traits, the A allele of rs1378942 was significantly associated with 
higher LDL (p-value= 5.6×10-5, Z.score= 4.03) and total cholesterol (p-value= 5.7×10-5, 
Z.score= 4.02). This allele was also significantly associated with higher systolic (p-value= 
3.4×10-10) and diastolic blood pressure (p-value= 3.5×10-12). Moreover, the minor allele 
A of rs1378942 showed a suggestive association with increased risk of CAD (p-value= 
9.2×10-4). Additionally, we generated regional association plots of the related genomic 
Table 2. Characteristics of seven miRNA seed variants with MAF> 0.01 and present in the HapMap project
sNP ID chr. coded 
allele
other allele MAF sNP proxy miRNA ID miRNA 
location
rs2910164 5 C G 0.24 - miR-146a-3p Intergenic
rs3734050 5 T C 0.098 - miR-6499-5p FAT2
rs7210937 4 C G 0.074 - miR-1269b ARHGAP44
rs7311975 12 C T 0.028 - miR-1178-5p CIT
rs515924 6 G A 0.15 rs676103a miR-548a Intergenic
rs2168518 15 A G 0.31 rs1378942b miR-4513 CSK
rs7227168 18 T C 0.12 rs7239066c miR-4741 RBBP8
Shown are seven miRNA seed SNPs with minor allele frequency (MAF) > 0.01 and available in the HapMap 
project (release 22). For those SNPs that were not present in HapMap imputed data, we used the proxy in 
high linkage disequilibrium (LD): including a, R2= 1.0, distance= 189bp (A/G); b, R2= 1.0, distance= 928bp 
(A/C); c, R2= 1.0, distance= 1351bp (A/G).
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region of this SNP for the identified traits using LocusZoom web tool (Version 1.1.) [15]. 
Figure s2 illustrates the association of rs1378942 with these traits in regional associa-
tion plots, showing that the SNP either has the strongest association with the trait in the 
given genomic region or is one of the strongest ones.
Rs2168518 affects the miR-4513 processing and expression
We observed 0.49 kcal/mol difference in the minimum free energy (MFE) of the ther-
modynamic ensemble of the mutant versus the wild type primary miR-4513 sequence, 
which may affect the processing of the primary miRNA (Figure s3). We cloned the pre-
miR-4513 sequence (containing the wild type or mutant alleles) behind the GFP in the 
expression plasmid to examine the effect of rs2168518 on the level of mature miR-4513 
expression. Transient transfection experiments in HEK293 cells showed a significant 
reduced level of miR-4513 from the mutant allele relative to GFP compared to the wild 
type allele (p-value= 0.0048) (Figure 2).
miR-4513 target genes are associated with cardiometaboenotyp
We examined the association of 109 predicted target genes of miR-4513 with the 
cardiometabolic traits to identify their putative mediatory roles in our findings (Table 
s3). After applying a Bonferroni correction to compensate for the multiple testing, we 
found five target genes to be significantly associated with the identified traits, including 
PSCK1 with fasting glucose (p-value= 8.1×10-6), BNC2 with LDL (p-value= 7.6×10-6) and 
total cholesterol (p-value= 6.6×10-6) , MTMR3 with total cholesterol (p-value= 3.6×10-5), 
GOSR2 with systolic blood pressure (p-value= 7.3×10-7) and CAD (p-value= 1.5×10-6) , 
and ANK3 with systolic blood pressure (p-value= 3.9 ×10-5) (Figure 3).
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Figure 2. The effect of rs2168518 on miR-
4513 expression containing the major allele 
G and the minor allele A. The pre-miR-4513 
sequences containing either G or A alleles 
were cloned behind the GFP in the expression 
plasmid MSCV-BC. HEK293 cells were vector 
transfected, and total RNA was isolated for 
subsequent analysis by qPCR to determine the 
levels of mature miR-4513 in these expression 
vectors. This experiment showed a significant 
reduced level of mature miR-4513 from the mi-
nor allele A relative to GFP compared with the 
major allele G.
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Association of rs2168518 with miR-4513 target genes expression
We examined the association of rs2168518 with expression levels of the five identified 
target genes of miR-4513 using blood trans-eQTL data in 2,336 individuals. We did not 
find a statistically significant difference in the expression levels of target genes PSCK1, 
BNC2, MTMR3, GOSR2, and ANK3 across different alleles of rs2168518. However, there 
was a positive trend in the mean RNA-expression levels of GOSR2 in individuals carry-
ing the minor allele of rs2168518 (Table s4). Our cis-eQTL analysis showed a significant 
association between rs2168518 (G) and expression of the miR-4513’s host gene CSK 
(Z.score= 16.2, p-value= 5.12×10-59).
Rs2168518 affects miR-4513 controlled expression of gosR2
Next, we investigated whether rs2168518 effects on the expression level of GOSR2 in 
vitro. We generated expression vectors with miR-4513 sequences containing either the 
major or the minor allele and co-transfected these constructs with Luciferase reporters 
containing the 3’ UTR of GOSR2. Overexpression of miR-4513 significantly decreased the 
Luciferase activity of GOSR2 3’UTR fragment by 45% (p-value= 0.04), indicating GOSR2 
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Figure 3. This figure shows the association of 2,261 SNPs in 109 predicted target genes of miR-4513 with 
17 cardiovascular risk factors and disease. Dashed line indicates the significance threshold set at p-value< 
2.2×10-5. We highlighted the target genes which are most suspected to be influenced by the significantly 
associated SNPs. F.G, Fasting glucose; G2H, Glucose after 2hours; F.In, Fasting insulin; Pro.In, Pro-Insulin; HB, 
Homa-B; HIR, Homa-IR; HbA1c; TC, Total cholesterol; TG, Triglyceride; HDL, High-density lipoprotein; LDL, 
Low-density lipoprotein; SBP, Systolic blood pressure; DBP, Diastolic blood pressure; T2D, Type 2 diabetes; 
CAD, Coronary artery disease; BMI, Body mass index; WHR, Waist to hip ratio.
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is a direct target of miR-4513 (Figure 4). In addition, the rs2168518 mutant allele causes 
a reduced miR-4513 activity compared to the wild type miRNA, when the miRNA was 
overexpressed at lower levels, suggesting that the target repression efficiency, but not 
the specificity is changed by this SNP (Figure 4).
Potential role of the identified miR-4513 target genes in cardiometabolic 
disorders
The IPA core analysis was performed to determine the canonical pathways and networks 
that link the five identified miR-4513 target genes with the associated phenotypes. In 
agreement with our findings in the association study, there was a link between PCSK1 
and the insulin biosynthesis pathway and hyperglycemia. In addition, MTMR3 and BNC2 
were correlated with lipid metabolism, GOSR2 was associated with CAD and myocardial 
infarction and ANK3 was linked with pulmonary and renal hypertension (Figure s4). We 
further generated interaction networks between these five target genes of miR-4513 
and their associated phenotypes. Figure s5 illustrates a potential pleiotropic effect of 
miR-4513 on cardiometabolic traits and diseases.
DIscussIoN
We found that rs2168518, a variant in the seed region of miR-4513, associates with 
fasting glucose, LDL and total cholesterol, and systolic and diastolic blood pressure. 
We identified five miR-4513 target genes, GOSR2, ANK3, PCSK1, BNC2, and MTMR3, as 
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Figure 4. Luciferase reporter activity of the 
GOSR2 3’UTR in presence of miR-4513 contain-
ing the rs2168518 major allele (G) or minor al-
lele (A). A significance differences of the mean 
relative luciferase activity between cells trans-
fected with pGL3 vector coupled to the 3’UTR 
region of GOSR2 with or without miR-4513 
marked by * sign. The figure also shows that 
the rs2168518 minor allele A in miR-4513 af-
fects the repression of GOSR2.
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potential mediators of these associations. We experimentally showed two mechanisms 
through which rs2168518 affects miR-4513 function. First, the rs2168518 minor allele A 
decreases miR-4513 expression. Second, the minor allele reduces the ability of miR-4513 
to repress its target genes (GOSR2) expression compared to the major allele.
In recent years numerous studies have provided strong evidence showing miRNAs as 
major players in complex disorders [43, 44]. In addition, large advances have been made 
to identify miRNAs regulatory role in the pathophysiology of cardiometabolic diseases 
[4, 45, 46]. Since each miRNA regulates the expression of a large number of genes, ge-
netic polymorphisms in miRNA corresponding sequences are expected to contribute to 
phenotypic variation and subsequently disease susceptibility [47, 48]. Previous studies 
have reported an appreciable level of variation at miRNA binding sites and associated 
some of them with complex disorders [49]. However, since genetic variation in miRNA 
seed regions has important phenotypic consequences, they are expected to be at a 
low frequency. Polymorphisms in the seed of miRNAs render a strong effect on miRNA 
interaction with its target genes. For instance mutation in the miR-96 seed results in a 
non-syndromic progressive hearing loss and variants in the seed regions of miR-146a-
3p and miR-499a-3p are associated with increased risk of cancer [19, 50, 51]. Although 
variants on the miRNA target sites have previously linked with metabolic disorders [52], 
the association of miRNA seed polymorphisms with cardiometabolic phenotypes were 
not defined yet. Here we applied a systematic approach to investigate the association 
of miRNA seed SNPs with different cardiometabolic phenotypes. In agreement with 
previous studies, we show that the occurrence of common variants in the seed region 
of miRNAs is relatively rare and because of that many of the SNPs are not present in 
HapMap imputed data and are of negligible population genetic importance [49].
We found that the SNP rs2168518 in miR-4513 is associated with fasting glucose, 
LDL and total cholesterol, blood pressure, and CAD. This is the first finding concerning 
the role of miR-4513 in disease since its discovery by deep sequencing in 2010 [53]. 
We showed that the mature miR-4513 expression from the minor allele of rs2168518 is 
significantly reduced. The lower miR-4513 levels may be explained two possible mecha-
nisms, which are not mutually exclusive. First, this variant could affect the expression 
of mature miRNA by interfering with miRNA processing efficiency and components 
such as the RNA-induced silencing complex (RISC) assembly and Dicer cleavage [54, 55]. 
Second, the stability of rs2168518 containing miR-4513 may be reduced due to aberrant 
RISC loading and RNA degradation mechanisms [56].
We highlighted five predicted target genes of miR-4513, PCSK1, BNC2, MTMR3, ANK3 
and GOSR2, as potential mediators of this effect on cardiometabolic phenotypes. We 
revealed a significant association between PCSK1 and fasting glucose. This gene is 
previously associated with obesity [57], glucose metabolism, insulin secretion and risk 
of T2D [58]. BNC2 is associated with HbA1c and glucose in type 1 diabetes [58, 59]. Our 
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results here indicate that this gene is also a regulator of cholesterol metabolism. MTMR3 
is an inositol lipid 3-phosphatase which is involved in lipid metabolism [60]. In agree-
ment with our study, a recent large-scale meta-analysis of GWA studies of lipid traits 
has reported MTMR3 to be associated with LDL cholesterol [61]. Our findings further 
showed an association between ANK3 and higher systolic blood pressure. This gene has 
been previously highlighted to be involved in cardiac arrhythmia [62] and psychological 
disorders like bipolar disorders [63]. In addition, our pathway analysis using Ingenuity 
showed ANK3 to be linked to pulmonary and renal hypertension. Finally, we report GOSR2 
to be associated with blood pressure and CAD by use of the GWAS data. Previous studies 
of other investigators have also shown it to be associated with increased hypertension 
[64] and pulse pressure [65]. These findings indicate that our approach is valid to identify 
miRNA target genes that may mediate the effect of a miRNA on the studied traits. Since 
each miRNA regulate a large number of target genes, miRNAs have this potential to 
play a pleiotropic role in biological pathways. We demonstrate the pleiotropic effect of 
miR-4513 on cardiometabolic traits may be through its highlighted target genes.
Gene expression patterns are highly variable across tissues. Therefore, although we 
did not find an association between rs2168518 and blood expression levels of the 
highlighted target genes in the trans-eQTL data, this does not rule out an effect in other 
tissues. Accordingly, previous studies have shown that trans-regulatory effects of gene 
expression are highly complex and with small effect size [66]. However, we identified a 
positive trend in the RNA-expression levels of GOSR2 in individuals carrying the risk al-
lele of rs2168518 in blood. Therefore, to have higher priority about the functional effect 
of rs2168518 on the expression of GOSR2, we employed the luciferase reporter assay 
system. We experimentally validated GOSR2 as target genes of miR-4513 which is the 
first report of a validated target gene for this miRNA. We then showed that miR-4513 
mediated regulation of GOSR2 was significantly affected by SNP rs2168518 at lower con-
centration. This dose-dependent effect of the miRNA concentrations can be explained 
by the minimal concentration that is necessary for a miRNA to regulate the target gene 
[67]. Alternatively, this may further indicates that rs2168518 changes the expression 
levels of mature miR-4513 rather than impairing the targeting. We found an association 
between rs2168518 and the expression of its host gene CSK in blood. Several reports 
demonstrate that the expression profiles of intragenic miRNAs are highly correlated 
with their corresponding host genes [68-70]. Therefore, it is possible to use the miRNA 
host gene expression as a proxy to monitor the expression of its embedded miRNA [71]. 
The identified association of rs2168518 with expression levels of CSK may subsequently 
indicate an altered expression of miR-4513 in individual carrying the mutant allele.
Previous GWAS reported rs1378942, the SNP we used as a proxy for rs2168518, to be 
significantly associated with systolic and diastolic blood pressure and annotated that to 
CSK [72]. Our results indicate that rs1378942 may tag the altered function of miR-4513 
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caused by rs216518, and may resulting in up-regulation of GOSR2. Furthermore, GOSR2 
has been robustly associated with blood pressure traits: in our study with systolic blood 
pressure, and previously with hypertension and pulse pressure [64, 65]. Our findings 
further indicate that GOSR2 is significantly associated with CAD. This may suggests miR-
4513 as a candidate miRNA for blood pressure and CAD. Further research on miR-4513 
are needed to investigate the expression levels of the miRNA in hypertensive and CAD 
patients.
To the best of our knowledge, this is the first study to systematically investigate the 
association of genetic variations in the seed regions of miRNAs with cardiometabolic 
phenotypes. We identified a cardiometabolic-associated variant in the miR-4513 region 
seed that affects the miRNA expression and activity. We provide data supporting a pleio-
tropic role for miR-4513 in cardiometabolic traits and highlight a number of its target 
genes including GOSR2 as potential mediators. This may improve our understanding 
of the pathophysiology of cardiometabolic disorders. Moreover, our work introduces 
the investigation of miRNA variants as a novel approach to study the putative role of 
miRNAs in complex disorders. Given the completion of the first phase of GWA studies 
and providing valuable information on the association of millions of SNPs with complex 
disorders, the time is ripe to apply this kind of approach to a wide range of traits and 
diseases to detect miRNA involved in complex disorders.
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supplemental Table s2. Association of seven miRNA seed sequence SNPs with cardiometabolic disorders
  Phenotype rs2910164 rs515924 rs3734050 rs2168518
*
rs7227168
*
rs7210937 rs7311975
  Proxy SNP - rs676103 - rs1378942 rs7239066 - -
  Effect Allele C A T A G C C
MAgIc              
  Fasting glucose 2.5×10-2 0.97 0.87 2.5×10-4 0.90 0.18 0.92
  Glucose after2h 0.49 0.15* 5.5×10-2 0.78 0.2 0.88 NA
  Fasting insulin 0.85 0.53 0.37 0.96 0.44 0.77 0.35
  Pro-insulin 0.75 9.8×10-2 0.5 0.84 0.31 0.62 0.62
  HOMA-B 0.37 0.15 0.29 0.42 0.71 0.42 0.37
  HOMA-IR 0.36 0.65 0.42 0.98 0.17 0.81 0.87
  HbA1c 0.47 1.8×10-2 0.83 0.94 0.98 0.8 0.31
DIAgRAM
  Type 2 Diabetes 0.52 0.51* 0.40 8.1×10-2 9.1×10-2 8.6×10-2 NA 
glgc
  Total-Chol 0.90 0.55 0.17 5.6×10-5 0.31 0.18 0.33 
  Tri Glyceride 0.82 0.86 0.41 0.74 0.78 4.5×10-2 0.3
  HDL- Chol 0.77 0.74 0.74 0.29 6.0×10-2 0.95 0.75
  LDL- Chol 0.82 0.86 0.60 5.7×10-5 0.82 0.34 0.52
gIANT
  BMI 0.33 0.56 0.49 1.6×10-2 0.19 0.43 0.46 
  WHR 0.36 0.93 * 0.16 0.13 0.59 0.93 NA
global bPgen 0.24  0.94  0.43 0.96  
  Systolic BP   0.51*   3.4×10-10     NA 
  Diastolic BP 0.34 0.65* 0.56 3.5×10-12 0.46 0.71 NA
cARDIogRAMc4D        
  CAD NA 8.3×10-3 NA 9.2×10-4 NA NA NA 
Shown are association between seven miRNA seed variants and different cardiovascular risk factors and 
disease. In this table, numbers are p-values that significant ones are shown in bold. Those associations that 
we used proxy SNP are marked by * sign.
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supplemental Figure s2. Regional plots showing the association of rs1378942 with different cardiometa-
bolic disorders.
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AbsTRAcT
Background. MicroRNAs (miRNAs) have been implicated in the regulation of cardiomet-
abolic disorders. Given the crucial role of miRNAs in gene expression, genetic variation 
within miRNA genes are expected to affect miRNA function and  contribute to disease 
risk.
Methods and Results. We retrieved 2,320 genetic variants in miRNA-encoding sequenc-
es and investigated their associations with 17 cardiovascular risk factors and disease, 
using genome-wide association studies (GWAS) on glycemic indices, anthropometric 
measures, lipid traits, blood pressure, coronary artery disease and type2 diabetes. We 
then examined whether target genes of the associated miRNAs may mediate their ef-
fects in the related phenotypes. Furthermore, we performed trans-eQTL analysis and 
Luciferase reporter assays to provide functional evidence for our findings. We found that 
rs11614913:C>T in miR-196a2 is associated with waist to hip ratio (p-value= 1.7×10-5, 
β= 0.023). We identified two target genes, SFMBT1 and HOXC8, which may mediate 
the effect of miR-196a2 and experimentally showed that they are direct targets of this 
miRNA. Moreover, we found rs174561:T>C in miR-1908 to be associated with total-
cholesterol (p-value= 6.5×10-16, β= 0.044), LDL-cholesterol (p-value= 4.3×10-18, β= 0.049), 
HDL-cholesterol (p-value= 1.7×10-6, β= 0.026), triglyceride (p-value= 7.8×10-14, β= 0.038) 
and fasting glucose (p-value= 4.3×10-10, β= 0.02). We further highlighted a number of 
putative target genes of miR-1908 as potential mediators.
Conclusion. Our results support the miRNA-dependent regulation of fat distribution by 
miR-196a2 and lipid metabolism by miR-1908.
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INTRoDucTIoN
Cardiometabolic disorders including cardiovascular disease (CVD) and type 2 diabetes 
mellitus (T2D) remain the leading cause of mortality and morbidity worldwide [1]. Al-
though a number of risk factors are identified for these disorders, the quest for further 
risk factors and new diagnostic markers remains to be a research priority. Over the past 
two decades, a large number of studies have provided evidence for the association 
between microRNAs (miRNA) and complex disorders [2, 3]. In addition, miRNAs have 
been highlighted as potential diagnostic biomarkers as well as therapeutic targets in 
cardiometabolic disorders [3, 4]. Consequently, miRNAs have recently gained extensive 
attention as important players in the pathophysiology of cardiovascular disease and 
metabolic syndrome [5].
MiRNAs are a class of small non-coding RNAs with a pivotal role in the regulation 
of a broad range of biological processes [6]. Since the discovery of the first miRNA in 
the early 1990s, more than 1500 miRNAs have been identified in human, that they are 
predicted to regulate the expression of approximately 60% of all protein-coding genes 
[7, 8]. MiRNAs regulate gene expression by binding to the 3’ untranslated regions (3’UTR) 
of their target messenger RNAs (mRNA). They inhibit translation of target mRNAs and 
to a lesser extent decay of the transcripts [9]. MiRNAs are initially transcribed as long 
primary-miRNA (pri-miRNA) transcripts in the nucleus which are cleaved by the enzyme 
Drosha to liberate precursor miRNAs (pre-miRNA) of 60-70 nt long. Following this initial 
processing, pre-miRNAs are transported to the cytoplasm to be further processed by 
the enzyme Dicer into double-stranded miRNA of approximately 21 nt in length. The 
mature single-stranded miRNA then integrate into the RNA-induced silencing complex 
(RISC) and interact with the target mRNAs [6, 9]. Genetic variation in miRNA genes, 
including pre- or mature miRNA sequences, are expected to affect the expression of 
miRNAs and their target genes and subsequently contribute to phenotypic variations 
[10, 11]. Previous studies have reported a few pathogenic variants within miRNA genes 
in cardiometabolic phenotypes [4, 12].
Here, we aimed to systematically investigate the association of genetic variants in 
miRNA-encoding sequences with different cardiometabolic traits and diseases. Fur-
thermore, we examined whether target genes of the identified miRNAs harboring the 
variants may mediate their effects on the associated phenotypes.
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MATeRIAls AND MeThoDs
Identification of genetic variants in miRNA-encoding sequences
We screened known human miRNAs report in the miRBase database (release 21) (http://
www. mirbase.org), to identify genetic variants in the miRNA corresponding sequences. 
Reviewing the literature and searching two online databases: PolymiRTS and miRNASNP 
[13, 14], we made a dataset of single nucleotide polymorphisms (SNPs) in human pre- 
and mature miRNAs, beyond the seed region (the nucleotides 2-8 of a mature miRNA) 
that we have been previously studied their associations with cardiometbolic pheno-
types [15]. We included SNPs with minor allele frequency (MAF)> 0.01, since variants 
with smaller MAF are more likely to have a low imputation quality and in most cases 
we are under powered to study them. Given that previous GWAS meta-analyses were 
conducted on the basis of the international HapMap imputed data, we focused on the 
SNPs present in the HapMap project (http://www.hapmap.org/). For miRNA-SNPs that 
were not present in HapMap, we used the SNAP web tool to find proxy SNPs in high 
Linkage Disequilibrium (LD) (R2 > 0.8 and distance < 200 kb) (http://www.broadinstitute.
org/mpg/snap/id) (Figure 1).
Focusing on miRNA variants available in HapMap 
(n=70) 
Retrieval of genetic variants within  
pre- and mature miRNA sequences (n=2,320) 
Including miRNA variants with MAF > 0.01 
(n=148) 
Association of 70 variants with cardiometabolic 
phenotypes using the publicly available GWAS  
Trans-eQTL analysis in adipose tissue for two associated 
miRNA variants and the miRNA target genes  
Luciferase reporter assays to validate the interaction 
between miR-196a2 and its two identified targets  
Figure 1. This figure shows our approach to examine the association between genetic variants in pre- and 
mature miRNA sequences and cardiometabolic phenotypes.
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Association between miRNA-sNPs and cardiometabolic phenotypes
We studied the association of SNPs within the miRNA-encoding sequences with 17 car-
diometabolic phenotypes using the publicly available GWAS meta-analyses on glycemic 
indices, anthropometric measures, lipid traits, systolic and diastolic blood pressure, 
coronary artery disease (CAD), and type 2 diabetes (T2D). A description of GWAS con-
sortia and cardiometabolic phenotypes are shown in Table s1. To compensate for the 
multiple testing in the association studies, we used the Bonferroni correction, in which 
the number of SNPs multiplied by the number of phenotypes.
Data on glycemic traits have been contributed by MAGIC investigators and have 
been downloaded from www.magicinvestigators.org. We included the following traits: 
fasting glucose, serum glucose after 2hr, fasting insulin, fasting pro-insulin, HbA1c, 
HOMA-B, and HOMA-IR from up to 133,000 individuals. The Genetic Investigation of 
ANthropometric Traits (GIANT) consortium has performed GWAS meta-analysis on 
anthropometric measures including body mass index (BMI) of over 120,000 and waist 
to hip ratio (WHR) adjusted for BMI of 77,000 individuals. We also used the sex-stratified 
GWAS including 270,000 individuals released by the GIANT [15, 16]. The Global Lipid 
Genetics Consortium (GLGC) has provided a GWAS meta-analysis on plasma concentra-
tions of total cholesterol, LDL-cholesterol, HDL-cholesterol and triglyceride for 187,000 
individuals [17]. The Global BPgen consortium has done GWAS meta-analysis on systolic 
and diastolic blood pressure in over 71,000 individuals [18]. The CARDIoGRAM GWAS is a 
meta-analysis of 22 GWAS of European descent imputed to HapMap 2 involving 22,233 
cases and 64,762 controls [19]. The DIAbetes Genetics Replication and Meta-analysis 
(DIAGRAMv3) consortium has done a GWAS meta-analysis in 12,171 T2D cases and 
56,862 controls [20].
effect of miRNA variants on the processing of pre-miRNAs
For those variants in miRNA corresponding sequences that were associated with car-
diometabolic phenotypes, we used the Vienna RNAfold algorithm (ViennaRNA package 
2.0) to predict the effect of the variants on the secondary structure and processing of the 
pre-miRNA sequences [21].
Association of miRNA target genes with cardiometabolic phenotypes
When a miRNA-variant was significantly associated with cardiometabolic phenotypes, 
we sought to identify the miRNA target genes that may mediate the effect of miRNA on 
the associated phenotypes. We used GWAS data on the identified phenotypes to detect 
target genes that are more likely to be involved in these phenotypes, in a candidate 
gene approach. We retrieved all genetic variants in the target genes of miRNA and as-
sessed their associations with cardiometabolic phenotypes. The significance threshold 
for this analysis was set by using the Bonferroni correction based on the number of in-
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dependent SNPs in the miRNA target genes. To obtain the number of independent SNPs, 
we used the linkage disequilibrium (LD) based SNP pruning in PLINK (http://pngu.mgh.
harvard.edu/~purcell/plink/), where we excluded the SNPs with R2 > 0.5. The TargetScan 
database (v6.2) was used to identify target genes information, including their context 
score and conserved sites of miRNAs, (http://www.TargetScan.org/).
expression quantitative trait loci (eQTl)
Polymorphisms in miRNA genes are expected to alter expression level of the miRNAs and 
subsequently affect their target genes expression. We performed trans-eQTL analysis, 
showing the downstream consequences of variants, to examine the association between 
miRNA-SNPs and expression levels of the miRNA target genes. We scanned trans-eQTL 
data in adipose tissue with 856 healthy female twins using data from the MuTHER Study. 
The design of the MuTHER Study has been described in detail elsewhere [22].
luciferase reporter assay
Primers were designed to amplify the pre-miR-196a2 sequence included in the restric-
tion enzyme sites XhoI for the forward primer and EcoRI for the reverse primer. The miR-
196a2 expression vector was cloned in the MSCV-BC vector. In addition, primers were 
designed to clone the 3’UTR sequences of SFMBT1 and HOXC8 included in the restriction 
enzyme sites XbaI for the forward primer and ApaI for the reverse. All primers are shown 
in Table s2. The 3’UTR sequences (wild-type and mutated), containing the putative 
binding site of miR-196a2, were cloned downstream of the Luciferase gene in the pGL3 
vectors [23]. The inserts of all constructs were validated by Sanger sequencing. HEK293 
cells were plated into 12-well plates and co-transfected with MSCV-miR-196a2, pGL3 
containing the different 3’UTR and a plasmid expressing the Renilla transfection control. 
Luciferase activity was measured with the Dual-Glo Luciferase Assay System according 
to manufacturer’s protocol. Renilla luciferase activity was used for normalization. The 
experiments were performed in triplicate.
ResulTs
genetic variants within miRNA-encoding sequences
We retrieved a total of 2,320 SNPs in human pre- and mature miRNA sequences. We 
included SNPs with MAF > 0.01 (n=148). Of these, 68 SNPs were present in the HapMap 
project, using GWAS on cardiometabolic phenotypes that were conducted on the basis 
of HapMap imputed data. By use of the SNAP web tool, we found 2 proxy SNPs in high 
LD with 2 other miRNA polymorphisms that were not present in HapMap. A total of 70 
SNPs within 66 different miRNAs were candidates for the association studies (Table 1). In 
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this study, we did not investigate variants in pri-miRNA transcripts, as they have different 
length and in many cases are comprised of more than one miRNA [24]. Thus it was chal-
lenging to disentangle the specific effect of such variants in each individual miRNA.
Table 1. Characteristics of 70 genetic variants in pre- and mature miRNA sequences 
sNP ID chr. Position effect 
allele
other 
allele
MAF miRNA ID miR-sNP 
location
rs10406069 19 40528370 a g 0.212 miR-5196 Pre-miR
rs10505168 8 113724928 t c 0.292 miR-2053 Pre-miR
rs1077020 4 4023371 t c 0.205 miR-943 Pre-miR
rs10878362 12 64703760 a c 0.358 miR-6074 Pre-miR
rs10934682 3 125934002 t g 0.15 miR-544b Pre-miR
rs11014002 10 24604659 t c 0.064 miR-603 Pre-miR
rs11032942 11 34920035 t c 0.125 miR-1343 Pre-miR
rs11176006 12 64703749 a g 0.312 miR-6074 Pre-miR
rs11237828 11 78810868 t c 0.225 miR-5579 Mature-miR
rs11259096 10 14518624 t c 0.075 miR-1265 Pre-miR
rs11614913 12 52671866 t c 0.442 miR-196a-2 Mature-miR
rs11713052 3 126353066 c g 0.025 miR-5092 Pre-miR
rs11907020 20 18399325 t c 0.028 miR-3192 Pre-miR
rs12314280 12 93479716 t c 0.085 miR-5700 Mature-miR
rs12456845 18 44830056 t c 0.04 miR-4744 Pre-miR
rs12473206 2 64421420 c g 0.254 miR-4433 Mature-miR
rs12523324 5 1761983 a g 0.314 miR-4277 Pre-miR
rs12780876 10 14465210 a t 0.288 miR-4293 Pre-miR
rs13186787 5 153706962 a g 0.017 miR-1294 Pre-miR
rs13299349 9 18563360 a g 0.275 miR-3152 Mature-miR
rs1683709 12 127344656 a g 0.164 miR-3612 Pre-miR
rs17022749 12 93479734 t c 0.068 miR-5700 Pre-miR
rs17091403 10 115923895 t c 0.098 miR-2110 Pre-miR
rs174561 11 61815236 t c 0.35 miR-1908 Pre-miR
rs17797090 12 102848396 a g 0.111 miR-3652 Pre-miR
rs2042253 5 143039626 t c 0.225 miR-5197 Pre-miR
rs2043556 10 52729412 t c 0.186 miR-605 Pre-miR
rs2060455 15 63798684 a g 0.181 miR-4511 Pre-miR
rs2114358 8 129090361 a g 0.417 miR-1206 Pre-miR
rs215383 12 46044299 a g 0.125 miR-4494 Pre-miR
rs2289030 12 93752417 c g 0.082 miR-492 Pre-miR
rs2291418 5 179157930 a g 0.05 miR-1229 Mature-miR
rs2292832 2 241044176 t c 0.268 miR-149 Pre-miR
rs2368392 10 29874009 a g 0.246 miR-604 Pre-miR
58 Chapter 2.2
Table 1. (continued)
sNP ID chr. Position effect 
allele
other 
allele
MAF miRNA ID miR-sNP 
location
rs243080 2 60468076 a g 0.458 miR-4432 Pre-miR
rs257095 5 9106945 t c 0.119 miR-4636 Pre-miR
rs2663345 17 872514 a g 0.322 miR-3183 Pre-miR
rs2910164 5 159844996 c g 0.235 miR-146a Seed-miR
rs356125 9 96612065 a g 0.067 miR-2278 Pre-miR
rs3734050 5 150881892 t c 0.111 miR-6499 Seed-miR
rs4112253 19 54282167 c g 0.35 miR-4752 Pre-miR
rs4351242 6 32825700 t c 0.075 miR-3135b Pre-miR
rs4414449 15 84169902 a g 0.325 miR-548ap Mature-miR
rs4577031 15 84169963 a t 0.325 miR-548ap Pre-miR
rs4674470 2 220479467 t c 0.158 miR-4268 Pre-miR
rs4822739 22 26555219 c g 0.045 miR-548j Pre-miR
rs4919510* 10 102724768 c g 0.177 miR-608 Mature-miR
rs515924 11 74399308 a g 0.177 miR-548al Seed-miR
rs521188 1 65296107 a g 0.025 miR-3671 Pre-miR
rs5997893 22 29886103 a g 0.354 miR-3928 Pre-miR
rs6505162* 17 25468309 a c 0.406 miR-423 Pre-miR
rs653667 1 12174395 t g 0.354 miR-4632 Pre-miR
rs701213 1 233624172 t c 0.237 miR-4427 Pre-miR
rs701214 1 233624193 t c 0.107 miR-4427 Pre-miR
rs702742 5 154189217 a g 0.111 miR-378h Pre-miR
rs7207008 17 43444845 a t 0.438 miR-2117 Pre-miR
rs7210937 17 12761371 c g 0.095 miR-1269b Seed-miR
rs7311975 12 119713688 t c 0.017 miR-1178 Seed-miR
rs7522956 1 222652581 a c 0.248 miR-4742 Pre-miR
rs7896283 10 12735183 a g 0.5 miR-4481 Pre-miR
rs7911488 10 105144079 a g 0.341 miR-1307 Pre-miR
rs8078913 17 6499492 t c 0.451 miR-4520a Mature-miR
rs832733 12 45867896 t c 0.333 miR-4698 Pre-miR
rs8667 19 55128183 a g 0.368 miR-4751 Pre-miR
rs877722 1 232508880 a t 0.127 miR-4671 Pre-miR
rs895819 19 13836478 t c 0.297 miR-27a Pre-miR
rs936581 5 153955769 a g 0.221 miR-3141 Pre-miR
rs9842591 3 152766381 a c 0.434 miR-5186 Pre-miR
rs9877402 3 40528370 a g 0.017 miR-5682 Pre-miR
Shown are 70 miRNA-variants that are present in the HapMap project (release 22). For those SNPs that 
were not present in the HapMap, marked them by * sign, we used their proxies in strong linkage disequilib-
rium (LD): including rs58078477 proxy for rs4919510 with R2=1 and distance=0, and rs61093106 proxy for 
rs6505162 with R2=1 and distance=0.
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Two variants in miR-196a2 and miR-1908 were associated with cardiometabolic 
phenotypes
Figure 1 shows our approach to examine the association between miRNA variants and 
cardio-metabolic phenotypes. We performed 1,190 tests (17×70) resulting in a p-value 
threshold of 4.2×10-5 (Bonferroni correction). Table s3 shows the associations between 
70 miRNA-SNPs and 17 cardiometabolic phenotypes. We found that rs11614913:C>T 
(chr12.hg19:54385599) in miR-196a2 is associated with WHR adjusted BMI (p-value= 
1.7×10-5, β= 0.023) in up to 73,014 individuals, suggesting that individuals who carrying 
the rs11614913 minor allele have a bigger WHR index. This SNP was associated with WHR 
adjusted BMI in 32,706 men (p-value= 9.4×10-4, β= 0.025) and in 40,308 women (p-value= 
5.0×10-3, β= 0.020). Furthermore, rs174561:T>C (chr11.gh19:61582708) in miR-1908 was 
significantly associated with multiple phenotypes, including total cholesterol (p-value= 
6.5×10-16, β= 0.044), LDL-cholesterol (p-value= 4.3×10-18, β= 0.049), HDL-cholesterol 
(p-value=1.7×10-6, β= 0.026), triglyceride (p-value= 7.8×10-14, β= 0.038), fasting glucose 
(p-value= 4.35×10-10, β= 0.02) and HOMA-B (p-value= 3.8×10-5, β= -0.014). These findings 
indicate that carriers of the minor allele T of rs174561 have increased serum lipid and 
fasting glucose (Table 2). Figure s1 illustrates regional association plots of rs11614913 
and rs174561 and their close by SNPs with the identified phenotypes, using LocusZoom 
web tool, Version 1.1.
rs11614913 and rs174561 with potential to affect the pre-miRNA secondary 
structure
Genetic variants in pre-miRNA sequences may affect the folding of RNA. Using the Vienna 
RNAfold algorithm, we found differences in the RNAfold predicted secondary structure of 
Table 2. Two miRNA variants associated with  cardiometabolic phenotypes
sNP ID miRNA ID MFe change Associated 
phenotype
effect 
estimate
P-value Associated target 
genes
rs11614913
(C/T)
miR-196a2 -4.6 kcal/mol Waist to hip ratio 0.023 1.7×10-5 SFMBT1, HOXC8
rs174561
(C/T)
miR-1908 -2.8 kcal/mol LDL-cholesterol 0.049 4.3×10-18 OTX1
      Total cholesterol 0.044 6.5×10-16 NEUROD2
      Triglyceride 0.038 7.8×10-14 PRRT1, SLC12A5, VPS37D
      Fasting glucose 0.020 4.35×10-10 -
      HDL-cholesterol 0.026 1.7×10-6 NEUROD2
      HOMA-B -0.014 3.8×10-5 EPHB3
Shown are the associations between two miRNA-variants and cardiometabolic phenotypes. MFE; minimum 
free energy. Associated target genes are the miRNA putative targets that show the most significant associa-
tions with the related phenotype using GWAS data.
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miR-196a2 and miR-1908 containing the wild type and mutant alleles, Figure 2 [21]. As 
shown in this figure, there is a 4.6 kcal/mol difference in the minimum free energy (MFE) 
of the thermodynamic ensemble of pre-miR-196a2 containing the mutant versus the wild 
type. Accordingly, we observed a 2.8 kcal/mol difference between the wild type and mutant 
pre-miR-1908 sequence. This suggests that these variants may affect the processing of the 
pre-miRNAs, the RNA structures with lower MFE are thermodynamically more stable.
miR-196a2 and miR-1908 target genes associated with the identified 
phenotypes
MiRNAs are implicated in phenotypic variation and human disease through regulation 
of their target genes expression. We assessed the putative mediatory roles of the target 
genes of miR-196a2 on WHR and miR-1908 target genes on serum lipid and fasting 
glucose. A list of the conserved target genes of these two miRNAs are shown in Table 
s4. The association of SNPs in 295 putative target genes of miR-196a2 with WHR were 
examined. After excluding SNPs in high LD (R2 > 0.8), we extracted 2,656 independent 
SNPs in all targets genes of miR-196a2 and using Bonferroni correction the significance 
threshold was set to 1.88×10-5. We identified one target gene of miR-196a2, SFMBT1, 
to be significantly associated with WHR (p-value= 2.8×10-6). Accordingly, we examined 
 
 
 
 
 
 
 
 
 
 
 
B. Pre-miR-1908 with minor allele U 
ΔG= -46.60 kcal/mol 
A. Pre-miR-196a2 with major allele C 
ΔG= -52.40 kcal/mol 
B. Pre-miR-196a2 with minor allele U 
ΔG= -46.90 kcal/mol 
A. Pre-miR-1908 with major allele C 
ΔG= -49.40 kcal/mol 
rs174561 
rs11614913 
Figure 2. Schematic view of the RNAfold predicted secondary structures of the two identified miRNAs 
with their wild type and mutant alleles. A. RNAfold predicted secondary structure of pre-miR-196a2 and 
pre-miR-1908 with major alleles (wild type) and their MFE of the thermodynamic ensemble (ΔG). b. The 
secondary structure of miRNAs with the mutant alleles. The pre-miRNA structures with lower MFE are ther-
modynamically more stable. The position of SNPs in the pre-miRNA sequences are shown by arrow.
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the association of SNPs in 68 targets genes of miR-1908 with lipid traits, fasting glucose 
and HOMA-B. We retrieved 890 independent SNPs in all targets genes of miR-1908 and 
therefore a significance threshold was set to 5.6×10-5. We found six target genes to be 
significantly associated with the identified phenotypes, including NEUROD2 with total 
cholesterol (p-value= 3.9×10-7) and HDL-cholesterol (p-value= 1.8×10-19), OTX1 with LDL-
cholesterol (p-value= 2.6×10-7), PRRT1 (p-value= 2.3×10-6), SLC12A5 (p-value= 1.4×10-5), 
and VPS37D (p-value= 2.1×10-5) with triglyceride, and finally EPHB3 with HOMA-B (p-
value= 4.5×10-5). These target genes of miR-196a2 and miR-1908 are more likely to play 
a role in mediating WHR and serum lipid and fasting glucose respectively (Table 2).
Association of rs11614913 and rs174561 with the miRNA target genes 
expression
We explored the effect of rs11614913 and rs174561 on the miRNA target genes expres-
sion using trans-eQTL data in adipose tissue, which is a relevant tissue for WHR and lipid. 
The SNP rs11614913 in miR-196a2 was associated with an increased expression levels of 
SFMBT1 (p-value= 2.2×10-3) and HOXC8 (p-value= 1.6×10-3) in individuals who carried the 
risk allele. For SNP rs174561 in miR-1908, we did not find significant association with the 
highlighted target genes. However, this SNP was significantly associated with its host 
gene, FADS1, across different genotypes (p-value= 1.6×10-5).
miR-196a2-mediated repression of SFMBT1 and HOXC8
Next, we investigated whether miR-196a2 control expression level of SFMBT1 and HOXC8 
in-vitro. We generated expression vectors containing the pre-miR-196a2 sequence 
and co-transfected the constructs with Luciferase reporters containing the 3’ UTR of 
SFMBT1 and HOXC8 (wild-type and mutated). Overexpression of miR-196a2 significantly 
decreased the Luciferase activity of wild type construct reporters of SFMBT1 (P-value= 
0.01) and HOXC8 (P-value= 4×10-5), while the miRNA did not significantly regulate the 
mutated reporters (Figure 3). These data indicate that SFMBT1 and HOXC8 are direct 
targets of miR-196a2.
The lD structure evaluation of rs11614913 and rs174561
We investigated the LD structure of proxy SNPs in high LD with rs11614913 and rs174561 
in the related genomic regions. Using the HaploReg and SNPinfo websites we found only 
4 SNPs in strong LD with rs11614913 that are located in HOXC5 and HOXC-AS1. Among 
them, rs11614913 has some predicted functions and is located within a miRNA, thus is 
more likely to be a functional SNP in this locus (Table s5). In addition, we found 23 prox-
ies for rs174561 that are in FADS1, C11orf9 and C11orf10. As shown in Table s5, there are 
predicted functions for rs174561 and some of these proxies that can be functional SNPs 
and may contribute to explain the observed GWAS associations.
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DIscussIoN
We found that rs11614913, a common variant in miR-196a2 associates with WHR and 
rs174561 in miR-1908 associates with LDL-cholesterol, HDL-cholesterol, total cholesterol, 
triglyceride and fasting glucose. We identified that these variants may affect processing 
of the pre-miRNAs to the mature forms. Furthermore, we identified a number of target 
genes of these two miRNAs that may mediate their effect on the associated phenotypes. 
We performed trans-eQTL analysis in adipose tissue and found positive association be-
tween rs11614913 in miR-196a2 with expression levels of its two target genes, SFMBT1 and 
HOXC8. We then demonstrated that these genes are direct targets of miR-196a2 in vitro.
In recent years large advances have been made in the discovering of the regulatory 
role of miRNAs in complex disorders [2, 9]. MiRNAs comprise a key regulatory layer that 
intersect with transcriptional and translational control mechanisms to maintain the 
metabolic homeostasis. Deregulation of miRNA activities is implicated in cardiovascular 
disease [3-5]. Accordingly, numerous studies have provided strong evidences for a crucial 
role of miRNAs in fat cell development and obesity [25]. Recently, genome-wide compu-
tational analyses and experimental studies have suggested that miRNA-SNPs contribute 
to phenotypic variations [11, 13, 26]. Variants in pre-miRNAs are expected to alter miRNA 
processing and expression [10]. This may affect the expression of miRNA target genes 
and subsequently play a role in disease [27]. In this study, we applied a systematic ap-
proach to identify miRNAs involved in cardiometabolic disorders by investigating the 
correlation of miRNA polymorphisms with phenotypes. We examined the association 
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Figure 3. miR-196a2-dependent regulation of SFMBT1 and HOXC8. This figure illustrates Luciferase report-
er activity of cells transfected with pGL3 vector coupled to the miR-196a2 and the 3’UTR regions of SFMBT1 
and HOXC8. A significant difference of the mean relative luciferase activity between cells transfected with 
pGL3 vector coupled to 3’UTR region of these genes with or without miR-196a2 was observed. The figure 
further shows that the miR-196a2-mediated regulation of the genes are abolished when the reporter con-
structs containing mutation.
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of miRNA variants with cardiometabolic phenotypes using the available GWAS data to 
find the associations deserve sufficient power. Our approach is statistically powerful 
since it benefits from extremely large GWA studies together with a liberal significance 
threshold. By implementing this approach, we found two miRNA variants, rs11614913 
and rs174561, to be significantly associated with cardiometabolic phenotypes.
Rs11614913 is a common variant located in pre-miR-196a2 that has linked to several 
disorders and phenotypes. This variant contributes to the increased risk of breast cancer, 
lung cancer and cancers of digestive system [28, 29]. A meta-analysis of GWAS on bone 
mineral density (BMD) demonstrates that the risk allele of rs11614913 is inversely as-
sociated with lumbar spine and femoral neck BMD [30]. Furthermore, rs11614913 has 
been reported to be associated with the risk of cardiovascular disease in type 2 diabetes 
patients [31] and congenital heart disease [32]. However, despite using a large sample 
size (22,233 cases and 64,762 controls) from the CARDIOGRAM consortium, we did not 
find a significant association between rs11614913 and risk of CAD [19]. Our findings 
showed a significant association between the rs11614913 mutant allele and higher 
WHR. We found that there is a difference between MFE of the thermodynamic ensemble 
of pre-miR-196a2 with the mutant versus the wild type allele which may affect the 
structure and processing of the pre-miRNA. In agreement with our conjecture, it has 
been shown experimentally that rs11614913 affects the processing of pre-miR-196a2 
and results in altered expression levels of the mature miRNA [27, 33]. Hoffman et al by 
delivering expression vectors containing either wild type or mutant precursors of miR-
196a2 have shown that mature miRNA levels in cells transfected with pre-miR-196a2 
hosting the mutant allele (T) is significantly lower than cells transfected with wild the 
type allele construct [27]. In addition, Hu el al have demonstrated that rs11614913 wild 
type allele (C) is associated with a significant increase in mature miR-196a2 expression 
[33]. Therefore, an altered expression level of mature miR-196a2 due to rs11614913 may 
serve as a functional mechanism underlying the observed association between the vari-
ant and WHR. MiRNAs regulate phenotypes through regulation of their target genes 
expression. We sought to identify target genes that may mediate the effect miR-196a2 
on WHR and found SFMBT1 and HOXC8. We showed these genes are bona fide targets 
of miR-196a2. Previous studies have provided evidence for co-expression of miR-196a2 
and its two highlighted targets in adipose tissue which is a pre-requisite for miRNA-
mRNA interaction. MiR-196a2 has been identified as a regulator in brown adipogenesis 
of white fat progenitor cells [22]. Accordingly, HOXC8 is known to increase white fat 
cells and the risk of obesity [34]. SFMBT1 has reported to be associated with circulating 
adiponectin levels [35]. In addition, it has experimentally shown that decreasing HOXC8 
expression by overexpression of miR-196a2 lead to an increased brown adipocytes [34]. 
Taken together, these findings suggest that depletion of miR-196a2 by rs11614913 
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mutant allele T elevate HOXC8 and SFMBT1 expression and subsequently contribute to 
higher WHR, potentially through an increase in white fat cells.
Rs174561 resides in the 5’ end of pre-miR-1908 and is strongly associated with fatty 
acid levels in plasma, serum phospholipid and adipose tissue [36]. This variant has a num-
ber of proxies in FADS1 that have been shown to be associated with lipid metabolism, 
glucose homeostasis and cardiometabolic outcomes [37]. However, the determination 
of the causal variant(s) in this locus remains a challenge. Here we suggest a potential 
functional mechanism for rs174561 to influence serum fatty acid levels through affect-
ing miR-1908 expression. We found that rs174561 change MFE of the thermodynamic 
ensemble of pre-miR-1908 sequence, which potentially affects the processing of the pre-
miRNA. MiR-1908 is highly expressed in mature human adipocytes and is highlighted as 
an important mediator in the development of obesity-related complications and lipid 
metabolism [38, 39]. Our findings may indicate that the reduced levels of miR-1908 due 
to rs174561 and subsequent change in target genes expression is a functional mecha-
nism behind the identified associations. We highlighted six target genes of miR-1908 as 
potential mediators on these associations. Among them, NEUROD2 has reported to be 
associated with HDL [17] and SLC12A5 has linked to body mass index and type 2 diabetes 
[40]. This is the first report about the associations of VPS37D, OTX1 and PRRT1 with lipid 
traits and EPHB3 with fasting glucose. We did not find a significant association between 
rs174561 and transcript expression levels of these genes in the trans-eQTL analysis. 
Lack of significant associations can be due to a limited statistical power. Furthermore, 
previous studies have shown that trans-regulatory effects of gene expression are highly 
complex and with small effects [22]. Therefore, we cannot rule out the effect of rs174561 
on the target genes expression. A second mechanism may explain the correlation of 
rs174561 with lipid and fasting glucose concentrations through FADS1. This gene is 
known to be involved in cholesterol homeostasis [36] and we found variations in FASD1 
transcript levels through different genotypes of rs174561 in adipose tissue.
We found two common functional variants in miR-196a2 and miR-1908 to be sig-
nificantly associated with WHR and serum lipid and glucose levels respectively. We sug-
gested a number of target genes of these miRNAs as potential mediators of their effects 
on the associated phenotypes. These findings may improve our understanding of the 
miRNA-mediated regulations of fat distribution and lipid metabolism. MiR-196a2 may 
have potential for further translation into the clinic to combat obesity. Furthermore, we 
successfully applied a new approach to identify miRNAs involved in complex disorders 
by investigating the association between miRNA-SNPs and selected phenotypes. Given 
that the first phase of GWA studies are completed, this approach can be applied to a 
wide range of phenotypes and diseases to detect candidate functional SNPs in miRNAs 
and may contribute to improving the annotation of GWAS findings.
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AbsTRAcT
Background. Genome-wide association studies (GWAS) enabled us to discover a large 
number of variants at multiple genomic loci contributing to cardiovascular and meta-
bolic disorders. Since the majority of the identified variants are thought to merely be 
proxies for other functional variants, the causal variants remain to be elucidated. We 
hypothesized that part of the functional variants involved in deregulating cardiometa-
bolic genes are located in microRNA (miRNA) binding sites within gene 3’UTRs.
Methods and Results. Using data from the available GWAS on glycemic indices, lipid 
traits, anthropometric measures, blood pressure, coronary artery diseases and type 2 
diabetes, we found 11,353 variants that are associated with different cardiometabolic 
phenotypes. Of these, 191 variants (at 129 genomic loci) were located in putative miRNA 
binding sites. Thirty-four out of 191 variants were found to fulfill our predefined criteria 
for being potentially functional in their loci. Ten variants were subsequently selected 
for experimental validation based on GWAS results, eQTL analyses and evidence for 
co-expression of their host genes and regulatory miRNAs. Luciferase reporter assays 
showed allele-specific regulations of mRNAs hosting the binding site variants by 
miRNAs. These co-transfection experiments revealed that rs174545 (FADS1:miR-
181a-2), rs1059611 (LPL:miR-136), rs13702 (LPL:miR-410), rs1046875 (FN3KRP:miR-
34a), rs7956 (MKRN2:miR-154), rs3217992 (CDKN2B:miR-138-2-3p) and rs11735092 
(HSD17B13:miR-375) abrogate miRNA-mediated regulation of the genes. Conversely, 
two variants, rs6857 (PVRL2:miR-320e) and rs907091 (IKZF3:miR-326), were shown to 
enhance the interaction between miRNAs and their host genes.
Conclusion. This study provides evidence for a model in which polymorphisms in miRNA 
binding sites can both positively and negatively affect miRNA-mediated regulation of 
cardiometabolic genes.
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INTRoDucTIoN
Cardiometabolic disorders including cardiovascular disease (CVD) and a number of 
metabolic abnormalities that increase CVD risk are major worldwide health problem 
[1]. Over the past few decades, remarkable progress has been made in identifying the 
genes that are responsible for cardiometabolic disorders. The recent development of 
novel techniques, including genome-wide association studies (GWAS) has led to the 
identification of a large number of single-nucleotide polymorphisms (SNPs) and specific 
genomic loci that contribute to the induction of different cardiometabolic traits and 
diseases [2-4]. A large proportion of the identified SNPs associated with cardiometabolic 
disorders are located in non-coding regions of the genome that are responsible for fine-
tuning gene expression regulation [2, 3, 5, 6]. Many studies thus far have focused on 
annotating GWAS hits and functional variants that are located in the 3’-untranslated 
regions (3’UTR) [6, 7]. Increasing evidence suggests that the genes 3’UTRs contain regu-
latory elements that play important roles in gene expression [7, 8]. Genetic variations in 
these regions may affect gene expression through different mechanisms. This includes 
altering recognition sites for microRNAs (miRNA), RNA-binding proteins, and the polyad-
enylation machinery [8, 9]. MiRNAs play an important role in modulating the susceptibil-
ity to and onset of complex disorders, therefore, research has focused on identifying 
polymorphisms in miRNA binding sites [10, 11].
MiRNAs are small non-coding RNAs, consisting of 20-24 nucleotides, that regulate 
numerous biological processes by post-transcriptional regulation of gene expression 
[12]. MiRNAs can repress translation and, to a lesser extent, decrease the stability of 
mRNAs by interacting with the complementary sequences in the 3’UTR of target genes 
[12]. The seed sequence, which has been defined as nucleotides 2-7/8 of a miRNA, is 
essential for target recognition and regulation [12]. Genetic variation in either a miRNA’s 
seed sequence or the complementary sequence in the 3’UTR of target gene could ad-
versely affect target recognition, resulting in aberrant gene expression [10, 13]. Both 
computational and experimental studies have revealed that variants in miRNA binding 
sites can modulate the risk for disease induction by disrupting the original recognition 
site or creating an alternative binding site for miRNAs [14-17]. MiRNAs have been shown 
to regulate the expression of genes that are involved in induction of cardiovascular 
disease and regulation of various metabolic processes, such as insulin production, 
glucose homeostasis, lipid metabolism and obesity [18, 19]. However, thus far, only a 
few pathogenic miRNA-related variants have been identified that affect the regulation 
of genes associated with cardiometabolic phenotypes [10, 11, 13].
In the present study, we hypothesized that genetic variants in miRNA binding sites 
could constitute part of the functional SNPs involved in deregulating cardiometabolic 
genes. To test this hypothesis, we have investigated whether variants that were previ-
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ously identified by GWAS of cardio-metabolic phenotypes reside in miRNA binding 
sites. In addition, we linked several publicly available datasets and tools (such as GWAS 
findings, eQTL data, miRNA and gene expression profiles) and combined them with 
experimental studies to identify functional variants that can alter miRNA-mediated 
regulation of their genes involved in cardiometabolic disorders.
MATeRIAls AND MeThoDs
Retrieval of cardiometabolic-associated variants
We used data from the recent GWAS meta-analyses on 17 cardiometabolic traits and 
diseases to identify genetic variants that are associated with cardiometabolic phe-
notypes. To increase our statistical power and robustness, we used the largest GWAS 
available on these phenotypes. The GWAS summary statistics of glycemic homeostasis 
indices (fasting glucose, serum glucose after 2hr, fasting insulin, fasting pro-insulin, 
HbA1c, HOMA-B, and HOMA-IR) from the Meta-Analyses of Glucose and Insulin-related 
traits Consortium (MAGIC) [20-24], lipid phenotypes (plasma concentrations of total 
cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol 
and triglyceride) from the Global Lipid Genetics Consortium (GLGC) [2], anthropometric 
measures (body mass index and waist to hip ratio) from the Genetic Investigation of 
ANthropometric Traits (GIANT) consortium [25, 26], systolic and diastolic blood pressure 
from the Global Blood Pressure Genetics (Global BPgen) consortium [27], coronary artery 
disease from the Coronary ARtery DIsease Genome wide Replication and Meta-analysis 
plus The Coronary Artery Disease Genetics (CARDIoGRAMplusC4D) consortium [4], and 
type 2 diabetes from the DIAGRAM consortium [3] were analyzed. A description of the 
GWAS meta-analyses on these cardiometabolic phenotypes, the consortia responsible 
for these analyses and the number of SNPs associated with each trait or disease is pro-
vided in Table 1. In total 11,067 unique SNPs (in 629 genomic loci) were found to be as-
sociated with 17 cardiometabolic phenotypes at a genome-wide statistical significance 
level (p-value < 5×10-8). We calculated the number of independent SNPs using Linkage 
disequilibrium based SNP pruning in PLINK tool-set with R2 > 0.8 (http://pngu.mgh. 
harvard.edu/~purcell /plink/). On this basis, 2,369 of these SNPs were independent.
genetic polymorphisms in miRNA binding sites
Multiple target prediction algorithms including the TargetScan (http://TargetScan.org/), 
miRTarBase (http://mirtarbase.mbc.nctu.edu.tw) and miRecords (http://miRecords.
umn.edu/miRecords) data bases were used to identify genes that are predicted to be 
targeted by human miRNAs. We subsequently determined all variants were located in 
miRNA binding sites in the 3’UTR of these genes using the following online databases: 
Contribution of microRNAs to cardiovascular risk factors and disease 75
PolymiRTS [16], Patrocles [17] and miRdSNP [28]. By adding the data from these databas-
es together, we made a comprehensive dataset of all variants located in miRNA binding 
sites. Since GWAS meta-analyses on cardiometabolic phenotypes have been performed 
using the HapMap imputed data, we focused on those variants that were present in the 
list of 2.5 million HapMap SNPs, release 22 (n=23,650). No copy number variants (CNVs) 
was studied as the HapMap project does not include CNVs. The approach we used to 
determine which variants were identified as cardiometabolic-associated SNPs and were 
localized in miRNA binding sites is visualized in Figure 1.
expression quantitative trait loci (eQTls) survey
Functional polymorphisms in miRNA binding sites are expected to alter the expression 
levels of their host genes by affecting the activity of miRNAs on the target transcripts. We 
examined cis-eQTL meta-analysis data that was generated from 8,086 peripheral blood 
Table 1. Description of GWAS meta-analyses of 17 cardiovascular risk factors and disease used in this study
Phenotype consortium sample size All gwAs 
associated 
sNPs
miR binding site 
associated sNPs 
(loci)
glycemic indices        
  Fasting glucose MAGIC 133,010 505 10 (6)
  Glucose after2h MAGIC 42,854 4 -
  Fasting insulin MAGIC 108,557 34 -
  Pro-insulin MAGIC 10,701 407 9 (7)
  HbA1c MAGIC 46,368 188 6 (4)
  HOMA-B MAGIC 46,186 119 -
  HOMA-IR MAGIC 46,186 - -
  Type 2 diabetes DIAGRAM 12,171 cases/56,862 
controls
236 7 (4)
lipid traits
  Total cholesterol GLGC 187,000 4,146 88 (58)
  Triglyceride GLGC 178,000 3,242 60 (39)
  HDL-cholesterol GLGC 187,000 3,523 69 (47)
  LDL-cholesterol GLGC 173,000 3,058 70 (43)
Anthropometric traits
  Body mass index GIANT 339,224 620 19 (18)
  Waist to hip ratio GIANT 224,459 725 12 (7)
cardiovascular disease
  Systolic blood pressure Global BPGen 71,225 111 2 (2)
  Diastolic blood pressure Global BPGen 71,225 88 1 (1)
  Coronary artery disease CARDIoGRM
plusC4D
63,746 cases/
130,681controls
369 13 (8)
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samples available through GeneNetwork (http://genenetwork.nl/bloodeqtlbrowser/) to 
determine the association between identified cardiometabolic SNPs in miRNA binding 
sites and the expression levels of their host transcripts. This particular cis-eQTL dataset 
was used because of its large sample size and power. In addition, two other online web 
browsers, including Genevar (http://www.sanger.ac.uk/resources/software/genevar) 
and GTEx (http://www.broadinstitute.org/gtex/), were searched for cis-eQTL data in rel-
evant tissues such as adipose tissue, liver, left ventricle, and muscle skeletal. The Genevar 
platform provides information on eQTL in adipose, skin and lymphoblastoid cell lines 
(LCLs) collected from 856 healthy female twins of the MuTHER Study [29]. To illustrate 
the strength of the correlation between alleles and gene expression levels, we used the 
eQTL plots were generated by the Genevar web tool with a subset of the MuTHER Study 
(n=160), in which the expression of target genes in both adipose tissue and blood was 
correlated to individual genotypes based on the Spearman’s rank correlation coefficient. 
SNPs determined to exhibit a cis-effect on the expression levels of their host transcripts 
(increase or decrease) were selected for further analyses.
expression of genes and miRNAs in cardiometabolic tissues
A functional pre-requisite for miRNA-dependent gene regulation is that a miRNA and its 
target mRNAs to be expressed in the same tissue [9]. To determine whether the genes 
11,067 unique SNPs in 629 genomic loci associated with 17          
cardiometabolic phenotypes (using publicly available GWAS data) 
230 3’UTR SNPs in 155 genes associated with cardiometabolic 
disorders are located in putative miRNA binding sites  
57 SNPs in 45 genes have cis-regulatory effect (cis-eQTL)  
on the expression levels of their host genes  
37 SNPs with evidence for expression of their genes and 
related miRNAs in relevant cardiovascular tissues 
10 SNPs were selected for experimental studies 
(Luciferase reporter assay) 
Figure 1. Identification of cardiometabolic-associated single-nucleotide polymorphisms (SNPs) that are located 
in miRNAbinding sites. eQTL , expression quantitative trait loci; GWAS, genome-wide association studies.
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hosting the identified SNPs and their related miRNAs express in relevant cardiovascular 
tissues, multiple web tools were used. We examined expression of the target genes 
across adipose tissue, liver, heart, skeletal muscle and blood using the Human BodyMap 
2.0 data (http://www.ensembl.info/blog/2011/05/24/ human-bodymap-2-0-data-from-
illumina/). To scan miRNA expression in cardiometabolic tissues, we used the mimiRNA 
(http://mimirna.centenary.org.au), PhenomiR (http://mips.helmholtz-muenchen.de/
phenomir), and HMDD (http://cmbi.bjmu.edu.cn/hmdd) online databases. We sub-
sequently used Pubmed to search through literature for those miRNAs that were not 
included in the above mentioned databases. Furthermore, to determine whether the 
interactions of the highlighted miRNAs and their target genes have previously been vali-
dated using functional experiments, multiple online databases, including miRTarBase, 
Tarbase (http://www.diana.pcbi.upenn.edu/tarbase) and miRwalk (http://www.umm.
uni-heidelberg.de/apps/zmf/mirwalk) were searched. Additional information on miRNA 
sequences, host genes, miRNA families and clusters, and miRNA conservation between 
species was obtained from the miRBase (release 20) and TargetScan (6.2).
selection of miRNA binding site variants for functional analysis
Specific criteria have been suggested to establish whether variants in miRNA binding 
sites are functional [9]. These criteria include an established association between the 
variant and the phenotype, the expression of the miRNA and its target gene in a relevant 
tissue and an allele-specific expression of the gene hosting the variant. We used the 
above mentioned criteria to prioritize the SNPs and experimentally examine the impact 
of a number of them on the miRNA and target mRNA interactions. Ten variants were 
subsequently selected for the validation phase based on the GWAS results (the sig-
nificance of association), the eQTL analysis (effect and p-value in a relevant tissue) and 
the evidence for co-expression of their host genes with regulatory miRNAs in relevant 
cardiometabolic tissues. In addition, when a gene is targeted by more than one related 
miRNA in our collection, the experiments were performed using a miRNA that is highly 
conserved, as the conserved miRNAs across mammals and /or primates are considered 
of functional significance [30].
luciferase reporter assay
Luciferase reporter assays were performed to first validate the selected genes as miRNA 
targets and then to investigate the effect of target site polymorphisms on the interac-
tion between miRNAs and target genes. The 3’UTR sequences of genes were amplified 
from genomic DNA of subjects homozygous for either major or minor alleles using a 
forward primer containing a XhoI restriction site and a reverse primer containing a EcoRI 
restriction site. The amplified 3’UTR fragments were subsequently cloned into the pGL3 
luciferase reporter vector downstream of the Luciferase open reading frame (Promega). 
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Similarly, mature miRNA sequences were amplified using a forward primer containing a 
XhoI restriction site and a reverse primer containing a EcoRI restriction site. The amplified 
miRNA sequences were then cloned into the MSCV-BC vector [31]. Sanger sequencing 
was performed to verify the DNA sequence of the plasmids. HEK293 cells, plated into 
12-well plates (Costar), were co-transfected with a 3’UTR luciferase reporter construct 
and a miRNA or empty vector control. Luciferase values were normalized to the Renilla 
luciferase value to correct for differences in transfection efficiencies. All experiments 
were performed in triplicate.
linkage Disequilibrium (lD) structure analysis of the validated sNPs
The list of cardiometabolic SNPs that were experimentally validated to have functional 
impact on the miRNA activity were submitted to the SNAP web tool (http://www.broad 
institute.org/mpg/snap/id) using R2 threshold > 0.8, limit distance 500 kb, and population 
panel CEU to retrieve their proxy SNPs in the HapMap project. To examine the functional 
potential of the SNPs, we utilized the HaploReg database (http://www.broadinstitute.
org/mammals/haploreg/) which predict the effect of a SNP on protein structure, gene 
regulation, and splicing using data from the ENCODE project.
ResulTs
cardiometabolic-associated variants in miRNA binding sites
A total of 11,067 unique SNPs in 629 genomic loci were identified to be associated with 
17 cardiometabolic phenotypes at a statistically significant level (p-value < 5×10-8). 
Table 1 shows a description of the cardiometabolic phenotypes, the number of vari-
ants associated with each phenotype and the consortia that generated these data. The 
proportion of these cardiometabolic-associated SNPs in different parts of the genes is 
shown in Figure 2.
 
 
Figure 2. The proportion of variants associated with cardiometabolic phenotypes in different parts of the 
genes. UTR indicates untranslated region.
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Searching through literature and various online databases, enabled us to identify 
409,853 variants that are located in putative miRNA binding sites within the 3’UTRs 
of genes. Subsequent analysis of the 2.5 million HapMap SNPs showed that 23,650 of 
these miRNA binding site variants were present in this list, indicating that around 1% 
of imputed SNPs from the HapMap project (release 22) are likely to reside in miRNA 
binding sites. We identified 16,370 independent SNPs in the collection of 23,650 miRNA 
binding site SNPs that were present in the HapMap, using the LD based SNP pruning 
function implemented in PLINK (R2 > 0.8). It is estimated that the number of independent 
common SNPs in the human genome are 1 million. This indicates that approximately 
1.7% of imputed independent SNPs from the HapMap are predicted to be in miRNA 
binding sites. Here we found 230 SNPs (157 independent SNPs) out of 11,067 SNPs 
(2,369 independent SNPs) associated with cardiometabolic phenotypes to be located 
in miRNA binding sites. Therefore, the frequency of cardiometabolic GWAS findings in 
miRNA binding sites is ~2 times larger than other parts of the genome (p-value < 0.05 as 
determined by Fisher’s exact test). If we consider the independent SNPs, this frequency 
is ~4 times higher than the expected number in other parts of the genome. The 230 
identified SNPs represent 2% and 24%, respectively, of all GWAS identified SNPs and loci 
associated with cardiometabolic phenotypes. As shown in Table s1, some of these SNPs 
were found to be associated with more than one phenotype. We generated regional 
association plots of 155 loci that harbored these 230 SNPs using the locuszoom web 
tool [33]. Many of these variants appeared to be either the lead SNP which showed the 
strongest association with phenotype in the given genomic region or were one of the 
SNPs with the strongest associations. Table s2 shows a list of miRNAs that, based on 
their binding sites, are likely to be affected by these 230 SNPs.
MiRNA binding site variants with cis-effect on the host gene expression
Cis-eQTL data was used to determine the correlation between the 230 SNPs and the 
expression levels of their host transcripts in tissues relevant for cardiometabolic pheno-
types, such as blood and adipose tissue. From 230 variants, 57 SNPs (located in 45 genes) 
were significantly associated with altered expression levels of their host transcripts 
(Table 2). More information about the observed GWAS associations of these 57 SNPs 
with cardiometabolic phenotypes are depicted in Table s3. A significant association 
was detected between the variants located in the 3’UTRs of FN3KRP, FADS1, CPEB4, LPL, 
MKRN2, GRINA, MMAB, KIAA0892 and NT5C2 and their transcripts expression levels in 
multiple tissues, suggesting the functional significance of these variants on the related 
gene expression in cardiometabolic disorders. We could generate eQTL plots for some 
of these variants using the Genevar web tool to illustrate the correlations between in-
dividuals carrying different genotypes, the eQTL plots of the eight candidate SNPs were 
shown in Figure 3 and plots of other SNPs are shown in Figure s1.
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Figure 3. Experimental validation of 7 variants that were predicted to decrease the interactions between 
miRNAs and their target genes. These experiments revealed that miRNA-mediated inhibition of FADS1, LPL, 
HSD17B13, MKRN2, CDKN2B, and FN3KRP is significantly reduced or abrogated when the 3’ untranslated 
regions harbor the minor allele (Mut). Data were depicted as fold reduction compared with empty vector 
(no miR), and wild-type (Wt) allele controls. Error bars represent SD of the mean. n=3 replicates for each 
condition. * indicates significant effect and NS means non-significant.
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expression of the identified target genes and miRNAs in relevant 
cardiometabolic tissues
Expression of a miRNA and its target genes in the same tissue is a pre-requisite for 
miRNA mediated regulation of target genes. We searched multiple online databases and 
literature to find evidence for expression of 45 genes that harbored the 57 identified 
variants with their regulatory miRNAs in cardiometabolic tissues. Table s4 shows the 
genes expression across different tissues, indicating that almost all of the studied genes 
are expressed in cardiovascular tissues. In addition, expression of their related miRNAs 
in adipose tissue, liver, heart, pancreas and skeletal muscle were investigated. These 
analyses revealed that 29 out of the 45 genes (hosting 37 of the variants) are expressed 
with their predicted miRNAs in relevant cardiometabolic tissues (Table 3).
Functional impact of miRNA binding site variants on the miRNA-mRNA 
interactions
Ten of the 37 highlighted miRNA binding site SNPs were selected for functional valida-
tion based on their GWAS results, eQTL analysis and expression of their related genes 
and miRNAs in cardiometabolic tissues, Table s5. Eight of these SNPs were predicted 
to disrupt miRNA-mRNA interactions (rs174545 (FADS1and miR-181a-2), rs1059611 (LPL 
and miR-136), rs13702 (LPL and miR-410), rs11735092 (HSD17B13 and miR-375), rs7956 
(MKRN2 and miR-154), rs2857101 (MMAB and miR-593-5p), rs3217992 (CDKN2B and 
miR-138-2-3p), and rs1046875 (FN3KRP and miR-34a)), while the other two SNPs were 
predicted to enhance the interaction between miRNAs and their target genes (rs6857 
(PVRL2 and miR-320e) and rs907091 (IKZF3 and miR-326)). The 3’UTR sequences of the 
selected genes were amplified from genomic DNA of subjects homozygous for either 
major or minor alleles and cloned into the pGL3 luciferase reporter vector (Table s6). 
All primers are shown in Table s7. In addition, mature miRNA sequences were amplified 
and cloned into the MSCV-BC vecto.r
Co-transfection of luciferase constructs with the major alleles for the 8 variants predict-
ed to disrupt miRNA-mRNA interactions with miRNAs, resulted in a significant decrease 
in luciferase activity in 7 variants (rs174545:G, rs1059611:T, rs13702:T, rs11735092:A, 
rs7956:T, rs3217992:G and rs1046875:T). This experiment confirmed that miRNAs can 
regulate the 3’UTRs harboring the wild type alleles. In addition, the co-transfection 
experiments revealed that the miRNA mediated inhibition of FADS1, LPL, HSD17B13, 
MKRN2, CDKN2B and FN3KRP is significantly reduced (p-value < 0.05 as determined by 
the Mann-Whitney test) when the 3’UTRs contain the mutant alleles (Figure 4). No sig-
nificant differences were observed between the luciferase activities of MMAB constructs 
containing either major or minor alleles (rs877710) in presence of miR-593-5p, indicat-
ing that this particular variant does not affect the miRNA-mediated regulation of MMAB 
at mRNA level.
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Similar experiments were performed to identify the role of other two variants in the 
miRNA-mRNA interactions. A dose-dependent effect was observed of miR-320e and 
miR-326 on the expression levels of PVRL2 and IKZF3, respectively, in presence of the 
minor alleles (Figure s2). The presence of a minor allele significantly increased the 
interaction between miR-320e and the 3’UTR of PVRL2 as was visualized by a decreased 
Luciferase activity (from 90% to 50%). Similarly, while co-transfection of the major allele 
construct of IKZF3 (rs907091) with miR-326, resulted in a non-significant reduction in 
luciferase activity, co-transfection of the minor allele further reduced luciferase activity 
(from 95% to 60%). These findings indicate that the mutant alleles in PVRL2 and IKZF3 
enable miR-320e and miR-326, respectively, to more efficiently regulate the expression 
of their host transcripts (Figure 5).
 
Figure 4. Plots showing the association between six of the miRNA binding site variants and expression 
levels of their host genes  generated using the Genevar data set.
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evaluation of the lD structure of the loci containing the experimentally 
validated sNPs
Proxy SNPs (R2 > 0.8 and MAF > 0.10) in strong LD with the nine selected variants were 
extracted and their predicted effects on protein structure and gene regulation, using 
the HaploReg database v3 were investigated. Detailed information of these proxies and 
their predicted functions was provided in Table s8. This data further showed that the 
nine studied variants have the potential to be functional variants in their loci associated 
with cardiometabolic phenotypes.
DIscussIoN
In this study, we performed a genome-wide scan to identify variants that may associate 
with cardiometabolic phenotypes through affecting miRNA-mediated regulation of 
cardiometabolic genes. We annotated 230 SNPs have been identified by GWAS for dif-
ferent cardiometabolic traits and diseases to miRNA binding sites. We determined that 
37 of these SNPs (representing 29 genes) fulfill our predefined criteria for being poten-
tially functional in their genomic loci. Using luciferase reporter assay for ten prioritized 
variants, we showed that rs174545 (FADS1), rs1059611 and rs13702 (LPL), rs1046875 
(FN3KRP), rs7956 (MKRN2), rs3217992 (CDKN2B) and rs11735092 (HSD17B13) decrease 
miRNA-dependent regulation of their corresponding transcripts. Conversely, rs6857 
(PVRL2) and rs907091 (IKZF3) were shown to enhance the activity of miRNAs on their 
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Figure 5. Experimental validation of two variants that were predicted to increase the interactions between 
miRNAs and their targetgenes. These variants significantly enhance miRNA-mediated regulation of their 
host genes (PVRL2 co-transfected with miR-320e, and IKZF3 co-transfected with miR-326). Data were de-
picted as fold reduction compared with empty vector (no miR), wild-type (Wt) allele controls. Error bars 
represent SD of the mean. n=3 replicates for each condition. * indicates significant effect and NS means 
non-significant.
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host transcripts. Our results suggest that allele-specific miRNA regulation of transcripts 
because of variants in miRNA binding sites could serves as a functional mechanism 
underlying GWAS findings.
Although GWAS have led to the discovery of thousands of variants that appear to 
contribute to cardiometabolic disorders, most of the identified variants are located in 
non-coding regions of the genome and their functionality remains to be investigated. 
To determine the most likely functional candidate SNPs in non-coding regions novel 
approaches are required. A potential mechanism for GWAS identified variants is to influ-
ence gene expression by affecting the interactions between miRNAs and target mRNAs. 
As the seed sequence in miRNAs have to be perfectly complementary to the miRNA 
binding site for target recognition and interaction, genetic variants in miRNA seed 
regions or miRNA binding sites can alter disease susceptibility [8, 10, 13, 15]. From the 
time that an association between a mutation in the binding site of miR-189 and the 
pathogenesis of Tourette’s syndrome has been demonstrated [14], a considerable level 
of variation in miRNA target sites has been reported. To date, catalogues and online 
databases for this variability have been developed which provide a valuable resource 
for epidemiologic studies [16, 17, 28]. However, these databases are mainly based on 
bioinformatics approaches and include only a limited number of functional annotations.
In this study, we linked several publicly available datasets and tools and combined 
them with experimental studies to identify the likely functional variants located in the 
3’UTR of cardiometabolic genes. We identified 230 cardiometabolic risk SNPs that were 
predicted to either abolish the existing miRNA binding sites or create new putative 
binding sites. This number is higher than the expected by chance and may suggest 
an enrichment of GWAS findings in miRNA binding sites. In addition, since miRNAs are 
highly conserved, and negative selection is stronger on their putative binding sites than 
on other conserved sequence motifs in the 3’UTR of genes [34], the vast majority of 
miRNA binding site variants are rare and absent in the GWAS data imputed from the 
HapMap project. Therefore, a higher enrichment level of cardiometabolic-associated 
variants in miRNA binding sites can be expected if dense genotyping methods (GWAS 
from 1000 genome imputed data) or sequencing will implement in association studies.
Specific criteria have previously been suggested to establish whether variants in 
miRNA binding sites are functional, including an established association between the 
variant and the phenotype, the expression of the host gene and regulatory miRNA in 
a relevant tissue and an allele-specific expression of the host gene [9]. We determined 
37 from the 230 SNPs that were found to be associated with cardiometabolic pheno-
types and located in miRNA binding sites fulfill the above-mentioned criteria for being 
functional. These 37 SNPs are likely functional candidate variants in their genomic loci 
and propose for experimental validation studies. These data may also indicate that ap-
proximately 16% of SNPs that are located in miRNA binding sites could be functional.
Contribution of microRNAs to cardiovascular risk factors and disease 91
Ten SNPs were selected for functional validation. Our results, first demonstrate the 
interaction between studied miRNAs and the 3’UTRs of FADS1 (miR-181a-2), LPL (miR-
136 and miR-410), HSD17B13 (miR-375), MKRN2 (miR-154), CDKN2B (miR-138-2-3p) and 
FN3KRP (miR-34a), resulting in reduced gene expression. We subsequently showed that 
the miRNA-dependent regulation of these genes is significantly decreased when mutant 
alleles are present in their 3’UTRs. Among all, the rs1173092 mutant allele completely 
abrogates the miR-375 binding site and results in the normal expression of HSD17B13. 
Other variants partially disrupt their related miRNA binding sites. This variability in dis-
rupting the miRNA binding sites may be fully explained by compensation of the miRNA 
binding to its target by match sequences outside the “seed” that is called “compensatory 
3’-end pairing [35]. In addition, the position of mutated nucleotide in a miRNA target site 
is important. Sometimes one SNP could completely disrupt the target site and strongly 
affect the binding of miRNA to the target mRNA, and sometimes just leads to the activity 
of miRNA on the target transcript with lower affinity.
Both FADS1 and its specified miRNA, miR-181a-2-3p, have been shown to be involved 
in regulation of lipid metabolism [36, 37]. In this study, we showed that the minor allele 
of rs174545 in the 3’UTR of FADS1 disrupts the binding site of miR-181a-2-3p. In addition, 
eQTL analysis revealed that carriers of this particular mutant allele display an elevated 
FADS1 expression. Thus, an allele-specific miR-181a-2-3p mediated regulation of FADS1 
expression may partly explain the observed GWAS association with lipid traits. LPL, one 
of the other genes shown to be regulated by miRNAs, exhibits a strong association with 
the levels of serum triglyceride and cholesterol and is implicated in the pathogenesis 
of cardiovascular disease [2, 38]. Its regulatory miRNAs, miR-410 and miR-136-5p, are 
highly expressed in adipocytes and are known regulators of adipogenesis [10, 39]. In 
this study, we determined that the rs13702 and rs1059611 mutant alleles can modulate 
respectively the interaction of miR-410 and miR-136-5p with the LPL 3’UTR. Similarly, 
Richardson et al have demonstrated that the interaction between miR-410 and LPL is 
disrupted by variant rs13702 [10]. Although the importance of rs13702 in disruption of 
miRNA mediated regulation of LPL expression has previously been shown, our results 
revealed that miRNA-mediated regulation of LPL can also be abrogated by variant 
rs1059611. Dysregulation of LPL by these miRNA binding site SNPs may be one of the 
functional explanation for the identified GWAS association between LPL and the level of 
serum cholesterol.
Our results demonstrated that, similar to FADS1 and LPL, mutant alleles significantly 
reduce the interactions between HSD17B13 (rs11735092) and MKRN2 (rs7956) and their 
regulatory miRNAs, miR-375 and miR-154-5p. Aberrant regulation of these genes by 
miR-375 and miR-154-5p could be a reason behind the associations between HSD17B13 
and triglycerides and between MKRN2 and total-cholesterol levels. In addition, while 
HSD17B13 has been shown to be expressed in adipose tissue, miR-375 is known to be 
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involved in regulation of glucose and lipid metabolism [40]. The expression patterns of 
both MKRN2 and miR-154-5p in adipocytes were also in accordance with our expecta-
tions [41].
CDKN2B has been shown to be associated with coronary artery disease (CAD), myocar-
dial infarction and type 2 diabetes [2, 42]. GWA and experimental studies have revealed 
that the rs3217992 minor allele is protective against incident CAD [4, 43]. MiR-138-2-3p 
has been reported to be required for normal cardiac development and function [44]. Fur-
thermore, Horswell et al have previously been exhibited that this miRNA has an effect on 
both CDKNB2 mRNA and protein levels [45]. In this study, we showed that the rs3217992 
minor allele disrupts miR-138-2-3p mediated regulation of CDKN2B, thereby increasing 
the transcript levels of the gene. These findings may indicate that allelic-specific regula-
tion of CDKN2B by miR-138-2-3p as a potential explanation for the association between 
CDKN2B (rs3217992) and the susceptibility to CAD. Finally, we revealed that although 
miR-34a-5p can interact with the wild type 3’UTR of FN3KRP, this interaction was signifi-
cantly reduced by the mutant allele (rs1046875). MiR-34a-5p is highly expressed in liver 
and plays important regulatory role in pancreatic development and insulin secretion 
[46]. The disruption of the interaction between miR-34a and FN3KRP by rs1046857 may 
provide a reason, at least in part, for the association of FN3KRP with HbA1c [23].
Although a large number of variants in 3’UTRs have been demonstrated to disrupt 
the existing miRNA binding sites, only a few studies have provided experimental 
evidence showing variants that improve the original recognition sites or create novel 
binding sites [47]. In this study, we investigated the functionality of two variants that 
were predicted to enhance the binding of miR-320e and miR-326 to PVRL2 and IKZF3, 
respectively. Previous GWAS on lipid traits have revealed associations between PVRL2 
and lipid traits and between IKZF3 and HDL-cholesterol. Furthermore, both miR-320e 
and miR-326 are highly expressed in adipose tissue and pancreas [40, 48, 49]. Lucifer-
ase experiments revealed that the mutant alleles rs6857 and rs907091 enhanced the 
binding of miR-320e to PVRL2 and miR-326 to IKZF3, respectively. It has previously been 
shown that target gene regulation requires a specific concentration of miRNAs [50]. This 
explains why, in our experiments, a dose-dependent effect could be observed. These 
results demonstrate an allele-specific regulation of PVRL2 and IKZF3 by miR-320e and 
miR-326 that may be the underlying cause of their GWAS associations with lipid traits.
A limitation of our study needs to be addressed. We tried to provide functional evidence 
for the miRNA-target gene interactions and the impact of miRNA binding site SNPs on 
these interactions. It should be noted that miRNA activities on the transcripts of interest 
are largely dependent on the cell type and expression levels of both miRNA and their 
competing targets. Therefore, it is optimal to do quantitative measure of co-expression 
for the identified genes and related miRNAs in the target cardiovascular tissues (such 
as liver, skeletal muscle or adipose tissue). In addition, the chain of evidences would be 
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more complete if we examine the influences of SNPs on post-transcriptional regulation 
of the miRNA targets. Unfortunately, we did not have a model system available to test 
expression levels of the protein products of the identified miRNA target genes in the 
right cellular context. However, to gain more insights in the function of the SNPs, we 
used the well-accepted in vitro experiments (Luciferase reporter assays) in combination 
with eQTL data, and miRNA and gene expression profiles that provide strong support for 
the functionality of these 3’UTR polymorphisms.
In conclusion, we have demonstrated that 3’UTR SNPs in miRNA binding sites can af-
fect miRNA-mediated regulation of genes involved in cardiometabolic disorders. These 
findings may improve our understanding of the roles of miRNAs in the pathophysiology 
of cardiovascular disease and metabolic syndromes. Our findings may also be of clinical 
importance since they indicate that specific miRNAs can modify gene expression profiles 
and affect cardiometabolic phenotypes. This study shows that a multidisciplinary ap-
proach, including bioinformatics, epidemiology, and molecular biology can be utilized 
to identify the most likely functional candidate variants in specific genomic regions. 
This approach could be applied to a wide range of phenotypes and may contribute to 
improving the annotation of GWAS findings.
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supplementary Table s5. Thirty-seven miRNA binding site SNPs fulfill criteria for being potentially func-
tional in their loci
sNP ID gwAs eQTl miR exp Asso. Phenotype gene miRNA Functional
rs174545 ✓✓ ✓✓ ✓✓ FG,HDL,LDL,TC,TG FADS1 miR-181a-3p Selected
rs174546 ✓✓ ✓✓ ✓✓ FG,HDL,LDL,TC,TG FADS1 miR-212-5p * High LD
rs1046875 ✓✓ ✓✓ ✓✓ HbA1c FN3KRP miR-34a-5p Selected
rs1046896 ✓✓ ✓✓ ✓✓ HbA1c FN3KRP miR-208a-3p *High LD
rs11735092 ✓✓ ✓✓ ✓✓ TG HSD17B13 miR-375 Selected
rs3217992 ✓✓ ✓✓ ✓✓ CAD CDKN2B miR-138-3P Selected
rs877710 ✓✓ ✓✓ ✓✓ HDL MMAB miR-593-5p Selected
rs1059611 ✓✓ ✓✓ ✓✓ HDL,TG LPL miR-136-5p Selected
rs907091 ✓✓ ✓ ✓✓ HDL IKZF3 miR-326 Selected
rs6857 ✓✓ ✓ ✓✓ TG, LDL, HDL,TC PVRL2 miR-320e Selected
rs7956 ✓ ✓✓ ✓✓ TC MKRN2 miR-154-5p Selected
rs13702 ✓ ✓✓ ✓✓ HDL,TG LPL miR-410 Selected
rs11350 ✓✓ ✓✓ ✓✓ HDL SLC7A6 miR-548e-5p Validated
rs11700 ✓✓ ✓✓ ✓ HDL E2F4 miR-520f-5p **
rs1063966 ✓ ✓✓ ✓✓ TG GATAD2A miR-30b-3p **
rs1572343 ✓ ✓✓ ✓✓ HDL TMED5 miR-511-5p **
rs4938353 ✓ ✓✓ ✓✓ TG, TC, HDL SIDT2 miR-183-3p **
rs1050488 ✓ ✓✓ ✓✓ TC NSMAF miR-196a-3p **
rs1050504 ✓ ✓✓ ✓✓ TC NSMAF miR-154-3p **
rs1054284 ✓ ✓✓ ✓✓ TC GATAD2A miR-215-3p **
rs1810126 ✓✓ ✓ ✓ CAD SLC22A3 miR-124-3P **
rs8102380 ✓ ✓ ✓✓ LDL ILF3 miR-101-3p **
rs1054623 ✓ ✓ ✓✓ HDL MYO1F miR-221-5p **
rs9909 ✓ ✓ ✓✓ Pro-Ins, HDL NUP160 let-7f-2-3p **
rs1052248 ✓ ✓ ✓✓ TC LST1 miR-153-5p **
rs1057233 ✓ ✓✓ ✓ Pro-Ins SPI1 miR-655-5p **
rs13964 ✓ ✓✓ ✓ TG, TC, LDL KIAA0892 miR-125a-5p **
rs2285628 ✓ ✓✓ ✓ TG, TC, LDL KIAA0892 miR-199a-5p **
rs2744937 ✓ ✓✓ ✓ HDL,TC C6orf106 miR-22-3p **
rs9818870 ✓ ✓ ✓ CAD MRAS miR-664a-3p **
rs1109166 ✓ ✓ ✓ HDL LCAT miR-622 **
rs4823006 ✓✓ ✓ ✓✓ WHR ZNRF3 miR-221 **†
rs879620 ✓✓ ✓ ✓✓ BMI ADCY9 miR-126-5p **†
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supplementary Table s5. (continued)
sNP ID gwAs eQTl miR exp Asso. Phenotype gene miRNA Functional
rs8024 ✓✓ ✓ ✓✓ BMI IPO9 miR-148-5p **†
rs2531995 ✓✓ ✓ ✓ BMI ADCY9 miR-346 **†
rs12321 ✓ ✓ ✓✓ WHR ZNRF3 let-7f-2-3p **†
rs4654 ✓ ✓ ✓ WHR ITPR2 miR-454-5p **†
Shown are 37 binding site SNPs that fulfill our criteria for being likely functional in their corresponding loci. 
* These SNPs are in high LD with twoother SNPs selected for functional experiments; ** Candidate for future 
studies; †New GWAS data; Validated, the miR-mRNA interaction is validated by previous studies. Ten out of 
37 SNPs were selected for experimental study based on the following criteria:
GWAS results (✓✓: top SNP or one of the top 10% SNPs with the strongest association with the phenotype 
on the given genomic loci, ✓: SNP is associated with the phenotype).
eQTL analysis (✓✓: a very significant association of SNP with the host gene expression in the right direction 
and in different relevant tissues, ✓: an association of SNP with the host gene expression).
miRNA expression (✓✓: evidence for the expression of the regulatory miRNA in multiple relevant cardio-
metabolic tissues, ✓: evidence for miRNA expression in a relevant tissue.
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supplemental Table s6. The paired miRNA-target gene sequences candidate for functional experiments.
miRNA and target gene corresponding sequences binding site variant
  miR-34a
FN3KRP (Major A allele)
FN3KRP (Minor G allele)
3’ uguuggucgauucuGUGACGGu 5’
| | | | | | |
5’ cauagguaccuuucCACUGCCu 3’
5’ cauagguaccuuucCgCUGCCu 3’
rs1046875
mirSVR score: -0.1433
PhastCons score: 0.4468
  miR-181a-2
FADS1 (Major G allele)
FADS1 (Minor C allele)
3’ ccauGUCA-GUUGCCAGUCACCa 5’
: : | |  | |  :  | | | | | | |
5’ ucacUGGUCCAUUUCUCAGUGgc 3’
5’ ucacUGGUCCAUUUCUCAGUGcc 3’
rs174545
mirSVR score:-0.0681
PhastCons score:0.5359
  miR-136
LPL (Major T allele)
LPL (Minor A allele)
3’ agguaguaguuuUGUUUACCUCa 5’
: :  | | | | | | | |
5’ auguguggauguGUAAAuGGAGc 3’
5’ auguguggauguGUAAAAGGAGc 3’
rs1059611
mirSVR score: -0.6354
PhastCons score: 0.6850
  miR-138-2-3P
CDKN2B (Major G allele)
CDKN2B (Minor T allele 
3’ uugggaccacaGCACUUUAUCg 5’
| | |  |  | | |  | | | | | | | |
5’ CCACCUGGUUGUAUUgAAAUAGu 3’
5’ CCACCUGGUUGUAUUuAAAUAGu 3’
rs3217992
mirSVR score:-0.6073
PhastCons score: 0.5099
  miR-154
MKRN2 (Major T allele) 
MKRN2 (Minor C allele)
3’ gcUUCCGUUGUGCCUAUUGGAu 5’
| |  |  | : |  : | | | | | |
5’ ugAAAGAUAUA-AAGuAACCUa 3’
5’ ugAAAGAUAUA-AAGcAACCUa 3’
rs7956
mirSVR score:-0.2392
PhastCons score: 0.5550
  miR-593-5p
MMAB (Major G allele)  
MMAB (Minor C allele)  
3’ ACUCGUUACGGA----CCGACCACGGa 5’
| | :  :  | | | | | |  |  :  | | | | | |
5’ UGGCUUAUGCCUCUGAGAUCgGUGCCa 3’
5’ UGGCUUAUGCCUCUGAGAUCcGUGCCa 3’
rs877710
mirSVR score:NA
PhastCons score: NA
  miR-410
LPL (Major T allele)
LPL (Minor C allele)
3’ uguccggUAGACACAAUAUAa 5’
| | | | | | | | |
5’ uccgaaaAACUUUGUuAUAUa 3’
5’ uccgaaaAACUUUGUcAUAUa 3’
rs13702
mirSVR score:-1.1589
PhastCons score: 0.6217
  miR-375
HSD17B13 (major A allele)
HSD17B13 (Minor G allele)
3’ agugCGCUCGGCUUGCUUGUUu 5’
|  | | : |  | | | | | | | | |
5’ agcaGC-AGUCAAACGAACAAg 3’
5’ agcaGC-AGUCAAACGgACAAg 3’
rs11735092
mirSVR score: -0.7667
PhastCons score: 0.5849
  miR-326
IKZF3 (Minor A allele)
IKZF3 (Major G allele)
3’ CCUCCAGUUCCCGGGUCUCC 5’
| | |  | |  | | | | | | |
5’ GGAAUGAGUGGUCCCAGAGA 3’
5’ GGAAUGAGUGGUCCCgGAGA 3’
rs907091
mirSVR score: NA
PhastCons score: NA
  miR-320e
PVRL2 (Minor T allele)
PVRL2 (Major G allele)
3’ GGAAGAGUUGGGUCGAAA 5’
| |  | : : | | | | | |
5’ CUGUUGAUCCCUUAGCuUUc 3’
5’ CCTTGATGGCCCCAGCcTTG 3’
rs6857
mirSVR score: -0.085
PhastCons score: 0.5628
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AbsTRAcT
Background. MicroRNAs (miRNAs) serve as key post-transcriptional regulators of gene
expression. Genetic variations in miRNAs and miRNA-binding sites can affect miRNA
function and contribute to disease risk.
Methods and results. We investigated the extent to which variants within miRNA-related
sequences could constitute a part of the functional variants involved in Alzheimer’s
disease (AD), using the largest available genome-wide association study. First, among
237 variants in miRNAs, we found rs2291418 in the precursor miR-1229 sequence to be
significantly associated with AD (p-value= 6.8×10-5, OR= 1.2). Our in silico analysis and
in vitro miRNA expression experiments demonstrated that the variant’s minor allele en-
hances the production of miR-1229-3p. Next, we found miR-1229-3p target genes that
are associated with AD and might be downstream targets of the miRNA in relation to
AD. Among them, we demonstrated that miR-1229-3p directly controls the expression
of its top AD-associated target gene (SORL1) using luciferase reporter assays. Addition-
ally, we showed that miR-1229-3p and SORL1 are both expressed in the brain. Second,
among 42,855 variants in miRNA-binding sites, we identified 10 variants (in the 3’UTR
of 9 genes) that are significantly associated with AD, including rs6857 that increases
miR-320e-mediated regulation of PVRL2.
Conclusion. Our results demonstrate that variants in miRNA-related sequences are as-
sociated with AD and may affect miRNA-dependent regulation of AD genes.
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INTRoDucTIoN
Alzheimer’s disease (AD) is the most common form of age-related neurodegenerative
diseases worldwide manifested by the progressive loss of memory and cognitive decline
[1]. A number of cellular and molecular mechanisms lead to AD occurrence [2-4]. Over
the past few decades, enormous efforts have been made to discover risk factors that
play a role in development of AD and new biomarkers that may help in early diagnosis
of AD [5, 6]. Recently, microRNAs (miRNAs), a class of small non-coding RNAs with 20–24
nucleotides (nt) long, have gained widespread attention as important modulators of
different biological processes. They have been shown to be involved in biological and
pathological processes in the brain [7-9]. In addition, a number of dysregulated miRNAs
have been reported to be associated with AD and are suggested as potential diagnostic
biomarker for AD [10-12]. MiRNAs repress translation or decrease the stability of target
messenger RNAs (mRNAs), by binding of the nucleotides 2-7/8 from their 5’ end (known
as the seed region) to complementary sequences in the 3’ UTR regions of target mRNAs
[13]. MiRNAs are predicted to regulate the translation of more than half of all protein
coding genes, indicating the involvement of miRNAs in most cellular processes [14].
Genetic variants in miRNA-encoding sequences can affect miRNA biogenesis and
function [15, 16]. Furthermore, variants that are located in the seed-matching regions
of target genes may interfere with the interaction between miRNA and its target genes,
resulting in an altered expression level of the target transcript [17, 18]. More recently,
we and others have been able to show a number of variants in genomic sequences
encoding miRNAs or in the 3’UTRs of miRNA target genes that contribute to phenotypic
variations and disease risk [18-22]. However, the association of such variants with the
risk of AD has not yet been systematically investigated.
In the present study, we hypothesized that miRNA-related variants could constitute a
part of the functional genomic variants influencing the risk of AD. To test this hypothesis,
we investigated the association of all genetic variants located in miRNA genes as well as
miRNA-binding sites in the 3’ UTR of coding genes with risk of AD using data from the
largest available GWAS on late-onset AD [23]. We subsequently integrated our results
with publicly available databases (e.g. miRNA and gene expression profiles) and per-
formed experimental studies to provide evidence for the potential function of identified
variants in relation to AD.
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MATeRIAls AND MeThoDs
Identification of genetic variants in miRNAs and miRNA-binding sites
We made a data set of genetic variants that are located in miRNA-related sequences
using two online databases: miRNASNP and PolymiRTS [24, 25]. The mature miRNAs of
20–24 nt in length are produced by processing of the precursor miRNAs (pre-miRNA)
(60-80 nt). We thus investigated all variants that are located in human precursor and
mature miRNA sequences. We retrieved a total of 2,420 variants in all miRNA-encoding
sequences. We excluded variants with minor allele frequency (MAF) < 0.01. Of these, we
included 237 single-nucleotide polymorphisms (SNPs) in 206 different miRNAs that were
available in the recent GWAS of AD [23]. In addition, we retrieved almost 401,000 vari-
ants in the 3’UTR of human miRNA target genes that are predicted to affect the match
to the seed region of miRNAs. We included 42,855 SNPs with MAF> 0.01 and available in
the AD GWAS [23].
genome-wide association study on AD
To examine the association of variants in miRNA-related sequences with AD, we used
the summary statistics data (stage 1) from the thus far largest GWAS on late-onset AD,
including data from 17,008 AD cases and 37,154 controls on 7,055,881 SNPs, was re-
ported by IGAP consortium. A description of the consortium data sets and participants
are described elsewhere [23]. We adjusted p-value using the Bonferroni correction for
the number of tests and significant threshold was set at 2.1×10-4 (0.05 /237) for SNPs in
miRNAs and 1.2×10-6 (0.05 / 42,855) for SNPs in miRNA-binding sites.
Prediction of the variant effect on the miRNA structure
When a miRNA-variant was associated with AD, we used the Vienna RNAfold algorithm
(ViennaRNA package 2.0) to predict the effect of that variant on the secondary structure
of the pre-miRNA (hairpin structure) [26]. The differences in minimum free energy (MFE)
of the thermodynamic ensemble of pre-miRNA sequences containing the mutant versus
the wild type alleles may affect the pre-miRNA that is processed to form mature miRNA.
Impact of variant on the miRNA expression
We cloned the pre-miRNA sequence containing either wild type or mutant allele behind
the gene encoding green fluorescent protein (GFP) in the expression plasmid MSCV-BC 
(Murine Stem Cell Virus-Bar Coded) [27], resulting in GFP-miRNA fusion transcripts. The
inserts of all constructs were validated by Sanger sequencing. HEK293 cell transfection,
total RNA isolation and quantitative PCRs were performed as previously described [27].
All primers are shown in Table s1. The experiment was performed in triplicate.
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Association of miR-1229-3p target genes with AD
We compiled a list of all predicted target genes of candidate miRNA using two online
databases, TargetScan v7.0 [28] and miRanda [29]. The miRNA target genes that are
listed in both databases were used for our analyses. We then examined which of the
miRNA putative targets are expressed in the human brain using the Human Body Map
2.0 data. Subsequently, we used the AD-GWAS data in a candidate gene approach to
identify those target genes that are likely to be involved in AD. We retrieved the sum-
mary statistics for the association of all genetic variants in the miRNA target genes with
AD from the GWAS data. The significance threshold was set using the Bonferroni correc-
tion based on the number of studied SNPs. Additionally, we explored whether target
genes of the identified miRNA may play a role in neurologic-related pathways. To do this,
we used Ingenuity Pathway Analysis (IPA) (http://www.ingenuity.com/products/ipa/), a
knowledge database generated from peer-reviewed scientific publications that enables
the discovery of highly represented biological mechanisms, pathways or functions most
relevant to the genes of interest from large, quantitative datasets. We uploaded all
miRNA target genes and performed a core IPA analysis with default settings. We mapped
the miRNA target genes to biological functions or canonical pathways to see whether
they are enriched in neurologic-related networks.
luciferase reporter assay
Primers were designed to amplify the 3’UTR sequence of target gene included in the
restriction enzyme sites XbaI for the forward primer and ApaI for the reverse. The gene
3’UTR sequences (wild-type and mutated), containing the putative binding site of
miRNA, were amplified and cloned into the pGL3 luciferase reporter vector downstream
of the Luciferase open reading frame (Promega). The primers are shown in Table s2.
Similarly, mature miRNA sequence was amplified using a forward primer containing a
XhoI restriction site and a reverse primer containing a EcoRI restriction site. The amplified
miRNA sequence was then cloned into the pMSCV-BC vector as previously described
[27]. The inserts of all constructs were validated by Sanger sequencing. HEK293 cells
were plated into 96-well plates and co-transfected with MSCV-miRNA, pGL3 containing
the different 3’UTR and a plasmid expressing the Renilla transfection control. Luciferase
activity was determined with the Dual-Glo Luciferase Assay System according to manu-
facturer’s protocol (Promega). Renilla luciferase activity was used for normalization. All
experiments were performed in triplicate.
expression of the identified miRNAs and target genes in the human brain
We examined the expression of miR-1229-3p in the human brain. The brain tissues (3
gray matter and 3 white matter) were obtained from the Netherlands Brain Bank (Am-
sterdam, The Netherlands). All samples were free of neurological disease. For isolation
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of total RNA, five cryopreserved sections of 40μm were homogenized in 250μl Trizol
reagent (Invitrogen, Carlsbad, CA, USA). Total RNA was isolated from 6 brain samples
and. the concentration and purity of RNA samples were determined with a NanoDrop
ND-1000 spectrophotometer (NanoDrop, Wilmington, DE). The expression level of miR-
1229-3p was determined with TaqMan MicroRNA Assay according to manufacturer’s
protocol (Applied Biosystems, Foster City, CA, USA). RNU6B was used as an endogenous
control. All experiments were performed in triplicate. The Human Body Map 2.0 data was
used to examine the expression of miRNA target genes across different tissues. To scan
the expression of other miRNAs in the brain, we used HMED (http://bioinfo.life.hust.edu.
cn/smallRNA/index.php) and miRmine (http://guanlab.ccmb.med.umich.edu/mirmine/
help.html) databases. Moreover, we used human miRNA expression data from four 
independent studies showing miRNAs that are differentially expressed (both up- and
down-regulated) in different brain tissues and also AD patients [30-33].
Functional characteristics of the identified miRNA-binding site variants
The list of identified variants in miRNA-binding sites associated with AD were submitted
to the SNAP web tool (http://www.broadinstitute.org/mpg/snap/id) using R2 threshold
> 0.8, limit distance 500 kb, and population panel CEU to retrieve their proxy SNPs in
the 1000 Genomes project. We used the HaploReg (v4) web tool to predicts the effect of
these SNPs on protein structure, gene regulation, and splicing. This analysis helps us to
know whether there are other variants in high LD with the identified SNPs that may drive
the association with AD. We scanned the expression quantitative trait loci (cis-eQTL)
data using GTEx (http://www.broadinstitute.org/gtex/) and HaploReg (4.1) that show
the correlation of the variants with the expression of nearby genes in several tissues
[34, 35]. Other information, including miRNA sequences, host gene, miRNAs family and
cluster amongst others, and miRNA conservation in different species was obtained from
miRBase (release 20) [36] and TargetScan (v7.0) databases.
ResulTs
A polymorphism in miR-1229 was associated with AD
A flow chart of our approach to detect genetic variants in miRNAs and in miRNA-binding
sites associated with AD is shown in Figure 1. Out of 237 variants located in 206 miRNAs,
we found rs2291418:A>G (Chr5:179225324), a low-frequency variant (MAF= 0.02) in the
pre-miR-1229 sequence, to be significantly associated with the risk of AD (p-value=
6.8×10-5 and OR= 1.2). Figure s1 shows the association of rs2291418 and other variants
in the related locus with AD. The associations of all miRNA-variants that are nominally
(p-value < 0.05) associated with AD are shown in Table s3.
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Impact of rs2291418 on the miR-1229 structure and expression
We generated the pre-miR-1229 hairpin structures containing the rs2291418 major
allele (G) and minor allele (A) using the Vienna RNAfold algorithm [26]. We observed a
-4.2 kcal/mol difference in the minimum free energy of the thermodynamic ensemble
of the predicted structure of pre-miR-1229 mutant compared to wild type (Figure 2).
This analysis indicated that the variant’s mutant allele enhances the stability of the pre-
miR-1229 hairpin, suggesting an improvement of the pre-miRNA processing into the
mature miR-1229.
To experimentally show the impact of rs2291418 on the pre-miR-1229 processing,
we examined the expression levels of mature miR-1229 from the wild type and mutant
 
All genetic variants in miRNA genes 
n= 2,420 
237 variants in 206 miRNAs present  
in the AD-GWAS data 
One SNP in the pre-miR-1229 sequence 
was associated with AD 
The SNP affects the expression of  
miR-1229-3p  
Several putative targets of miR-1229-3p  
were associated with AD 
Validation of miR-1229-3p-mediated regulation of 
SORL1 (the top AD-associated target gene) 
All genetic variants in miRNA-binding sites 
n= 401,000 
42,855 variants in miRNA-binding sites 
present in the AD-GWAS data 
Ten SNPs located in the 3’UTR of 9 genes 
were associated with AD 
Correlation of the SNPs with expression  
level of the host genes (cis-eQTL)  
Check the expression of host genes and 
related miRNAs in the brain 
LD structure evaluation of loci harboring the 
binding site SNPs associated with AD  
p-value < 1.2×10-6 p-value < 2.1×10-4 
Association of miRNA-related genetic variants
with AD using GWAS data  
Figure 1 Our approach to detect variants in miRNAs and miRNA-binging sites that are associated with AD.
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pre-miRNA construct. To this end, HEK293 cells were transfected with pMCSV vectors
expressing transcripts with EGFP and wild type or mutant pre-miR-1229. Both the pre-
miR-1229 wild type and pre-miR-1229 mutant transfected cells had equal levels of the
EGFP-miRNA transcripts. However, the mature miR-1299-3p levels were significantly
increased by 70% in cells transfected with pre-miR-1299 containing the mutant allele
compared to the wild-type allele (p-value= 0.002) (Figure 3), indicating that the variant
improves the processing or stability of miR-1229.
miR-1229-3p target genes associated with AD
We assessed which target genes of miR-1229-3p are implicated in pathways in nervous
system or neurological disorders and may have a role in developing AD. To this end, we
compiled a list of all predicted target genes of miR-1299-3p using the two most com-
monly used miRNA target prediction algorithms (TargetScan and miRanda) (n=960).
Both miRNA and its target genes should be expressed in the same tissue for any biologi-
cal function to be exerted. Thus, we checked the expression of miR-1229-3p in the brain.
Our data showed that miR-1229-3p is abundantly expressed (average Ct-value: 28.8) in
both white and gray matter of the human brain (Table s4). In addition, miRNA expression
rs2291418 
Pre-miR-1229 with wild-type allele G 
ΔG= -31.90 kcal/mol 
Pre-miR-1229 with mutant allele A 
ΔG= -36.10 kcal/mol 
Figure 2. Schematic view of the RNAfold predicted secondary structures of the pre-miR-1229 with the 
wild-type and the mutant allele. The pre-miRNA structure with lower minimum free energy of the thermo-
dynamic ensemble (ΔG) is expected to thermodynamically be more stable.
P = 0.002 
miR-1229-3p  
(G) 
miR-1229-3p  
(A) 
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Figure 3. The effect of rs2291418 on the expres-
sion level of miR-1229-3p. This figure illustrates a 
significant increase in the expression level of ma-
ture miR-1229-3p from the minor allele A compared 
to the major allele G relative to GFP.
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databases (HMED and miRmine) show that miR-1229-3p is expressed at higher levels in
the brain compared to other tissues, indicating an active regulatory role of miR-1229-3p
on its target genes in the brain. Using the Human Body Map 2.0 data, we subsequently
found that 750 miR-1229-3p target genes are expressed in the brain,.
We then used the AD-GWAS data in a candidate gene approach to identify those target
genes that are likely to be involved in developing AD [23]. We assessed the association of
genetic variants in the 750 brain-expressed target genes of miR-1229-3p with AD. Table 
s5 shows top ten target genes of miR-1229-3p with the most significant association
with AD. In addition, our pathway analysis using IPA demonstrated several target genes
of miR-1229-3p to be involved in the network of Nervous System Development and
Neurological disease (Table s6).
miR-1229-3p-mediated regulation of SORL1
We selected SORL1 which is the most significant AD-association target gene and exam-
ined whether miR-1229-3p controls its expression level in vitro. We generated expression
vector containing the pre-miR-1229-3p sequence and co-transfected the construct with
Luciferase reporters containing the 3’ UTR (wild-type or mutant miR-1229-3p binding
site) of SORL1. We found that over-expression of miR-1229-3p significantly decreases the
Luciferase activity of the reporter containing the wild type SORL1 fragment, compared
to the mutated SORL1 reporter (p-value= 0.003) (Figure 4). In addition, this experiment
showed a dose-dependent regulation of SORL1 by miR-1229-3p (Figure s2). As both
the miRNA and SORL1 are expressed in thebrain, our data suggest for miR-1229-3p-
mediated regulation of SORL1 in the human brain.
SORL1 mutated 
miR-1229-3p 
SORL1 wild-type 
miR-1229-3p 
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P = 0.003 
Figure 4. miR-1229-3p-mediated regulation of 
SORL1. This figure illustrates a significant decrease 
of the mean relative luciferase activity of the wild-
type 3’UTR of SORL1 reporter, compared to the 
mutated 3’UTR of SORL1 reporter in the presence of 
miR-1229-3p.
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Ten miRNA binding site variants were associated with AD
We examined the association of 42,855 variants in putative miRNA-binding sites with
AD that are illustrated in a Manhattan plot (Figure 5). Of these, ten variants located in
the 3’UTR of 9 different genes passed the Bonferroni corrected significance threshold
(p-value < 1.2×10-6). These variants would potentially interfere with miRNA-mediated
regulation of their host genes by disrupting, creating or modifying a number of miRNA-
binding sites that are depicted in Table s7. Out of 9 genes hosting the identified variants,
the association of 7 genes with AD have been reported in the original GWAS (p-value <
5×10-8) [23]. In addition, we found two new susceptibility genes to be potentially as-
sociated with AD, including DMWD (p-value= 8.48×10-7) and HBEGF (p-value= 3.96×10-7).
Regional plots showing association of the ten miRNA-binding site SNPs and their close
by variants with AD are shown in Figure s3.
Functional annotation of the miRNA-binding site variants associated with AD
We searched the literature and several web tools to identify evidence supporting the
functional role of ten miRNA-binding site SNPs associated with AD. Table s8 shows a
list of all web tools and databases that we used for our analyses. First, we examined
the cis-expression quantitative trait loci (eQTLs) for 9 genes hosting the identified SNPs.
We found that rs6857, rs2070736, rs2847655, rs10119 and rs610932 are correlated with
differential expression levels of their host genes in blood (Table 1), showing that these
SNPs alter expression levels of their host genes. In addition, the cis-regulatory effects of
Figure 5. The Manhattan plot shows the association of 42,855 SNPs in miRNA-binding sites with AD. 
Dashed line indicates the significant study threshold which was set at 1.2×10-6. Genes hosting the variants 
significantly associated with AD are highlighted. The two newly identified genes for AD are depicted in red.
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rs610932 and rs714948 on the expression of MS4A6A and PVR in cerebellum and tempo-
ral cortex have been reported [37]. Using the HaploReg web tool (v4), we found that 7 of
the identified SNPs have no non-synonymous proxy SNPs in their loci, might suggesting
the identified SNPs in miRNA binding sites to drive the observed associations (Table 
s9). The Human Body Map 2.0 data show that 8 out of the 9 host genes are expressed
in the human brain. In addition, miRNA expression databases show that miR-214-3p,
miR-212-5p, miR-204-3p, miR-362-3p, miR-450a and miR-320 are expressed in the brain.
A summary of our findings regarding on potential functionality of the ten identified
variants in miRNA-binding sites are shown in Table 1 and Table s9.
DIscussIoN
Recent studies have shown the critical role of miRNAs in neuronal development and
function [19, 38-40]. In addition, a number of miRNAs have been reported to be impli-
cated in the development of AD [7-12]. However, these studies are mainly focused on
differentially expressed miRNAs using expression arrays in a small number of samples. 
A few studies have linked miRNAs with neuro-degenerative disorders using genetic as-
sociation in a candidate gene approach [41, 42]. In this study, we performed a genome-
wide investigation to identify genetic variants in miRNAs and miRNA-binding sites that
are associated with AD using data from the thus far largest GWAS on AD [23].
We found that rs2291418 in the miR-1229 precursor, a miRNA which is abundantly
expressed in the brain, is associated with AD. The pre-miR-1299 is precursor of two ma-
ture miRNAs (miR-1229-3p and miR-1229-5p), however, the 3p miRNA has been shown
to be the predominant product [43]. In silico analysis indicated that the mutant allele
improves the stability of the hairpin structure of pre-miR-1229. Our miRNA expression
experiments further showed that the mutant allele enhances the stability of mature
miR-1229-3p. It has been shown previously that variants located at the stem region of
miRNA precursors could alter Drosha-mediated processing [22, 44, 45]. Although many
studies have shown that genetic variants within pre-miRNA sequences reduce the
mature miRNA levels [22, 44, 45], a few studies have reported such variants to enhance
miRNA processing and expression [45].
We revealed miR-1229-3p target genes that are associated with AD and might be
downstream targets of the miRNA in relation to AD. An optimal approach would have
been to check the co-expression of all potential target genes of miR-1229-3p in brain
tissues and examine their correlation with the miRNA expression to distill the potential
mediators. However, collecting samples carrying the rare mutant allele (MAF=0.03) of
miR-1229-3p is challenging and was not possible for the investigators. Alternatively,
we used GWAS data to identify the target genes that are more likely to be involved in
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the development of AD. By this approach, we could highlight a number of miR-1229-
3p target genes that are known for neurological-related pathways and diseases, such
as SORL1, MCFD2, COL25A1 and BMP2 [47-49]. This approach, however, may overlook
certain target genes that mediate the miRNA function on AD. Next, we experimentally
verified that miR-1229-3p interacts with the predicted target site in the 3’UTR of SORL1, 
the most significant AD-associated miR-1229-3p target, which is abundantly expressed
in the human brain. These data indicate that miR-1229-3p directly controls the expres-
sion of SORL1 in the brain. Several studies have reported decreased SORL1 expression
to be mechanistically involved in causing AD [49]. It has been shown that SORL1 directs
trafficking of the amyloid precursor protein (APP) into recycling pathways and that when
SORL1 is reduced, APP is sorted into amyloid beta peptide in AD [47]. Higher expression
levels of miR-1229-3p in rs2291418 mutant allele carriers may reduce SORL1 level and
subsequently increase AD risk.
We identified ten miRNA-binding site variants associated with AD. Among them,
rs6857 in PVRL2 has the most significant association with AD [50, 51]. The rs6857 mutant
allele is predicted to create a target site for miR-320e in the 3’UTR of PVRL2. Previously,
we have demonstrated that expression of the mutant PVRL2 is regulated by miR-320e,
resulting in decreased levels of the PVRL2 transcript [18]. The eQTL data also show a
correlation between the rs6857 mutant allele and lower expression levels of PVRL2. Both
PVRL2 and miR-320e are also expressed in the brain [33]. These data may indicate that
rs6857 increases AD risk through down-regulation of PVRL2 expression by miR-320e.
We found that two SNPs in miRNA-binding sites of MS4A6A and MS4A2 are associated
with AD susceptibility. The first SNP is rs610932 in the 3’UTR of MS4A6A predicted to
disrupt a binding site of miR-382-3p. MS4A6A is a well-known gene for susceptibility
to AD [37, 52, 53], and miR-382-3p is expressed in the brain. We observed that carriers
of the minor allele containing rs610932 SNP, have a higher expression level of MS4A6A 
transcript in the blood eQTL data. The variant has been also shown to be associated with
an altered expression level of MS4A6A in cerebellum and temporal cortex [37]. Therefore,
an allele-specific regulation of MS4A6A by miR-328-3p can serve as an explanation for
the observed association with AD. We also identified two SNPs in the 3’UTR of PPP1R37 
which potentially disrupt binding sites of miR-214-3p and miR204-3p. PPP1R37 gene has
previously been reported to be associated with AD and is expressed in the brain [23,
54]. Both miRNAs have been shown to be implicated in neurodegenerative disorders
including Parkinson’s and Huntington’s disease [55]. A disruption of miR-214-3p and
miR-204-3p mediated regulations of PPP1R37 may be considered as a reason for the
association of rs74846209 and rs1048699 with AD. Future experimental studies warrant
to determine the function of the variants and miRNAs in AD.
We report DMWD and HBEGF as two new susceptibility genes for AD that need to
be replicated in future association studies. Rs2070736 in the 3’UTR of DMWD creates
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potential binding sites for miR-362-3p and miR-329-3p. These miRNAs and DMWD are
expressed in the brain [32, 56] and the eQTL analysis showed that the mutant allele is
associated with lower expression level of the DMWD transcript. These data suggest that
rs2070736 may change the expression level of DMWD by affecting miRNA-mediated reg-
ulation. DMWD plays a role in developing mental symptoms in severe cases of myotonic
dystrophy [57]. Interestingly, Alzheimer’s neurofibrillary changes in brain are reported to
be present in myotonic dystrophy [58]. Together, the link between myotonic dystrophy
and AD is notable and may indicate a potential role for DMWD in AD as well. Rs7268 in
the 3’UTR of HBEGF is expected to create a binding site for miR-205-5p, a brain-expressed
miRNA. It has been reported that the membrane bound for HBEGF is constitutively ex-
pressed and present on the blood-brain barrier. HBEGF expression is also shown to be
abundantly up-regulated in cerebral blood vessels in inflammatory situations such as
AD, Parkinson’s disease, stroke, epilepsy and encephalitis [59, 60]. Therefore, the aber-
rant miR-205-5p regulation of HBEGF could be a potential mechanism underlying the
identified association.
Collectively, in a genome-wide investigation we identified a variant in pre-miR-1229
and ten variants in miRNA-binding sites associated with AD. Our in silico and in vitro anal-
yses showed a miR-1229-mediated regulation of SORL1, which is a known gene involved
in AD. Further experimental studies on the identified variants as well as miRNA profiling
in AD patients are needed to determine the role of highlighted miRNAs and target genes
in the pathogenesis of AD. Our study further suggest altered miRNA-dependent regula-
tion of genes due to variants in 3’UTRs may explain part of the associations identified
by GWAS for AD.
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Supplement available online at:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916596/
supplemental Figure  s1. Regional plot showing the association of miR-1229 variant with Alzheimer’s 
disease generated by Locuszoom web tool.
supplemental Table s5. Putative miR-1229-3p target genes with the most significant association with AD
gene sNP ID P-value gene name expression 
in the brain
*SORL1 rs11218343 4.98E-11 Sortilin-Related Receptor, L(DLR Class) A Repeats Containing 26.94
PFDN1 rs6580473 8.73E-06 Prefoldin Subunit 1 54.75
*MCFD2 rs6715234 8.82E-06 Neural Stem Cell-Derived Neuronal Survival Protein 34.90
RAB31 rs1015228 1.20E-05 Ras-Related Protein Rab-22B 61.99
LRRC32 rs1893306 3.35E-05 Leucine Rich Repeat Containing 32. 10.29
*COL25A1 rs11736110 3.63E-05 Alzheimer Disease Amyloid-Associated Protein 1.12
ZNF594 rs8081019 3.72E-05 Zinc Finger Protein 594 1.02
JARID2 rs764650 5.90E-05 Jumonji, AT Rich Interactive Domain 2 4.10
*BMP2 rs6054767 5.92E-05 Bone Morphogenetic Protein 2 2.56
RFX3 rs10972598 6.59E-05 Regulatory Factor X 3 4.60
The p-value for each target gene is p-value of the SNP in the gene with the most significant association 
in GWAS of AD (Lambert, et al., 2013). The expression values are as fragments per kb of exon per million 
reads (FPKMs), which is a measure of gene expression normalized to size of the gene and RNA-seq library 
size in the Human Body Map 2.0 data. *Genes that have been shown to be involved in neurological-related 
pathways (GeneCards database).
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AbsTRAcT
Background. MicroRNAs (miRNAs) are small non-coding RNAs that serve as key regula-
tors of gene expression. MiRNAs have been shown to be involved in a wide-range of
biological processes including neurodegenerative diseases. Genetic variants in miRNAs
and in miRNA-binding sites on their target genes could affect miRNA function and
contribute to disease risk.
Methods and results. We investigated the association of miRNA-related genetic variants
with Parkinson’s disease (PD) using data from the largest available GWAS on PD. Out
of 243 variants in miRNAs, we identified rs897984:T>C in miR-4519 (p-value= 1.3×10-5,
OR= 0.93) and rs11651671:A>G in miR-548at-5p (p-value= 1.1×10-6, OR= 1.09) to be
associated with PD. We showed that the variant’s mutant alleles change the second-
ary structure and decrease expression level of their related miRNAs. Subsequently, we
highlighted target genes that might mediate the effects of miR-4519 and miR-548at-5p
on PD. Among them, we experimentally showed that NSF is a direct target of miR-4519.
Furthermore, among 48,844 variants in miRNA-binding sites, we found 32 variants (in
13 genes) that are associated with PD. Four of the host genes, CTSB, STX1B, IGSF9B and
HSD3B7, had not previously been reported to be associated with PD. We provide evi-
dence supporting the potential impact of the identified miRNA binding site-variants on
miRNA-mediated regulation of their host genes.
Conclusion. Our findings support the idea that miRNAs play a role in PD and highlight
a number of variants in miRNA-related sequences that may affect miRNA-mediated
regulation of PD genes.
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INTRoDucTIoN
Neurodegenerative diseases collectively represent one of the major worldwide causes
of morbidity and healthcare costs to society [1]. Parkinson disease (PD) is the second
most common neurodegenerative disorder [2], and its prevalence and burden at the
population level are projected to grow dramatically as the size of elderly populations in-
creases [3]. Clinically, PD is characterized by a combination of motor symptoms, known
as parkinsonism, and a range of non-motor symptoms, such as cognitive decline and
autonomic dysfunction, that contribute to a devastating loss of quality of life [4, 5]. PD
is a complex disease, and genetic factors have a substantial impact on the phenotypic
variation of the disease [6]. Over the past few decades, enormous efforts have been
done to discover genetic factors that play a role in development of PD. In recent years,
the large-scale genome-wide association studies (GWAS) have enabled the discovery of
hundreds genetic variants that are associated with PD [7, 8]. Nevertheless, most of the
identified variants are mapped to non-coding regions of the genome, and their causal
mechanisms remain to be investigated.
MicroRNAs (miRNA) are a class of small non-coding RNAs, that post-transcriptionally
regulate gene expression [9, 10]. MiRNAs have been shown to be involved in a wide
range of biological processes and human diseases including neurodegenerative disor-
ders [11-13]. In addition, a number of dysregulated miRNAs have been reported to be
associated with PD in patients and animal models [14-16]. The regulatory functions of
miRNAs are accomplished through binding of the nucleotides 2-8 from their 5’-end (the
seed region) to the complementary sequences at the target mRNAs, resulting in repres-
sion of translation or a decreased stability of target mRNAs [9, 10]. Genetic variants that
fall in miRNA-related sequences may affect miRNA function and due to aberrant expres-
sion of the miRNA target genes, the variants could modify susceptibility to disease [17].
Recently, we and others have been able to show a number of polymorphisms in miRNAs
or their target genes that may contribute to phenotypic variations [18-22]. Further,
no systematic investigation of the impact of such variants on the risk of PD has been
published to date.
In this study, we examined the association of variants in miRNAs as well as miRNA
binding sites with PD using data from the largest available GWAS. We integrated GWAS
findings with various in silico information and performed experimental studies to pro-
vide evidence for functionality of the miRNA-related variants associated with PD.
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MATeRIAls AND MeThoDs
Identification of genetic variants in miRNAs and miRNA-binding sites
We retrieved genetic variants that are localized in miRNAs and in miRNA binding sites 
within the 3’UTR of their target genes by reviewing the literature and using two online 
databases: miRNASNP (v2.0) [23] and PolymiRTS (v3.0) [24]. We retained a total of 2,420 
variants in all human precursor (60-80 nt) and mature (20-24 nt) miRNA sequences. We 
excluded variants with minor allele frequency (MAF) < 0.01. Of the remaining variants, 
we included 243 single-nucleotide polymorphisms (SNPs) in 214 miRNAs that were pres-
ent in the recent GWAS of PD [8]. Furthermore, we retained around 401,000 miRNA bind-
ing site-variants that were predicted to affect the match to the seed region of miRNAs. 
Of these, 48,845 SNPs with MAF > 0.01 and present in the GWAS of PD were included 
(Figure 1).
genome-wide association study on PD
We examined the association of retrieved variants in miRNAs and miRNA-binding sites 
with PD using summary statistics data from the largest GWAS on PD across 13,708 PD 
cases (39% female) and 95,282 controls (46% female) [8]. The GWAS data were imputed 
to 1000 Genomes project reference panel, providing data for 7,893,274 variants. All 
participating studies in the PD-GWAS had provided informed consent for participation 
in genetics studies and were approved by their local ethical committees. More details 
about the consortium and participants are described elsewhere [8]. We used the Bon-
ferroni correction, to adjust p-value for the number of tests, and significant threshold 
was set at 2.06×10-4 (0.05 / 243) for variants in miRNAs and 1.02×10-6 (0.05 / 48,844) for 
variants in miRNA binding sites.
Analyzing the effect of miRNA variants on the miRNA structure and expression
For miRNA variants that were associated with PD, we used the Vienna RNAfold algorithm 
(package 2.0) to predict the variant effect on the hairpin structure of miRNA [25]. Dif-
ference in minimum free energy (MFE) of the thermodynamic ensemble of precursor 
miRNA (pre-miRNA) sequence containing the mutant versus the wild type allele may 
indicate an altered miRNA processing. Furthermore, to experimentally examine the 
variant’s effect on the expression level of mature miRNA, we cloned the pre-miRNA 
sequences containing either the wild type or mutant allele behind the gene encoding 
green fluorescent protein (GFP) in the expression plasmid MSCV-BC, resulting in GFP-
miRNA fusion transcripts [26]. The inserts of all constructs were validated by Sanger 
sequencing. HEK293 cell transfection, total RNA isolation and quantitative PCRs were 
performed as previously described [26]. The primers are shown in Table s1. The experi-
ment was performed in triplicate.
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quantitative-PcR of miRNAs
We examined whether miRNAs hosting the variants associated with PD are expressed
in the human brain. The brain samples were obtained from the Netherlands Brain Bank
(Amsterdam, the Netherlands). All samples were free of neurological disease. For isola-
tion of total RNA, five cryopreserved sections of 40 μm were homogenized in 250 μl Trizol
reagent (Invitrogen, Carlsbad, CA, USA). Total RNA was isolated from 6 brain samples (3
white matter and 3 gray matter). The concentration and purity of RNA samples were
determined with a NanoDrop ND-1000 spectrophotometer (NanoDrop, Wilmington,
DE). The expression levels of miRNAs were determined with TaqMan MicroRNA Assays
according to manufacturer’s protocols (Applied Biosystems, Foster City, CA, USA). RNU6B
was used as an endogenous control. All experiments were performed in triplicate.
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Figure 1. This flow chart describes our approach to identify genetic variants in miRNAs and miRNA-bind-
ing sites that are associated with Parkinson disease. MAF, minor allele frequency; LD, linkage disequilibrium.
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Association of miRNA target genes with PD
For miRNAs that were associated with PD, we further examined which of the target
genes may mediate the effect of miRNAs on PD. To do this, we extracted all predicted
target genes of the identified miRNAs using two online databases, TargetScan v7.0
(http://www.targetscan.org) [27] and miRDB (http://mirdb.org/miRDB) [28]. The miRNA
target genes that are listed in both databases were used for our analyses. Next, we used
the PD-GWAS data in a candidate gene approach to identify those target genes that are
likely to be involved in PD. We retrieved the summary statistics for the association of all
genetic variants in the target genes with PD. The significance threshold for this analysis
was set using the Bonferroni correction based on the number of studied variants. Ad-
ditionally, we performed Ingenuity Pathway Analysis (IPA) to explore the pathways in
which target genes of the identified miRNAs may play a role (http://www.ingenuity.
com/products/ipa/). A list of all putative target genes of each miRNA were uploaded and
a core IPA analysis were performed using the default settings. We mapped the miRNA
target genes to biological functions or canonical pathways to determine whether they
are enriched in neurological networks. The p-values are calculated using the right-tailed
Fisher Exact Test and a p-value less than 0.05 indicates a statistically significant, non-
random association.
luciferase reporter assay
The pre-miRNAs were amplified and cloned in pMSCV-BC as previously described [26].
The 3’UTR sequence of the candidate target gene (either wild-type or mutated), contain-
ing the putative binding site of the miRNA, were cloned downstream of the Luciferase
gene in the pGL3 vectors as previously described [26]. The primers are shown in Table 
s1 and Table s2. The inserts of all constructs were validated by Sanger sequencing. COS
cells were plated into 96-well plates and co-transfected with pMSCV-miRNA, pGL3 con-
taining the different 3’UTRs and a plasmid expressing the Renilla transfection control.
Luciferase activity was determined with the Dual-Glo Luciferase Assay System according
to manufacturer’s protocol (Promega, Madison, WI). Renilla luciferase activity was used
for normalization. All experiments were performed five times.
expression quantitative trait loci (eQTls)
We scanned cis-eQTL data to examine the correlation between miRNA-binding site
variants and the related transcript expression levels. We used two online web browsers:
Genenetwork (http://genenetwork.nl/bloodeqtlbrowser/) and GTEx V4 (http://www.
broadinstitute.org/gtex/). The GTEx platform provides information on eQTL in different
tissues including brain. In addition, we used the eQTL data in whole blood from the
Gene network because of a very large sample size (n= 5,311). The designs of these stud-
ies have been described in detail elsewhere [29, 30].
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expression of the identified target genes and related miRNAs in the brain
To search for expression of the identified target genes and their regulatory miRNAs in
relevant tissues, we employed several web tools. The Illumina’s Human Body Map 2.0
data (http://www.ensembl.info/blog/2011/05/24/human-bodymap-2-0-data-from-
illumina/) were used to examine the expression of the genes hosting miRNA binding
site-variants across different tissues. This database provides RNASeq data of 16 human
tissue types, including brain. To scan the expression of related miRNAs in the brain, we
used the Human MiRNA Expression Database (HMED) [31], mimiRNA [32] and PhenomiR 
[33] databases. We further searched the literature via PubMed using the search terms of
miRNA ID and expression for those not implicated in the listed databases.
Analyzing functional characteristics of the identified miRNA binding site-
variants
We evaluated LD blocks of the identified miRNA binding site variants to examine whether
there are other SNPs in high LD in the related loci that may drive the observed GWAS
associations. To this end, the list of PD-associated variants in miRNA binding sites were
submitted to the SNAP web tool (http://www.broadinstitute.org/mpg/snap/id) using R2 
threshold > 0.8, limit distance 500 kb, and population panel CEU to retrieve their proxy
SNPs in the 1000 Genomes project. We then utilized the HaploReg web tool v3 (http://
www.broadinstitute.org/mammals/haploreg/haploreg_v3.php) to predict the effect of
SNPs on protein structure, gene regulation, and splicing. Other information, including
miRNA sequences, miRNA host genes and miRNA conservation in different species was
obtained from TargetScan v7.0 and miRBase (release 20) [34] databases.
ResulTs
Two miRNA variants were associated with PD
We studied the association of 243 SNPs (with MAF > 0.01) located in 214 miRNAs with PD.
Of these, rs11651671:A>G (Chr17:42494785) in miR-548at-5p (p-value= 1.06×10-6, OR=
1.09) and rs897984:T>C (Chr16:30875322) in miR-4519 (p-value= 1.34×10-5, OR= 0.93)
were significantly associated with PD. Table s3 shows miRNA variants that are associ-
ated with PD with a p-value < 0.05. The forest association plots showing meta-analysis
of the association of the two identified miRNA variants with PD are shown in Figure s1.
The effect of variants on miR-4519 and miR-548at-5p structure and expression
We generated the hairpin structures of miR-4519 and miR-548at-5p containing the wild
type and the mutant allele using the Vienna RNAfold algorithm [25]. We noted a 6.1 kcal/
mol difference in the minimum free energy of the predicted thermodynamic ensemble
164 Chapter 3.2
of the mutant versus the wild type miR-548at-5p structure (Figure s2), which may af-
fect the processing of pre-miRNA. The predicted change in minimum free energy of the
thermodynamic ensemble of the hairpin structure of miR-4519 containing the mutant
versus the wild type was 0.3 kcal/mol (Figure s3). We then examined the expression
levels of these miRNAs from two instances: the wild type pre-miRNA and the mutant
pre-miRNA. We cloned the pre-miRNAs sequences (containing either wild-type or
mutant allele) behind the GFP in the expression plasmid. Transient transfection of the
miRNAs in HEK293 cells showed significantly reduced levels of the mature miRNAs from
the mutant constructs relative to GFP compared with the wild-type constructs, where
the rs897984 mutant allele reduced the expression level of miR-4519 by 90% (p-value=
0.003) and the rs11651671 mutant allele decreased the expression level of miR-548at-5p
by 30% (p-value= 0.049) (Figure 2).
Association of miR-4519 and miR-548at-5p target genes with PD
MiRNAs act through regulation of their target gene expression. We further assessed
whether 342 putative target genes of miR-4519 and 676 putative target genes of miR-
548at-5p are implicated in neurological pathways using IPA. This analysis indicated that
several target genes of miR-4519 are directly or indirectly linked with Nervous System
Development and Function Networks, Table s4. We then examined the association of
genetic variants in all putative target genes of miR-4519 and miR-548at-5p with PD
using GWAS data. We studied 76,457 SNPs in 342 target genes of miR-4519, with the
significant threshold of 6.5×10-7, and found four target genes, NSF, TMEM163, CCNT2 and
SH3GL2, to be significantly associated with PD (Table 1). For miR-548at-5p, we assessed
153,018 SNPs in 676 target genes, with the significance threshold of 3.3×10-7, and identi-
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Figure 2. This figure shows the impact of rs897984 in miR-4519 and rs11651671 in miR-548at-5p on the ex-
pression levels of the mature miRNAs. As shown, the levels of miR-4519 and miR-548at-5p are significantly 
reduced from the mutant constructs (minor allele) relative to GFP compared to the wild-type constructs.
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fied GCH1, MMRN1, CCNT2 and DCUN1D1 to be associated with PD (Table 1). The Human
Body Map data showed that the highlighted target genes of miR-4519 and miR-548at-
5p are expressed in the brain (Table s5). Next, we asked whether the identified miRNAs
are expressed in the brain. Our data showed that miR-4519 is expressed at detectable
levels (average Ct-value: 32.5) in both white and gray matter of the human brain (Table 
s6). Subsequently, we examined whether miR-4519 control the expression level of its
top identified target gene, NSF, in vitro. We generated expression vector containing the
pre-miR-4519 sequence and co-transfected the construct with Luciferase reporters con-
taining the wild-type and mutant 3’ UTR of NSF. We found that expression of miR-4519
significantly decreases the Luciferase activity of wild type NSF reporter, compared to
the mutated NSF reporter, p-value= 2.0×10-4 (Figure 3). These data indicate that NSF is a
direct target of miR-4519.
Table 1. Association of two variants in miR-4519 and miR-548at-5p with Parkinson disease
miRNA ID sNP ID
(A1/A2)
sample size
in gwAs
oR
gwAs
p-value 
gwAs
PD-associated
target genes (p-value)
miR-4519 rs897984 (G/A) 108,990 0.93 1.3×10-5 NSF (3.9×10-29)
TMEM163 (2.7×10-13)
CCNT2 (8.6×10-9)
SH3GL2 (1.3×10-7)
miR-548at-5p rs11651671 (A/G) 108,990 1.09 1.1×10-6 MMRN1 (4.4×10-15)
GCH1 (2.0×10-10)
CCNT2 (8.6×10-9)
DCUN1D1 (8.7×10-8)
A1, Allele 1; A2, Allele 2; OR, Odd ratio; GWAS, Genome-wide association study of PD (Nalls et al., 2014). 
 The p-value for the highlighted target genes is p-value of the SNP in the gene with the most significant 
association with PD.
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Figure 3. miR-4519-mediated regulation of NSF. 
This figure illustrates a significant difference be-
tween the mean relative luciferase activity of the 
wild-type NSF 3’UTR reporter compared and the 
mutated NSF 3’UTR reporter in the presence of miR-
4519.
166 Chapter 3.2
Multiple miRNA binding site-variants were associated with PD
We examined the associations of 48,844 miRNA binding site-variants with PD, (Figure 
4). Of these, 32 SNPs located in the 3’UTR of 13 genes were significantly associated with
PD (p-value < 1.02×10-6) (Table 2). These SNPs are predicted to affect miRNA-mediated
regulation of their host genes by disrupting, creating or modifying a number of miRNA
binding sites that are depicted in Table s7 and Table s8. Out of 13 genes hosting the 32
SNPs, the association of 9 genes with PD had already been reported by GWAS [8]. Four
others have not previously reported for PD include HSD3B7 (p-value= 5.2×10-8), IGSF9B 
(p-value= 2.6×10-7), CSTB (p-value= 4.8×10-7) and STX1B (p-value= 1.2×10-7).
supporting evidence for potential functionality of the identified miRNA-
binding site variants
We searched for cis-eQTL of 13 genes hosting the 32 identified miRNA-binding site vari-
ants and found 6 SNPs that are correlated with expression levels of their host genes. This
includes rs10420958, which was associated with SPPL2B expression in the brain, and five
SNPs (including rs708723 and rs2645425) that were associated with expression levels
of CTSB and RAB7L1 in blood. Using the HaploReg web tool v3, we searched for poten-
tial functionality of the 32 SNPs and their proxies in high LD on gene regulation. This
analysis showed that some of the miRNA binding site SNPs have no proxy or only week
proxies in the related loci, such as rs8327, rs356165, rs708723 and rs1128402 (Table 3).
Figure 4. The Manhattan plot shows the association of miRNA-binding site variants (with a p-value < 0.05) 
with Parkinson’s disease. Dashed line indicates the significant study threshold (1.02×10-6).
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Table 2. miRNA binding site variants associated with Parkinson disease
sNP ID chr: position A1/A2 MAF gene P-value
gwAs
oR
gwAs
rs4763 chr17:43471489 A/G 0.14 ARHGAP27 5.0×10-8 <1
rs8327 chr17:43472507 G/A 0.24 ARHGAP27 3.5×10-9 1.21
rs16940681 chr17:43912159 C/G 0.17 CRHR1 5.0×10-8 <1
rs4482334 chr17:43912830 T/C 0.22 CRHR1 5.0×10-8 >1
rs4640231 chr17:43912786 C/G 0.22 CRHR1 5.0×10-8 <1
rs878886 chr17:43912490 C/G 0.22 CRHR1 5.0×10-8 >1
rs878888 chr17:43912635 A/G 0.22 CRHR1 5.0×10-8 >1
rs2740592 chr8:11701253 A/G 0.21 CTSB 4.8×10-7 0.91
rs2645425 chr8:11701278 A/G 0.21 CTSB 5.2×10-7 0.91
rs4839 chr8:11701933 C/T 0.21 CTSB 6.0×10-7 0.91
rs3947 chr8:11702375 A/G 0.21 CTSB 6.4×10-7 0.91
rs4583705 chr4:973036 T/C 0.14 DGKQ 1.5×10-11 1.24
rs3733349 chr4:954311 T/C 0.43 DGKQ 3.4×10-13 0.89
rs3733345 chr4:954247 T/G 0.45 DGKQ 1.0×10-14 0.88
rs4690326 chr4:953698 C/A 0.45 DGKQ 5.4×10-15 0.88
rs2305880 chr16:30999462 T/C 0.25 HSD3B7 5.2×10-8 0.91
rs3802922 chr11:133786945 C/A 0.19 IGSF9B 2.6×10-7 1.11
rs3802921 chr11:133786993 C/T 0.20 IGSF9B 2.7×10-7 1.11
rs3802920 chr11:133787001 T/G 0.19 IGSF9B 3.4×10-7 1.11
rs1052594 chr17:44102689 C/G 0.20 MAPT 5.0×10-8 <1
rs11012 chr17:43513441 T/C 0.15 PLEKHM1 5.0×10-8 <1
rs62064654 chr17:43513896 T/C 0.15 PLEKHM1 5.0×10-8 <1
rs62064655 chr17:43514954 A/G 0.42 PLEKHM1 5.0×10-8 <1
rs11557080 chr1:205737739 G/A 0.23 RAB7L1 7.6×10-9 0.87
rs708723 chr1:205739266 C/T 0.44 RAB7L1 1.4×10-13 0.89
rs356165 chr4:90646886 A/G 0.48 SNCA 2.9×10-62 0.76
rs3857053 chr4:90645674 T/C 0.11 SNCA 4.3×10-25 1.34
rs1045722 chr4:90645671 A/T 0.11 SNCA 4.6×10-25 1.34
rs10420958 chr19:2353368 A/G 0.48 SPPL2B 4.9×10-7 0.92
rs1128402 chr19:2353150 A/C 0.28 SPPL2B 8.4×10-9 1.12
rs8060857 chr16:31002720 G/A 0.24 STX1B 1.2×10-7 0.91
rs748483 chr4:952409 G/A 0.14 TMEM175 1.8×10-16 1.22
Chr, chromosome; A1, ancestor allele; A2, alternative allele; MAF, Minor Allele Frequency in 1000G CEU; OR, 
Odd ratio; GWAS, Genome-wide association study on PD.
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Furthermore, through scanning the expression of 13 host genes using the Human Body
Map 2.0 data, we found that SNCA, CTSB, MAPT and STX1B are abundantly expressed
in the brain (Table s9). We found evidence for expression of several of the regulatory
miRNAs in the brain, in particular miR-342-3p, miR-29a-5p, miR-9-5p, using the miRNA
expression databases (Table s7). A summary of the evidence that we found suggesting
the potential functionality of the identified miRNA binding site-SNPs in their related loci
are depicted in Table 3.
DIscussIoN
In this study, we investigated the association of variants located in miRNAs and miRNA-
binding sites with PD using genetic data. We found two common miRNA variants,
rs897984 in miR-4519 and rs11651671 in miR-548at-5p, that are associated with PD. We
showed that the variant’s mutant alleles have the potential to affect the hairpin second-
ary structures of pre-miRNAs and decrease the expression levels of mature miR-4519
and miR-548at-5p. We highlighted target genes that might mediate the effects of miR-
4519 and miR-548at-5p in relation to PD. We experimentally showed that NSF is a direct
target of miR-4519. Furthermore, we identified 32 miRNA binding site-variants (within
13 genes) that are associated with PD. Four of the host genes, CTSB, STX1B, IGSF9B and
HSD3B7, had not previously been reported for PD. Finally, we provide evidence support-
ing some of the identified miRNA binding site-variants to affect miRNA-mediated gene
regulation in PD.
An increasing number of studies have shown the critical role of miRNAs in neuro-
degenerative disorders including PD [35-37]. Most of these studies are mainly focused
on differentially expressed miRNAs and genes detected by expression arrays in a small
sample size. In addition, some studies have linked a number of miRNAs with neurode-
generative disorders using the candidate gene approach. For example, Saba et al. have
recently reported a catalog of SNPs overlapping miRNA-binding sites in a subset of
genes that are implicated in neurological diseases [38]. Here, we systematically inves-
tigated the association of all miRNA-related genetic variants with PD using population
level data in a large scale.
The GWAS data shows that carriers of the rs897984 mutant allele in miR-4519 have a
decreased risk of PD. Our functional experiments showed that the mutant allele dramati-
cally decreases the expression level of mature miR-4519. SNP rs897984 occurs 1 nt after
the 5’ end of pre-miR-4519 and overlaps the site of Drosha cleavage. The maturation
of miRNAs is a complex and highly regulated process, which is characterized by two-
step sequential processing by RNase III enzymes, Drosha and Dicer [39, 40]. It has been
shown that polymorphisms residing within (±)1 nt of the Drosha or Dicer cleavage sites
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may affect miRNA biogenesis [41, 42]. Therefore, the observed effect of rs897984 on the
miR-4519 level can be explained with the SNP impact on the processing of miR-4519 by
Drosha enzyme. We showed that miR-4519 is expressed in both gray and white matter
of the human brain. Interestingly, data from the GTEx database showed that miR-4519
is expressed in higher levels in substantia nigra, the primary area of the brain that is
affected by PD [43]. In agreement with our findings, two recent studies have demon-
strated this miRNA to be expressed in the human brain tissues [44, 45].
We suggested that the effect of miR-4519 on PD might be mediated by four target
genes (NSF, TMEM163, CCNT2 and SH3GL2) that were found to be potentially associ-
ated with PD. Among them, NSF showed the most significant association with PD (in
the GWAS data) and is the most abundantly expressed gene in the brain. We further
experimentally showed that NSF is a direct target of miR-4519. NSF is known as a crucial
factor in intracellular membrane-fusion events, such as the fusion of synaptic vesicles
with the presynaptic membrane during neurotransmission [46]. This gene has also been
shown to be associated with different neurodegenerative disorders including PD [47,
48]. Furthermore, previous studies have shown that expression of NSF is decreased in
PD substantia nigra [49-51]. These data may indicate that the rs897984 mutant allele
influences the risk of PD through reducing the level of miR-4519 and increasing the
expression of NSF gene.
We found that the rs11651671 mutant allele in miR-548at-5p is associated with an
increased risk of PD. In silico analysis indicated that the SNP rs11651671 may affect the
hairpin structure of precursor miR-548at-5p. In agreement with this conjecture, our in 
vitro experiments demonstrated that the mutant allele significantly reduces the level of
miR-548at-5p. In our expression analysis, miR-548at-5p was no detectable in the gray
and white matter of the human brain, however, we were not able to examine its expres-
sion level in more relevant tissue such as substantia nigra.
Interestingly, ATP6V0A1, which hosts miR-548at-5p in a sense direction, is abundantly
expressed in the brain tissues (using the Human Body Map data). Previous studies
have suggested that the expression of an miRNA host gene can be used as a proxy for
miRNA expression when both the host gene and the miRNA are in the same direction
[52]. Future studies are thereby needed to examine the miR-548at-5p expression in the
more relevant tissues. Moreover, our results showed four target genes of miR-548at-5p,
including GCH1, MMRN1, CCNT2 and DCUN1D1, that are associated with PD and are
likely to be potential mediators of the miRNA effects on PD. Among them, GCH1, also
called Dopa-Responsive Dystonia1, has been shown to be associated with movement
disorders including early-onset PD [53-55]. These results suggest that decreased levels
of miR-548at-5p in carriers of the rs11651671 minor allele may influence PD risk through
altering the expression of these target genes.
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We identified 32 miRNA binding site-SNPs that are associated with PD. Among 13
genes hosting the variants, SNCA (alpha-synuclein) plays an important role for normal
brain function and is a major risk factor for PD [56]. Genetic variants in SNCA have been
shown to be associated with the common sporadic form of PD [57-59]. However, some
of the associated variants are mapped downstream of the SNCA gene and a direct
functional effect is thus unlikely. SNP rs356165 is located in the 3’UTR of SNCA and is
one of the top associated SNPs with PD in the related locus. We found that the rs356165
mutant allele is predicted to disrupt a binding site of miR-6508, presumably resulting in
an elevated level of SNCA expression. An allele-specific regulation of SNCA transcript by
miR-6508 might serve as a functional explanation behind the association of rs356165
with PD. Future studies are needed to determine the effect of rs356165 on SNCA expres-
sion and the function of miR-6508 in PD patients. On the other hand, our results showed
that some of the identified miRNA-binding site SNPs improve the original recognition
sites or create new binding sites for miRNAs. For example, rs1128402 is predicted to
create a binding site for miR-29a-5p in the 3’UTR of SPPL2B. This variant is one of the
top SNPs associated with PD in the related locus and has no non-synonymous proxy. In
addition, several independent studies have shown miR-29a-5p to be involved in PD and
other neurodegenerative diseases [60-63]. Down-regulation of SPPL2B by miR-29a-5p
may be a functional reason for the association of rs1128402 with PD.
We suggested four new genes, CTSB, STX1B, IGSF9B and HSD3B7, that are potentially
associated with PD. Of these, CTSB (Cathepsin B1) encodes a protein that is known as
amyloid precursor protein secretase and is involved in the proteolytic processing of
amyloid precursor protein (APP). Incomplete proteolytic processing of APP has been
suggested to be a causative factor in Alzheimer disease [64, 65]. We found three miRNA-
binding site SNPs in the 3’UTR of CTSB that are associated with PD. Of these, rs2645425
is predicted to create a potential binding site for miR-342-3p. Using blood eQTL analysis,
we showed that rs2645425 mutant allele carriers have lower expression levels of CTSB. 
The expression data further demonstrated that the CTSB gene is abundantly expressed
in the brain. Notably, miR-342-3p has been shown to be upregulated in the brain of pa-
tients with prion disease [62, 66] and has been suggested as a biomarker for Alzheimer’s
disease [67]. The observed association of rs2645425 with PD be through increasing the
miR-342-3p-dependent regulation of CTSB. Among the other three genes, STX1B (syn-
taxin-1B) has been found to be directly implicated in the process of calcium-dependent
synaptic transmission in the rat brain and has been suggested to play an important role
in the excitatory pathway of synaptic transmission [68]. IGSF9B is known as Immuno-
globulin Superfamily Member 9B and has reported as a novel, brain-specific, homophilic
adhesion molecule that is strongly expressed in GABAergic interneurons [69]. Finally,
HSD3B7 has been shown to be associated with congenital bile acid synthesis defect and
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liver diseases [70]. This gene has also been linked with the etiology of Alzheimer disease
through deactivation pathway of LXR ligands in the brain [71].
Collectively, we identified two miRNA variants and multiple miRNA binding site vari-
ants that are associated with PD and could potentially affect miRNA-mediated regula-
tion of a number of genes involved in PD. These results may contribute to increase our
understanding of the role of miRNAs in the pathogenesis of PD. Our findings may also
be of clinical importance as they suggest a number of miRNAs that modify gene expres-
sion profiles and affect PD risk. Experimental assays of the identified variants and miRNA
profiling in PD patients will be the next step towards determining the functionality of
the variants, related target genes, and miRNAs in PD.
Supplement available online at:
http://onlinelibrary.wiley.com/doi/10.1002/humu.22943/suppinfo
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AbsTRAcT
Background. Age-related macular degeneration (AMD), the leading cause of blindness
in the elderly, is a complex disease that results from multiple genetic and environmental
factors. MicroRNAs (miRNAs) are small non-coding RNAs that post-transcriptionally
regulate target mRNAs and are frequently implicated in human disease.
Methods and Results. Through a genome-wide scan, we investigated the association
of genetic variants in miRNAs and miRNA-binding sites within gene 3’UTRs with AMD
using data from the largest AMD genome-wide association study. First, we identified
three variants in miRNAs significantly associated with AMD. These include rs2168518
in the miR-4513 seed sequence, rs41292412 in pre-miR-122/miR-3591 and rs4351242
in the terminal-loop of pre-miR-3135b. We demonstrated that these variants reduce
expression levels of the mature miRNAs in vitro and pointed the target genes that may
mediate downstream effects of these miRNAs in AMD. Second, we identified 54 variants
(in 31 genes) in miRNA-binding sites associated with AMD. Based on stringent prioritiza-
tion criteria, we highlighted the variants that are more likely to have an impact on the
miRNA-target interactions. Further, we selected rs4151672 within the CFB 3’UTR and
experimentally showed that, while miR-210-5p downregulates expression of CFB, the
variant decreases miR-210-5p-mediated repression of CFB.
Conclusion. Our findings support the notion that miRNAs may play a role in the patho-
genesis of AMD.
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INTRoDucTIoN
Age-related macular degeneration (AMD) is the primary cause of irreversible vision loss
in the elderly, estimated to affect around 200 million people by 2020 [1]. The disease is
characterized by loss of function of the retinal pigment epithelium (RPE) and subsequent
loss of photoreceptors in the macula [2]. The early stages of AMD are characterized by
yellow-white deposits called drusen, while advanced stages of the disease are character-
ized by either geographic atrophy of the RPE (dry AMD) or choroidal neovascularization
(wet AMD) [2]. Susceptibility to AMD is influenced by multiple genetic variants as well as
environmental and lifestyle factors such as smoking [3]. Recent genome-wide associa-
tion studies (GWAS) have identified a large number of variants and genomic loci associ-
ated with AMD [4, 5]. Most of the associated variants, however, are located in regions of
the genome that do not encode proteins [5]. The non-coding regions are responsible
for fine-tuning regulation of gene expression and genetic variants in these regions can
be linked to human diseases [6]. These include variants located in microRNAs (miRNAs)
and their binding sites within the 3’-untranslated region (3’UTR) of coding genes [7, 8].
MiRNAs are defined as small non-coding RNAs, consisting of 19-22 nucleotides, that
post-transcriptionally regulate gene expression [9]. The biogenesis of miRNAs is a multi-
step coordinated process and miRNA transcripts need to fulfill structural and sequential
prerequisites in order to result in expression of the correct mature miRNAs [10]. In the
nucleus, miRNA genes are initially transcribed as long primary transcripts (~1000 nt)
containing an extended stem-loop structure called a pri-miRNA. These transcripts fold
into a hairpin shaped structure and are processed by an RNase-III enzyme, Drosha,
into a smaller (~70 nt) hairpin precursor miRNA (pre-miRNA). After being transported
to the cytoplasm, a second RNase-III enzyme, Dicer, cleaves the loop structure of the
pre-miRNA, resulting in a mature miRNA (~20 nt). The mature miRNA is subsequently
incorporated into the RISC complex, and the active complex interacts with the 3’UTR
of a target mRNA, resulting in mRNA degradation or translational repression [11, 12].
Sequence variability in miRNAs or in their binding sites could affect miRNA function,
resulting in aberrant gene expression. Previous computational and experimental studies
have shown that such variants may have a significant impact on disease risk [8, 13-15].
There are strong indications that miRNAs play a role in the pathogenesis of AMD. For
example, miR-23 and miR-27 are involved in angiogenesis of choroidal neovasculariza-
tion [16], and miR-184 promotes RPE degeneration in vitro [17]. In addition, a number of
miRNAs have been reported as potential diagnostic biomarkers or therapeutic targets for
AMD [18, 19]. Nevertheless, these studies are mainly focused on differentially expressed
miRNAs detected by expression arrays in a small sample size, which makes it difficult
to extrapolate their results to the general population. Moreover, no systematic inves-
tigation of the impact of miRNA-related genetic variation on the risk of AMD has been
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published to date. In the present study, we performed a genome-wide scan for miRNAs
associated with AMD using data from the largest available GWAS. Further, we performed
functional validation studies through various in silico and in vitro experiments to provide
evidence for the potential function of the identified miRNAs in relation to AMD.
MATeRIAls AND MeThoDs
genome-wide association studies on AMD
To study the association of genetic variants in miRNA-related sequences with AMD, we
used the publicity available summary statistics of the largest GWAS on AMD, including
1000 Genome imputed data from 16,144 advanced AMD cases and 17,832 controls on
approximately 12 million variants [5]. All participating studies in the AMD GWAS had
provided informed consent for participation in genetics studies and were approved
by their local ethical committees. More details about the AMD Gene Consortium and
participants have been described elsewhere [4, 5].
Identification of genetic variants in miRNAs and miRNA-binding sites
A total number of 2,420 variants located in precursor miRNA sequences were retrieved
from miRNASNP (v2) [20]. We excluded variants with minor allele frequency (MAF) <0.01.
Of the remaining variants, we analyzed 413 single-nucleotide polymorphisms (SNPs) in
331 miRNAs that were available in the GWAS data for association with AMD. Likewise,
we extracted almost 401,000 variants (including SNPs and INDELs) in predicted miRNA-
binding sites within gene 3’UTRs using PolymiRTS (v3) [21]. Of these, 82,051 SNPs were
included for our analysis (with MAF > 0.01 and present in the AMD GWAS data). The
Bonferroni correction was used to adjust the significance threshold for the number of
variants in each category. Manhattan and regional plots showing the association of 
miRNA-related variants and flanking variants in the corresponding loci with AMD were
generated by R and LocusZoom web tool, Version 1.1 [22].
The impact of variants in miRNA genes on the secondary structure and
expression of miRNAs
The Vienna RNAfold algorithm (package 2.0) was used to predict the effect of miRNA-
variants on the hairpin stem-loop structure of the pri-miRNAs [23]. This program cal-
culates the changes in minimum free energy (MFE) of the thermodynamic ensemble
of the hairpin structure of miRNAs (wild type and mutant). To examine the functional
impact of the variants on the expression levels of mature miRNAs, pre-miRNA sequence
containing either major or minor allele were cloned behind the gene encoding green
fluorescent protein (GFP) in the expression plasmid MSCV-BC, resulting in GFP-miRNA
Contribution of microRNAs to ophthalmic diseases 201
fusion transcripts as described previously [24]. For cloning purposes, the restriction
enzyme sites XhoI and EcoRI were inserted in forward and reverse primers, respectively.
The primers are listed in Table s1. Inserts of all constructs were validated by Sanger se-
quencing. HEK293 cells transfection, total RNA isolation and quantitative PCRs of EGFP
and miRNAs were performed as described previously [13, 24, 25]. Expression levels of
miRNAs containing the major and minor allele were calculated relative to EGFP. Experi-
ments were performed in triplicate.
expression of miRNAs in retinal pigment epithelium (RPe) cells and human
brain tissues
The retinal pigment epithelium cells (ARPE) were obtained from the Department of
Ophthalmology, Erasmus MC (Rotterdam, the Netherlands). The human brain samples
(3 gray matter and 3 white matter) were obtained from the Netherlands Brain Bank
(Amsterdam, the Netherlands) and were a kind gift of Dr. Marvin van Luijn. RNA from RPE
cells and brain cryopreserved sections was isolated using Trizol LS reagent (Invitrogen, 
Carlsbad, CA, USA) according to manufacturer’s protocols. TaqMan MicroRNA Assays
were performed according to the manufacturer’s protocols (Applied Biosystems, Foster
City, CA, USA) to determine the miRNA expression levels. RNU6B was used as an internal
control. All experiments were performed in triplicate and repeated three times.
Association of target genes of the identified miRNAs with AMD
To identify target genes that may mediate the downstream effects of miRNAs associated
with AMD, we extracted the miRNA putative target genes from TargetScan v7.0 (Total
context++ score > 0.1) (http://www.TargetScan.org/) [26]. In addition, we extracted
the miRNA validated target genes, based on crosslinking and immunoprecipitation 
sequencing data (CLIP-seq), from miRTarBase v6.0 (http://mirtarbase.mbc.nctu.edu.tw/
index.php) [27]. Next, we examined the association of genetic variants in these miRNA
target genes with AMD using the GWAS data [5]. The Bonferroni correction in this analy-
sis was set based on the number of variants in the target genes of each miRNA.
Functional prioritization of miRNA-binding site variants
To determine whether variants in miRNA-binding sites are functional, specific criteria
have been suggested (e.g. a strong association between the variant and the phenotype,
the expression of the host gene and regulatory miRNA in a relevant tissue, an allele-
specific expression of the host gene) (Table s2) [8, 28]. The miRNA-binding site variants
associated with AMD were prioritized based on these criteria (see supplementary data
for details). To this end, all proxies in high LD (R2 threshold > 0.8, limit distance 100
kb, and population panel CEU) with the binding site variants were extracted and their
effects on protein structure, gene regulation and splicing were analyzed using HaploReg
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v4 (http://www.broadinstitute.org/mammals/haploreg/haploreg.php). Further, Hap-
loReg was used to study the haplotypes and the functional potential of variants in the
corresponding loci. The correlation between the binding site variants and expression
levels of their host transcripts, were determined by GTEx V6 (http://www.gtexportal.org/
home/), which provide information on the expression quantitative trait loci (cis-eQTL) in
different tissues, and GeneNetwork (http://www.genenetwork.nl/bloodeqtlbrowser/).
Genetic variants in miRNA genes Genetic variants in miRNA-binding sites 
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and miR-3135b associated with AMD  
The effect of SNPs on the hairpin 
secondary structure of the miRNAs 
prioritization of the associated SNPs based 
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predictions of the associated SNPs  
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Figure 1 Schematic workflow of our analyses to identify miRNA-related variants associated with AMD. The 
figure shows our in silico and experimental studies to identify genetic variants in miRNAs as well as miRNA-
binding sites within gene 3’UTRs that are associated with AMD. GWAS, Genome-wide association study; 
SNP, Single-nucleotide polymorphism; MAF, Minor allele frequency.
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The Ocular Tissue Database (https://genome.uiowa.edu/otdb/) and the Illumina’s Hu-
man Body Map 2.0 (http://www.ensembl.info/blog/2011/05/24/human-bodymap-2-0-
data-from-illumina/) were used to examine the expression of genes in eye and brain 
tissues. Expression of miRNAs in relevant tissues was checked in several databases were 
screened including miRetina (http://miretina.tigem.it/index.php), miRmine (http://
guanlab.ccmb.med.umich. edu/mirmine/help.html), HMDD [29] and PhenomiR [30]. Ad-
ditional information, such as conservation of miRNA in different species, was obtained 
from miRBase (release 21) [31]. A list of all web tools and databases that were used for 
our in silico analysis is shown in Table s3.
luciferase reporter assay
Luciferase reporter assays were performed to assess the interactions between candidate 
miRNAs and the 3’UTR of their target genes. In addition, these assays were performed 
to determine the impact of miRNA-binding site variants on the expression levels of 
the target genes. Primers were designed to amplify 3’UTR sequences of miRNA target 
genes. Forward and reverse primers contained restriction enzyme sites XbaI and ApaI, 
respectively. The 3’UTR sequences, containing the putative binding site of a miRNA with 
either major or minor allele, were amplified and cloned into the pGL3 Luciferase reporter 
vector (Promega) downstream of the Luciferase open reading frame [24]. All primers 
are shown in Table s4. Inserts of all constructs were confirmed by Sanger sequencing. 
HEK293 cells were cultured in DMEM containing 10% fetal bovine serum (FBS) and 100 
units/ml penicillin/streptomycin in a 37° C incubator with 5% CO2. Cells (n=10,000) were 
plated into 96-well plates and co-transfected with 1 μg of pGL3 3’UTR constructs, miRNA 
mimic (mirVanaTM Mimics), and a plasmid expressing the Renilla Luciferase, which 
served as transfection control, using LipofectamineR RNAiMAX (Invitrogen). Empty 
3’UTR vector was used as control, to define the basal expression level of luciferase. The 
optimal miRNA concentration for regulation of the putative target was determined by 
testing increasing amounts of miRNA mimic (0, 7.5, 15, 30, 45, and 60 nmol/l). Luciferase 
activity was determined using the Dual-Glo Luciferase Assay System (Promega) accord-
ing to manufacturer’s protocol. Renilla activity was used for normalization of the data. 
All the experiments were performed triplicate and repeated in at least three times.
western blot analysis
Western blot was performed to examine the influence of miR-210-5p on the endogenous 
CFB protein levels. HEK293 and A549 cells (n=250,000) were cultured in DMEM contain-
ing 10% fetal bovine serum (FBS) and 100 units/ml penicillin/streptomycin in a 37°C 
incubator with 5% CO2. The next day, miRNA-mimic (50 pmol) was transfected using 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer’s instruc-
tions. After 48 hour (h), whole cell extracts were obtained by lysis in SDS loading buffer 
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and were heated at 95 °C for 5 min. Proteins were subjected to a 12.5% sodium dodecyl 
sulphate-polyacrylamide gel (SDS-PAGE) and separated at 120V for 100 min. Proteins 
were electrophoretically transferred onto a polyvinylidene difluoride (PVDF) membrane 
(pore size: 0.45µm, Invitrogen) for 1.5h with an electric current of 250 mA. Subsequently, 
the membrane was blocked with blocking buffer (LI-COR Biosciences, Lincoln, USA) in 
1×PBS containing 0.1% Tween-20. Membranes were incubated with primary antibodies 
overnight at 4°C. Rabbit anti-CFB (#HPA001817; Atlas Antibodies, Stockholm, Sweden) 
(1:150) antibody was diluted in 5% (mass/vol) BSA in 1×PBS containing 0.1% Tween-20 
and β-actin (1:500, mouse antibody). The membrane was washed 3 times followed 
by incubation for 1 h with goat anti-rabbit and goat anti-mouse IRDye®-conjugated 
secondary antibodies (Li-COR Biosciences, Lincoln, USA) (1:5000) at room temperature. 
β-actin levels served as standardization of sample loading. The membrane was scanned 
and bands were quantified by Odyssey Infrared Imaging System (Li-COR Biosciences, 
Lincoln, USA). The experiments were performed triplicate and repeated at least three 
times.
ResulTs
Three variants in miRNAs were associated with AMD
We tested the association of 413 variants (MAF > 0.01 and present in the AMD GWAS 
data) in miRNA-encoding sequences with AMD (Figure 1). These include 42 variants 
in miRNA seed regions, 80 variants in mature miRNAs and 291 variants in pre-miRNA 
sequences. Three variants passed the Bonferroni corrected significance threshold of p-
value < 1.2×10-4 (0.05/413). The three variants could potentially change the biogenesis 
or function of four distinct miRNAs, i.e. one of the variants overlaps two pre-miRNAs 
located on opposite strands. The variants include rs2168518: G>A (Chr15:75081078) in 
the miR-4513 seed sequence (p-value= 3.3×10-6), rs41292412: C>T (Chr18:56118358) in 
the stem regions of pre-miR-122 and pre-miR-3591 (p-value= 2.5×10-5), and rs4351242: 
C>T (Chr6:32749945) in the loop sequence of pre-miR-3135b (p-value= 4.1×10-4) (Table 
1 ). Regional association plots showing the association between the variants in the cor-
responding loci and AMD are presented in Figure s1.
The miRNA-variants affect expression levels of the mature miRNAs
The secondary structure of a pri-miRNA is critical for its biogenesis [34]. A variant’s ef-
fect on the miRNA biogenesis can be predicted by performing structural analysis of the 
miRNA hairpin [25]. We examined the changes in MFE of the thermodynamic ensemble 
of the hairpin structure of the identified miRNAs for both wild type and mutant alleles 
using the Vienna RNAfold algorithm [25]. Figure 2 shows the predicted hairpin structure 
Contribution of microRNAs to ophthalmic diseases 205
of the host miRNAs and the position of the three identified variants. The difference in 
MFE between mutant and wild type variants was 0.70 kcal/mol for pre-miR-4513 and 2.5 
kcal/mol for pre-miR-122/miR-3591, suggesting that these variants affect the structure 
of the pre-miRNA hairpins and thereby would affect miRNA maturation. In contrast, 
the change in MFE between pre-miR-3135b mutant and wild type was small (0.01 kcal/
mol). To experimentally show the impact of the variants on pre-miRNA processing, we 
determined mature miRNA expression levels for both wild type and variant miRNAs. We 
have previously demonstrated that the rs2168518 mutant allele decreases the expres-
sion of mature miR-4513 (40%, p-value= 0.005) (Figure 2) [35]. For other three miRNAs, 
we cloned the miRNA precursor sequences (wild type and mutant) behind GFP in the 
pMSCV-BC vector. HEK293 cells were transfected, resulting in expression of GFP-miRNA 
transcripts containing the wild type or mutant pre-miRNAs. Mature miRNA levels were 
significantly decreased in cells transfected with pre-miRNAs containing mutant alleles; 
(miR-3135b [70%, p-value= 0.0055], miR-122-5p [60%, p-value= 0.0021] and miR-3591-
5p [95%, p-value= 0.0003]) (Figure 2).
Potential downstream target genes of the identified miRNAs associated with 
AMD
We aimed to identify the target genes that may mediate the downstream effects of the 
four identified miRNAs in relation to AMD. Since we expect these target genes to be 
associated with AMD as well, we used the GWAS data in a candidate gene approach and 
analyzed their associations with AMD. For each of the four miRNAs, the total number of 
putative target genes and those that are associated with AMD are shown in Table s5. 
The AMD-associated target genes of these miRNAs included TIMP3 (a common target 
of miR-3135b, miR-4513 and miR-3591), C3 (a common target of miR-122-5p and miR-
3135b), ARMS2 and CFH (two targets of miR-3135b). Of these, the interactions between 
C3 and miR-3135b and miR-122-5p have been confirmed by CLIP-seq (Table 1) [27].
Table 1. Characteristics of the three variants in miRNAs associated with AMD
sNP ID MAF A1/A2 miRNA ID sNP position 
in miRNA
p-value in 
gwAs
validated target genes 
associated with AMD
rs2168518 0.39 A/G miR-4513 Seed seq. 3.3×10-6 FAM126B (4.5×10-6)
rs41292412 0.01 T/C miR-122 Stem region 2.5×10-5 C3 (3.8 ×10-69)
HLA-DQA1 (1.1×10-13)
      miR-3591 Mature seq. 2.5×10-5 SERPINH1 (1.01×10-6)
rs4351242 0.06 T/C miR-3135b Terminal loop 4.1×10-4 C3 (3.8 ×10-69)
MAF, minor allele frequency; Chr. Chromosome; A1, major allele; A2, minor allele. The AMD-associated tar-
get genes are the genes with most significantly association with AMD using the GWAS data. * This SNP is 
present only in the HapMap GWAS.
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Figure 2. Predicted hairpin structure of four miRNAs hosting the AMD-associated variants and the variant 
effect on the miRNA expression levels. The mature miRNA sequences are shown in red and the positions of 
variants associated with AMD are depicted by arrows.
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Since a miRNA and its target mRNA should be expressed in the same tissue in order for 
the miRNA to regulate the expression of its target, we examined whether the identified 
miRNAs and their highlighted target genes are expressed in the eye and brain tissue. 
Expression of miR-3135b was detected in RPE cells (average Ct-value: 33) and human 
brain samples (in both the white and gray matter) (average Ct-value: 30), whereas ex-
pression of the other three miRNAs was not detectable (Table s6). In addition, gene 
expression data from the Ocular Tissue Database and Human Body Map 2.0 revealed 
that the majority of the AMD-associated target genes of miR-3135b are also expressed 
in the eye and brain tissue (Table s7).
Fifty-four miRNA-binding site variants were associated with AMD
In the second part of our study, we examined the associations of 82,051 3’UTR variants 
located in miRNA-binding sites with AMD (Figure s2). Fifty-four variants (in the 3’UTR of 
31 genes) passed the significance threshold of p-value < 6.1×10-7 (0.05 / 82,051). These 
variants are predicted to change the regulatory interaction between their host genes 
and miRNAs by disrupting, creating or modifying a number of miRNA-binding sites that 
are listed in Table s8. Out of the 54 identified variants, 53 are located in the loci that 
have previously been reported to be associated with AMD in the GWAS of the AMDGene 
Consortium [4, 5]. We further suggest CDKN2B at 9p21 locus as a new susceptibility gene 
for AMD. The lead variant in this locus, rs3217992 within the CDKN2B 3’UTR, is predicted 
to disrupt the binding site of miR-138-2-3p. Our LD evaluation for the 54 identified vari-
ants showed that some of them had proxy variants in strong LD (R2 > 0.8) in the coding 
regions of related genes (Table s9). We performed various functional annotations and in 
silico predictions for the 54 binding site variants to prioritize those that are more likely to 
alter AMD risk through affecting miRNA-target interactions (Table s2). Through cis-eQTL 
analysis, we identified that 18 of the variants are correlated with the expression levels 
of their host gene in whole blood and/or other tissues (Table s9). Gene expression data 
from the Ocular Tissue Database showed that 29 out of 31 host genes are expressed in 
the eye (Table s10). Further, we found evidence for expression of several miRNAs in 
our collection in the eye-related tissues using the miRNA expression databases (Tables 
s11). We integrated the results of our analyses for these variants and prioritized them 
based on their potential functionality score (Table s11). Table 2 shows the top ten vari-
ants with the highest credibility for functionality to affect miRNA-binding sites. Regional 
plots showing the association of these top ten miRNA-binding site variants with AMD 
are displayed in Figure s3.
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The functional impact of miRNA-binding site variants on the miRNA-target 
interactions
Three of the prioritized binding site variants, including rs6857:C>T (PVRL2:miR-320e), 
rs3217992:C>T (CDKN2B:miR-138-3p) and rs334348:A>G (TGFBR1:miR-628-5p), have 
been confirmed previously to affect miRNA-mediated regulation of their genes in vitro 
[14, 31]. We further selected two of the variants (rs4151672:C>T and rs760070:A>G) 
that were expected to affect the miRNA-binding sites through two converse scenarios 
(disruption vs. creation). Rs4151672 in the CFB 3’UTR was expected to decrease the 
interaction between miR-210-5p and CFB. The regulatory connection between miR-
210-5p and CFB was first substantiated by assessing the endogenous protein levels of 
CFB in two different cell lines (HEK293 and A549) using Western blot analysis (Figure 3). 
Luciferase reporter assays further verified that the relative luciferase activity of the CFB 
3’UTR construct containing the rs4151672 major allele C is decreased in the presence 
of miR-210-5p, indicating that CFB is a direct target of miR-210-5p (Figure 3 and Figure 
s4). Next, we showed that the miR-210-5p-mediated repression of the CFB reporter is 
reduced in the presence of minor allele T (p-value < 0.05) (Figure 3). Together, our results 
suggest that rs4151672 diminishes miR-210-5p-mediated regulation of CFB, which may 
consequently result in increased CFB expression in AMD patients.
Rs760070 in the 3’UTR of NELFE (also known as RDBP) was predicted to improve the 
interaction between miR-552-5p and NELFE. Luciferase reporter assays showed that 
miR-552-5p downregulates the expression of the NELFE 3’UTR construct containing 
the major allele G by 45%, although the seed sequence dose not pair perfectly (Figure 
s5). The minor allele A of rs760070 makes a perfect match between the miR-552-p seed 
and the 3’UTR of NELFE. Luciferase reporter assays further showed that the miR-552-5p 
mediated repression of NELFE reporter construct containing the minor allele A is slightly 
(~10%), but non-significantly, increased (Figure s5). This may indicate that the effect of 
rs760070 on the binding of miR-552-5p to NELFE is minor and not detectable with this 
experimental setup. The non-significant difference can also be explained by compensa-
tion of miR-552-5p binding to the NELFE 3’UTR by match sequences outside the miRNA 
seed, so called compensatory 3’ pairing [32].
DIscussIoN
In this study, we performed a genome-wide scan for miRNAs associated with AMD 
using GWAS data. First, we identified three variants in miR-4513, miR-122/miR-3591 
and miR-3135b significantly associated with AMD. We demonstrated that the variants 
reduce expression levels of the mature miRNAs. We then highlighted the target genes of 
these miRNAs that are associated with AMD and may mediate the downstream effects 
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Figure 3. miR-210-5p-mediated regulation of CFB and the effect of rs4151672 on the miRNA-mRNA in-
teraction. A) Downregulation of CFB protein levels by miR-210-5p.Western blot analysis was performed to 
determine the effect of miR-210-5p on endogenous protein levels of CFB in HEK293 and A549 cell lines. 
β-actin was used as a loading control. This experiment shows that miR-210-5p mimic downregulates CFB 
protein levels around 20% in both cell lines. B) Luciferase reporter assays indicating miR-210-5p-mediated 
repression of CFB. HEK293 cells were co-transfected with CFB 3’UTR luciferase reporter vector containing 
the major allele C and (±) miR-210-5p mimic. This experiment shows that the relative luciferase activity of 
the CFB 3’UTR construct is decreased in the presence of miR-210-5p. C) Luciferase reporter activity of the 
CFB 3’UTR construct containing the rs4151672 minor allele T is increased. This experiment suggests that the 
variant diminishes the regulatory interaction between miR-210-5p and CFB, and consequently results in 
increased CFB expression levels. Error bars, standard deviation (SD); * p-value < 0.05 and ** p-value < 0.005 
compared with the control group.
Contribution of microRNAs to ophthalmic diseases 211
of the miRNAs. Second, we found 54 variants in miRNA-binding sites (within the 3’UTR 
of 31 genes) that are associated with AMD. Based on stringent prioritization criteria, we 
highlighted ten variants that are more likely to have a functional impact on the miRNA-
target recognitions. Three of these variants, including rs3217992 (CDKN2B:miR-138-3p), 
rs6857 (PVRL2:miR-320e) and rs334348 (TGFBR1:miR-628), have been previously verified 
to affect miRNA-mediated gene regulation in vitro. Additionally, we selected rs4151672 
within the 3’UTR of CFB and demonstrated that, while miR-210-5p downregulates 
CFB expression, the variant diminishes miR-210-5p-mediated regulation, resulting in 
increased level of CFB. 
Previous studies have suggested two main strategies to study if and which miRNAs are 
involved in the pathogenesis of human diseases: miRNA profiling and genetic approach 
[35]. In the first approach, affected tissue of patients is subjected to miRNA expression 
profiling and compared to expression profiles of the same tissue of healthy individuals 
[36]. In the genetic approach, the starting point is a linkage or an association analysis 
of miRNA-related variants between patients and controls. We and others have proven 
that the genetic approach is efficient and successful for identification of new miRNAs 
for complex diseases [8, 13, 25, 28, 37-39]. The main advantage of the genetic approach 
compared to miRNA profiling is that when a miRNA variant is associated with disease 
risk, it supports the idea that the miRNA has a primary effect in the disease mechanisms 
[35]. Nevertheless, differential expression of miRNAs is not providing evidence for a 
causal role of the miRNAs in relation to the disease. Expression profiling studies are 
subject to confounding bias or reverse causation. For instance, differential expression 
of miRNAs can be a secondary effect of disturbed pathways due to the disease or other 
characteristics that are correlated to the patient group, such as lifestyle.
The genetic approach may overcomes both challenges. Given that genetic variants 
are randomly inherited, it is unlikely that other extrinsic factors are associated with them 
(no confounding bias). In addition, as the genetic information is constant over the life 
course, reverse causation is refuted. Another advantage of the genetic approach is that 
diseases with no accessible affected tissues (e.g. eye tissue of AMD patients) can still be 
studied since genomic DNA is available from other patient tissues such as blood. The 
genetic approach, however, has some limitations that need to be addressed. One limita-
tion is that the occurrence of common variants in miRNAs is relatively low and because 
of that the majority (~80%) of genetic variants in miRNA genes are not available in GWAS 
data. To investigate the association of the rare miRNA variants with human disease, high 
density genotyping methods or whole-genome sequencing is needed.
In this study, we identified significant association between three miRNA variants and 
AMD. The first variant, rs4351242, is located in the terminal loop region of miR-3135b. 
Previous studies have indicated that the structure of the stem loop region of pre-miRNAs 
is critical for miRNA processing by Drosha and Dicer enzymes [40, 41]. Furthermore, poly-
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morphisms in the terminal loop of miRNAs have been shown to block miRNA biogenesis 
[40, 42]. Rs4351242 could significantly decrease expression of mature miR-3135b. The 
location of rs4351242, in the center of the terminal loop of miR-3135b, suggests that 
this variant may affect the binding of RNA-binding proteins that are involved in pre-
miRNA processing and consequently reduces miRNA maturation [43, 44]. Next, in order 
to investigate the downstream effect of miR-3135b in AMD, we performed an in silico 
search for the miRNA putative targets that are associated with AMD and are expressed in 
the eye. Among the identified target genes, C3 is of particular interest because this gene 
is one of the key AMD genes and its interaction with miR-3135b has been confirmed by 
CLIP-Seq data [27]. We showed that miR-3135b is expressed in the RPE cells, a retina cell 
line, and previous studies have also demonstrated C3 mRNA expression in the retinal 
pigment epithelium [45, 46]. Higher levels of C3 contribute to increased risk of AMD [47]. 
Therefore, reduced expression levels of miR-3135b in rs41275792 minor allele carriers 
may result in increasing C3 expression and alter the risk of AMD.
The second variant, rs41292412, is located in a locus in which the forward and reverse 
DNA strands encode two distinct functional miRNAs, respectively miR-122 and miR-
3591. In silico analysis indicated that the mutant allele reduces the stability of the hairpin 
structures of both pre-miR-122 and pre-miR-3591. Our in vitro experiments confirmed 
that rs41292412 significantly decreases the expression levels of both miRNAs. MiR-3591-
5p is only recently discovered by deep sequencing [48] and we are the first to report the 
association between this miRNA and a human disease. For miR-122, the pre-miRNA is a 
precursor of two mature miRNAs, miR-122-3p and miR-122-5p, of which the 5p miRNA 
is the predominant product [31]. Our results showed that rs41292412 decreases the 
miR-122-5p expression level. Most likely, this is due to the localization of this variant 
in the stem region of the pre-miRNA that can interfere with normal biogenesis [35, 49]. 
Among the miR-122-5p putative targets that are associated with AMD, the interaction 
between miR-122-5p and C3 has been confirmed by CLIP-Seq data [27]. However, the 
expression level of miR-122-5p was not detectable in RPE cells. A number of studies 
have reported the abundant expression and activation of miR-122-5p in liver and serum 
[50-52]. C3 is also predominantly synthesized in the liver and is expressed in serum [46, 
53]. Collectively, reduced expression levels of miR-122-5p in carriers of the rs41292412 
minor allele may affect miR-122-5p-mediated repression of C3 in liver or serum. Future 
studies are needed to investigate the mechanisms at stake in relation to AMD.
The third variant, rs2168518, is located at the seed sequence of miR-4513. The seed se-
quence is defined as the nucleotide position 2-8 from the 5’-end of a mature miRNA and 
has to be perfectly complementary to the binding site of a target mRNA to be functional 
[12]. It is expected that polymorphisms in miRNA seed sequences strongly influence 
miRNA activity and risk of human disease [37]. Previously, we experimentally showed 
two mechanisms through which rs2168518 affects miR-4513 function [25]. First, the 
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minor allele decreases the expression level of miR-4513 by reducing miRNA processing, 
and second, the minor allele reduces the ability of miR-4513 to interact with its target 
genes. We have already reported miR-4513 to be associated with cardio-metabolic traits 
[25]. These data suggest that miR-4513 plays a pleiotropic role in cardiovascular disease 
and AMD. Pleiotropic roles of miRNAs could be through regulating distinct target genes 
that have cell type specific expression profiles and are involved in different pathways. 
Several miRNAs have been reported to function as pleiotropic modulators of physiologi-
cal and pathological processes, such as miR-206 in cell proliferation, miR-221 in acute 
liver failure and miR-26a in metabolic regulations [54, 55].
Increasing evidence suggests that 3’UTR of genes contain regulatory elements that 
play an important role in gene expression [56]. Many studies have recently focused on 
annotating GWAS hits and functional variants that are located in gene 3’UTRs [28, 57-
59]. In this study, we identified 54 3’UTR variants associated with AMD that are located in 
miRNA-binding sites. Some of these variants had high LD proxies in the protein coding 
regions of their genes, which hampered interpretation of the miRNA-binding site vari-
ants in driving the association with AMD. To gain insight into loci harboring the trait-
associated variants identified by GWAS, several bio-informatics strategies have been 
developed [60-62]. However, these approaches are mainly based on in silico analyses 
and include only a limited number of functional annotations. Here, we performed vari-
ous functional annotations and in silico prediction to prioritize the identified variants 
based on their potential to work through affecting miRNA-target interactions [8, 28]. The 
top three prioritized variants (rs3217992, rs6857 and rs334348) have previously been 
confirmed to affect miRNA-mediated regulation of their genes [14, 33]. Among them, 
rs3217992, the lead variant at the 9p21 locus, disrupts the binding site of miR-138-2-3p 
within the 3’UTR of CDKN2B [28]. CDKN2B has not been reported in the original GWAS 
for AMD, because the lead variant is under the GWAS significance threshold [5]. Poly-
morphisms in this gene have been shown previously to be associated with open-angle 
glaucoma, an eye disease that results in damage to the optic nerve and vision loss [63]. 
Here, we suggest CDKN2B as a susceptibility gene for AMD that need to be replicated in 
future association studies. Further, our results may indicate dysregulation of CDKN2B by 
the miR-132-3p binding site SNP as a functional explanation underlying the association 
with AMD.
Further, we demonstrated that rs4151672 in the 3’UTR of CFB decreases miR-210-5p-
mediated repression, resulting in increased expression level of CFB. Notably, rs4151672 
is in strong LD with rs4151667, a frequently reported AMD-associated missense variant 
in CFB. Smailhodzic et al have shown that the rs4151667 minor allele carriers have re-
duced levels of CFB in serum samples of both AMD cases and controls [64], which seems 
to be in contrast to our results. In the study of Smailhodzic, however, CFB serum levels 
are analyzed representing the net result of all functional variants that are in LD with the 
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missense variant. In our study, we investigated the effect of the 3’UTR rs4151672 allele 
without interference of nearby or distant alleles. In addition, a recent study has shown 
increased CFB protein levels in RPE cells of AMD compared to age-matched normal 
subjects [65]. Further research is needed to unravel how these two alleles work together 
in opposite directions to balance the CFB expression level [66].
CFB is a critical regulator of the alternative complement pathway [67] and comple-
ment has a central role in AMD. We showed that miR-210-5p downregulates CFB protein 
levels. Both miR-210-5p and CFB are expressed in ocular tissues [68, 69]. These data sug-
gest a protective role of miR-210-5p in AMD that may be mediated through regulating 
CFB expression. Previous studies have also verified the role of miR-210 in angiogenesis 
and hypoxia, which are two main mechanisms in the pathogenesis of AMD [70, 71]. 
Thus, miR-210 could be a promising therapeutic target for AMD that warrant further in 
vitro and in vivo investigations. A number of complement-targeted therapeutics (e.g. 
antibodies against complement factors) are currently tested in clinical trials to prevent 
and treat AMD development [72]. The easy accessibility of the eye by injection makes 
the eye a suitable organ for miRNA therapeutics. Local delivery of miRNA inhibitors and 
mimics for treating vascular disorders of the retina has been recently suggested as a 
potentially clinical approach [16].
This study has strengths and limitations that need be considered in interpreting of the 
reported results. The main strength of the study is leveraging genetic data from thus far 
the largest GWAS of AMD which provided us a proper statistical power to detect a num-
ber of miRNA-related variants associated with AMD. Moreover, we used a wide range 
of in silico information to guide our study towards the genetic variants that are likely 
to be functional in the corresponding loci. Unfortunately, we were not able to perform 
the functional experiments in a relevant cell line for AMD such as RPE cells, because of 
slow growth rate and low transfection efficiency of RPE cells in culture. However, to gain 
insights into the functionality of the identified variants and miRNAs, we performed our 
experiments using available human cell lines (HEK293 and A549) that are commonly 
used in these types of studies.
Collectively, this is the first systematic investigation in which miRNAs contributing to 
AMD are identified using genetic evidence in a population level. Our results showed 
that aberrant miRNA activities due to genetic variants in miRNA genes as well as miRNA-
binding sites within gene 3’UTRs may contribute to an alteration of the AMD risk. Future 
studies are warranted to dissect the mechanisms of how the identified miRNAs can 
contribute to the pathogenesis of AMD and their therapeutic potentials. In particular, 
miR-3135b and miR-210-5p are of interest since they have the potential to regulate C3 
and CFB, two genes which play a central role in the alternative complement pathway 
and contribute to AMD.
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supp. Table s2. List of criteria for prioritization of miRNA-binding site variants
criterion Description
SNP functional annotation Minor allele frequency, Variant position, Predicted function
Strength of the association The largest GWAS meta-analysis on the studied trait
Haplotype evaluation Number of proxies, Non-synonymous proxies, Missense variant
Host gene expression Expression of the gene in tissue relevant with the trait
Host gene significance The importance of the gene in pathways related to the trait
miRNA conservation Conservation of the regulatory miRNA in different species
miRNA expression Expression of the regulatory miRNA in tissues relevant with the trait
Binding site conservation Conservation of the miRNA binding site in different species
expression-Quantitative Trait Loci Correlation of 3’UTR variant with its host gene expression (cis-eQTL)
miRNA-target interaction Evidence supporting the interaction between miRNA and target gene
Context score change Predicted effect of binding site variant on the miRNA-target interaction
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supplemental Table s5. Association of putative  and validated target genes of four identified miRNAs 
with AMD
miRNA ID Putative 
targets
(# sNPs)
Associated 
putative 
targets
Top sNP gwAs
p-value
validated 
targets
(# sNPs)
Associated 
targets
miR-3135b 2,325 ARMS2 rs10490924 1.86E-734 245 C3
  (220,120) CFH rs1061147 3.98E-590 (27,880)  
    C3 rs2230199 3.77E-69    
    PVRL2 rs6857 2.42E-33    
    TOMM40 rs2075650 4.73E-26    
    TIMP3 rs5754189 2.15E-14    
    CASP6 rs1800627 4.76E-11    
    C6orf15 rs2233956 4.83E-11    
    HERPUD1 rs9989419 3.30E-10    
    TGFBR1 rs1626340 3.82E-10    
    PILRA rs7783550 5.62E-09    
miR-122-5p 1,563 ZBTB41 rs12724106 1.62E-111 438 C3
  (180,300) CRB1 rs10754220 1.27E-99 (57,640) HLA-DQA1
    C3 rs2230199 3.77E-69    
    SLC44A4 rs6907185 1.24E-43    
    HLA-DQA1 rs9272723 1.11E-13    
    CASP6 rs1800627 4.76E-11    
    RORB rs10781180 2.60E-09    
    CLIC1 rs3131383 2.45E-08    
    SARM1 rs2027993 3.31E-08    
miR-3591-5p 1,174 ZBTB41 rs12724106 1.62E-111 81 SERPINH1
  (205,400) TIMP3 rs5754227 1.07E-24 (13,157)  
    HERPUD1 rs9989419 3.30E-10    
    TBC1D23 rs2289509 8.19E-09    
    TNFAIP1 rs2073867 2.80E-08    
    FAM124B rs2098533 2.21E-07    
miR-4513 861 TIMP3 rs5754227 1.07E-24 58 FAM126B
  (134,490) COL8A1 rs1610258 6.78E-09 (10,265)  
    TNFRSF10A rs11777697 8.76E-09    
    RLBP1 rs3825991 1.90E-07    
    CDKN2A rs3218020 3.70E-07    
Shown are target genes of the four identified miRNAs that are associated with AMD. The Bonferroni cor-
rection (based on the number of SNPs in target genes of each miRNA) was used to set the significance 
levels. The SNPs shown in the table are the top SNP in the miRNA target genes associated with AMD using 
the AMD GWAS (Fritsche et al. 2016). TargetScan v7.0 (Total context++ score > 0.1) was used to extract the 
predicted target genes of each miRNA and miRTarBase v6.0 was used to extract the validated miRNA-target 
interactions based on the CLIP-seq data.
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supplemental Table s11. Prioritization of the 54 miRNA-binding site variants associated with AMD based 
on different criteria
sNP ID gwAs
Associ.
eQTl Proxy 
sNPs
(non-syn)
gene ID gene 
exp
& sign
conserved miRNA-bs
disruption / creation
miRNAs 
exp.
score
rs6857 ✓✓ ✓✓ 0 PVRL2 ✓✓ miR-645/ miR-320e ✓✓ 10
rs3217992 ✓✓ ✓✓ 5 (0) CDKN2B ✓✓ miR-138-3p/ miR-374c ✓✓ 9
rs10119 ✓✓ ✓ 0 TOMM40 ✓✓ -/ miR-516b-5p ✓ 9
rs73203613 ✓✓ - 2 (0) BRAP ✓✓ miR-582-5p/- ✓✓ 8
rs4151672 ✓✓ ✓ 20 (3) CFB ✓✓ miR-210-5p/ miR-188 ✓✓ 8
rs7674356 ✓✓ ✓✓ 20 (0) CASP6 ✓✓ miR-548at-5p/ miR-628 ✓✓ 8
rs3087680 ✓✓ ✓✓ 1 (0) CNN2 ✓ miR-378a-5p/ miR-200b - 8
rs201075702 ✓✓ - 0 DENND1B ✓ -/ miR-153-3p ✓✓ 8
rs705866 ✓✓ ✓✓ 60 (0) PILRB ✓✓ miR-374-5p/- ✓✓ 8
rs760070 ✓✓ ✓✓ 15 (2) RDBP ✓✓ miR-548an/ miR-552-5p ✓✓ 8
rs334348 ✓✓ - 16 (0) TGFBR1 ✓✓ miR-628-5p/ miR-32-3p ✓ 8
rs12724106 ✓✓ - 0 ZBTB41 ✓ miR-551b-5p/ - ✓ 8
rs1045216 ✓ ✓✓ 20 (0) PLEKHA1 ✓✓ -/miR-604, miR-647 ✓✓ 8
rs1055890 ✓✓ ✓✓ 1 (0) HLA-B ✓✓ -/ miR-6804-5p - 7
rs2239907 ✓ ✓✓ 20 (0) SARM1 ✓ miR-1285-5p - 7
rs7405453 ✓ ✓✓ 20 (0) TSPAN10 ✓ miR665/ - - 7
rs45529339 ✓ - 6 (0) ATP6V1G2 ✓✓ miR-520d-5p/ miR-340 ✓✓ 6
rs12140421 ✓ - 1 (0) CFHR3 ✓✓ miR-510/ - ✓✓ 6
rs1073 ✓ ✓ 60 (0) MEPCE ✓ - / miR-340-3p,-942-5p ✓ 6
rs17103541 - ✓✓ 30 (0) PLEKHA1 ✓✓ miR-371-5p/ - ✓ 6
rs522162 ✓ ✓✓ 15 (3) RDBP ✓✓ - - 5
rs1128161 ✓ - 20 (0) SLC46A1 ✓✓ miR-567/ miR-148,-152 ✓✓ 6
rs868 ✓ - 100 (0) TGFBR1 ✓✓ miR-192/ - ✓✓ 5
rs4639796 ✓ - 20 (2) ZBTB41 ✓ miR-101/ miR-875 ✓✓ 5
rs12028827 ✓ - 20 (2) ZBTB41 ✓ - / miR-452-3p ✓✓ 5
rs2672602 - ✓✓ 9 (1) ARMS2 - -/ miR-214 ✓✓ 4
rs390837 - - 100 (0) CFHR3 ✓✓ miR-182-5p,miR-96/- ✓✓ 4
rs9923834 ✓ - 50 (0) CHST6 ✓ -/ miR-29b ✓✓ 4
rs142641895 ✓ - 0 CUX2 - miR-660-5p/ - - 4
rs150697472 - - 0 CYP21A2 ✓ -/ miR-455-3p ✓✓ 4
rs1057151 ✓ - 5 (0) HLA-B ✓✓ miR-199/ miR-214 ✓✓ 4
rs11284139 - ✓✓ 100 (0) PILRB ✓ -/ miR-587 - 4
rs143086805 - - 30 (0) PLEKHA1 ✓✓ - - 4
rs1128162 ✓ - 20 (0) SLC46A1 ✓✓ -/ miR-548an - 4
rs2239908 ✓ - 20 (0) SLC46A1 ✓ -/ miR-20a-3p ✓✓ 4
rs2239911 ✓ - 20 (0) SLC46A1 ✓ miR-92a-5p/ miR609 ✓✓ 4
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supplemental Table s11. (continued)
sNP ID gwAs
Associ.
eQTl Proxy 
sNPs
(non-syn)
gene ID gene 
exp
& sign
conserved miRNA-bs
disruption / creation
miRNAs 
exp.
score
rs8079943 ✓ - 20 (0) SLC46A1 ✓ miR-296-5p/ miR-361 ✓✓ 4
rs334349 ✓ - 20 (0) TGFBR1 ✓✓ - - 4
rs1590 ✓ - 20 (0) TGFBR1 ✓✓ - - 4
rs114550651 - - 10 (0) ZBTB41 ✓ miR-526/ miR-516 ✓✓ 4
rs2672603 - ✓✓ 9 (1) ARMS2 - miR-155-5p/miR-331 ✓✓ 3
rs12677 - - 100 (5) ASPM ✓ - / miR-602 ✓ 3
rs115247800 - - 4 (0) BAG6 ✓✓ - - 3
rs402372 - - 100 (0) CFHR3 ✓✓ - - 3
rs7383 ✓ - 20 (0) DMBT1 ✓ - - 3
rs1057387 ✓ - 5 (0) HLA-B ✓✓ - - 3
rs41265225 - - 0 ASPM ✓ -/ miR-548a-3p - 2
rs390679 - - 50 (0) CFHR1 ✓✓ - - 2
rs10922153 ✓ - 5 (0) CFHR5 - - - 2
rs71131768 - - 1 (0) DENND1B ✓ - - 2
rs71750332 - - 0 EGFL8 ✓ -/ miR127-5p - 2
rs41267086 - - 0 EHMT1 ✓ - - 1
rs1042891 - - 100 (1) CASP6 ✓ - - 1
rs3182325 - - 100 (0) CASP6 ✓ - - 1
Prioritization of miRNA-binding site SNPs associated with AMD based on the below criteria. A functional 
score (between 1 and 10) was calculated for the SNPs by combining the results of related criteria. 1. The 
strength of association in the GWAS results (✓✓: Lead SNP, ✓: One of the top 10% SNPs, -: Only passed 
the threshold). 2. eQTL (✓✓: Correlation between SNP and expression of the host gene, ✓: Correlation of 
SNPs with expression of nearby genes, -: No correlation). 3. Expression and importance of gene in the eye 
(✓✓: Abundantly expressed / Known gene, ✓: Expressed at low level/ Just association, -: Not expressed / 
No data). 4. Expression and importance of related miRNA in the eye (✓✓: Abundantly expressed / In vitro 
evidence, ✓: Expressed at low level / In silico data , -: Not expressed/ No data). In this table only conserved 
miRNAs are mentioned.
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supplemental Figure s1. Regional plots showing the association of three miRNA-variants with AMD. The 
p-values of variants are plotted (as ×log10 values) against their physical position on corresponding chro-
mosomes. The p-values for the miRNA variants at the GWAS are represented by a purple diamond (depicted 
by arrow). Estimated recombination rates from the 1000 Genome project (European population) show the 
local LD structure. The variant’s colors indicate LD with the miRNA variants according to a scale from r2= 0 
to r2= 1 based on pairwise r2 values from the 1000 Genome project. The gene annotations from the UCSC 
genome browser are shown below.
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supplemental Figure  s2. Manhattan plot showing genome-wide p-values of the association between 
miRNA-binding site variants and AMD. The plot shows the association between 82,051 3’UTR variants lo-
cated in putative miRNA-binding sites and AMD using data from the recent GWAS of AMD [5]. The dashed 
line indicates the significance threshold of 6.1×10-7. Genes hosting the binding site variants significantly 
associated with AMD are highlighted.
Contribution of microRNAs to ophthalmic diseases 221
   miR-552-5p         5’ GTTTAACCTTTTGCCTGTTGG 3’ 
                         |܄||||||     ||     | 
    NELFE 3’UTR   3’ ATTTCCGAATTGGGGTTAGGGTTCACGACTT 5’ 
   miR-552-5p         5’ GTTTAACCTTTTGCCTGTTGG 3’ 
                         ||||||||     ||     | 
   NELFE 3’UTR   3’ ATTTCCAAATTGGGGTTAGGGTTCACGACTT 5’ 
 
 
NELFE (G) 
No miR 
NELFE (G) 
miR-552-5p 
NELFE (A)  
miR-552-5p 
Lu
cif
er
as
e 
re
po
rt
er
 a
ct
iv
ity
 (%
) 
NS 
* * 
supplemental Figure s5. miR-552-5p-mediated regulation of NELFE and the effect of rs760070 on the 
miRNA-target interaction. Luciferase reporter assays indicating miR-552-5p-mediated repression of NELFE. 
HEK293 cells were co-transfected with NELFE 3’UTR luciferase reporter vector containing the major allele G 
and (±) miR-552-5p mimic (15 nM). This experiment shows that the relative luciferase activity of the NELFE 
3’UTR construct is significantly decreased in the presence of miR-552-5p. This experiment further showed 
that Luciferase reporter activity of the NELFE 3’UTR construct containing the rs760070 minor allele A is 
slightly (~10%), but non-significantly, reduced. * p-value < 0.05 compared with the negative control (no 
miR) (Students’ t-test). NS, non-significant.
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MiRNAs are important post-transcriptional regulators of gene expression, and deregula-
tion of gene expression is a mechanism in the pathophysiology of human diseases [1]. 
Given the broad clinical and therapeutic potentials of miRNAs, it is of interest to inves-
tigate whether miRNAs may play a role in age-related disorders, such as cardiovascular, 
neurodegenerative and ophthalmic diseases. Previously, the expression and function 
of several miRNAs have been shown to be dysregulated in these complex disorders 
[2-7]. Further, a number of miRNAs have been suggested as potential diagnostic bio-
markers and therapeutic targets for each of the diseases [8-11]. Nevertheless, previous 
studies have mainly focused on differentially expressed miRNAs in a small number of 
samples, which is difficult to be generalized to the general population. In recent years, 
technological advances have made it possible to apply high-throughput omics data (e.g. 
genomics and transcriptomics) in large scale to epidemiological studies. For instance, 
genome-wide association studies (GWAS) have been implemented in past decade and 
led to the discovery of a large number of loci contributing to complex traits and diseases 
[12-15]. The availability of these omics data encourages researchers to develop new 
methods to understand the complexity of the genomic mechanisms behind diseases. 
In addition, the reliance of miRNA biogenesis to sequences to determine the required 
secondary structure for correct processing and target recognition increases the possibil-
ity that variants in miRNAs may have the potential to affect functionality of miRNAs, and 
consequently alter disease risk [16-18]. In this thesis, we aimed to identify miRNAs that 
are involved in age-related disorders using genetic data followed by various in silico and 
in vitro validation studies.
MAIN FINDINgs AND INTeRPReTATIoN
genetic variants of miRNA sequences
MiRNA seed sequence variants. The seed sequence, nucleotides 2-7/8 from the 5’ end of 
a mature miRNA, is the core of a miRNA for target gene recognition and interaction [19]. 
Genetic variation in this critical region of miRNA may alter both the miRNA expression 
level and the miRNA interaction with its target transcripts [20, 21]. Our analyses in this 
thesis showed that the occurrence of genetic variants in miRNA seed sequences is rela-
tively rare and the majority of them (> 80%) are not available in the current GWAS data. 
Since the miRNA seed sequence variant render a strong effect on the miRNA function, 
they are expected to be present at a low frequency in the human genome. This is in line 
with previous in silico analyses of genetic variants in miRNA sequences that show miRNAs 
have lower variant densities than their flanking regions and the human genome [22-25]. 
In addition, it was shown that within the miRNA-encoding sequence, the mature miRNA 
sequence has a lower SNP density than the precursor, and the seed sequence has the 
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lowest SNP density [22]. In this thesis we found two variants in miRNA seed sequences
that were significantly associated with age-related disorders. In chapter 2.1 we showed
that rs2168518 in the miR-4513 seed is associated with a number of cardiometabolic
traits and diseases. We demonstrated two mechanisms through which rs2168518 may
affect miR-4513 function. First, the SNP minor allele significantly reduces the expression
of miR-4513 compared to the major allele, which could be through interfering with the
miRNA processing efficiency [26]. Second, the SNP minor allele decreases the ability of
miR-4513 to interact and repress its target genes expression. We were the first study to
implicate miR-4513 in human diseases. In a second study, Li et al recently investigated
the association of rs2168518 with clinical outcome in coronary heart disease (CHD) [27].
In 1,004 patients with angiographic CHD, they found that miR-4513 was associated with
even free survival and mortality, further demonstrating the importance of miR-4513 in
cardiovascular disease. In chapter 4.1 we also found the association of rs2168518 in
miR-4513 with age-related macular degeneration (AMD). These data suggest a pleiotro-
pic role for miR-4513 in cardiometabolic traits and AMD that could be through regulating
distinct target genes involved in the associated disorders. In chapter 4.2 we identified
another seed sequence variant, rs2273626, located in miR-4707 which was significantly
associated with two glaucoma endophenotypes, vertical cup to disk ratio (VCDR) and
cup area. Our in silico analysis predicted a large alteration in the minimum free energy of
miR-4707, suggesting that the variant may affect miRNA’s secondary structure. However,
we observed no significant difference between mature miR-4707 levels in cells transfect-
ed with vectors containing pre-miR-4707 sequence with the minor allele and the major
allele at the SNP site. We then examined the second possibility that the seed sequence
variant affect miR-4707 function by disrupting the interaction between the miRNA and
its target genes. Our in vitro experiments showed that rs2273626 reduces the ability of
miR-4707 to repress expression of its candidate target gene CARD10, which is a known
glaucoma-associated gene [28, 29]. These findings support the functional importance
of miRNA seed sequence variants in affecting miRNA function, which depends on the
position of a variant in the seed sequence and can affect both miRNA expression and
targeting or only one of these (Figure 1).
Pre-miRNA sequence variants. Genetic variants in pre-miRNA transcripts can affect
miRNA expression levels by influencing the miRNA maturation process. These variants
can lead to change the binding affinity of the miRNA hairpin to biogenesis enzymes
(Drosha and Dicer) or lead to altered strand loading bias into RISC complex accessory
proteins [22]. These changes could result in altered expression of the canonical miRNA,
and consequently lead to deregulation of target genes. In chapters 2-4 we found ten
variants in miRNA-encoding sequences, beyond the seed sequence, that are associated
with different age-related disorders. These variants fall in different parts of the hairpin
precursor of miRNAs, ranging from the stem region to terminal-loop (Figure 1). It has
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been suggested that the effect of variant on the miRNA biogenesis can be predicted by
performing structural analysis of the pre-miRNA sequence [30]. Our in silico analyses
showed two of the variants located in pre-miR-1229 and pre-miR-3135b had no altera-
tions in minimum free energy (MFE) of the thermodynamic ensemble of their pre-miRNAs
structure. This leads to the assumption that these variants would not affect the miRNA
maturation. Our in vitro experiments, however, showed that one of the SNPs significantly
decreases miR-3135b expression and the other SNP significantly increases the expres-
sion of miR-1229. Thus, miRNA variants may affect the mature miRNA expression even in
Figure 1. Predicted hairpin structures of the ten identified miRNAs hosting the variants associated with 
age-related disorders. The mature miRNA sequences are shown in purple and the position of variants are 
depicted by arrows.
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the absence of predicted effects on the miRNA secondary structure. It has been shown
before for miRNA let-7 that rs41275792 (19 nt downstream of the miRNA precursor)
reduces the mature miRNA levels in vivo, although the miRNA secondary structure was
not predicted to be changed [31]. The processing and maturation of miRNAs in vivo are
thereby more complex and subtle than that can be currently predicted.
Target genes mediating downstream effects of the identified miRNAs. In order to
identify the downstream targets that may mediate the effect of identified miRNAs in age-
related disorders, we performed various in silico and in vitro experiments. These analyses
highlighted a number of target genes associated with the studied traits as potential
mediators of the miRNA effects (Figure 2). As an example, in chapter 3.1 we found the
association of miR-1229, a brain expressed miRNA, with Alzheimer’s disease (AD). Per-
forming in silico analyses, we filtered the miR-1229-3p target genes that are associated
with AD and are expressed in the brain. We experimentally showed that miR-1229-3p
controls expression of SORL1, which is the top AD-associated target gene of miR-1229-
3p [32, 33]. We proposed that higher expression levels of miR-1229-3p in rs2291418
minor allele carriers may increase risk of AD, at least in part, through repression of SORL1 
expression. While our work was under revision, miR-1229 was also reported by another
group to be dysregulated across the brain regions of Alzheimer’s patients (in 87 AD and
74 non-demented controls) [34]. These data convincingly implicate miR-1229 to AD. To
gain insight into the mechanisms that the altered expression levels of miR-1229 equate
to change in the biological function and contribute to the pathology of AD further ex-
perimental studies are needed. The next step would be to inhibit (LNA-antagomiR) and
overexpress (mimic) the miRNA in the right cellular context (e.g. iPSC-derived neurons)
or brain tissue and assess the expression levels of the highlighted target genes (at mRNA
and protein levels). Further, generating an animal model in which miR-1229 is deleted
(e.g. knockout mouse) followed by assessment of the expected phenotypic changes and
expression levels of the miRNA target genes in the brain sections of animal models can
provide great insight into the function and biological role of miR-1229 in relation to AD.
Such in vitro and in vivo experiments would help to be able to fully grasp the regula-
tion and the genesis of the identified miRNAs and their highlighted target genes in the
pathogenesis of age-related disorders.
miRNAs as a source for pleiotropic effect. Genetic studies have shown in many in-
stances that a certain gene could be related to more than one phenotype, that so-called
pleiotropic gene [35-37]. GWAS have also identified several genes that are associated
with multiple age-related disorders. For instance, ANKRD26 is a gene associated with
cardiovascular and neurodegenerative diseases [35]. Understanding the extent of plei-
otropy is important as it may reveal information regarding the underlying pathways of
disease. In this thesis we found at least two miRNAs that show pleiotropic effects. In
chapter 2.1 and chapter 4.1 we showed that miR-4513, hosting the seed sequence
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variant rs2168518, is associated with fasting glucose, LDL and total cholesterol, blood
pressure, coronary artery disease and age-related macular degeneration. In chapter 2.2 
we found that miR-196a2, hosting the SNP rs11614913, is associated with waist to hip
ratio (WHR). This miRNA variant has also been reported to contribute to an increased
risk of breast and lung cancer [38, 39]. In addition, a meta-analysis of GWAS on bone
mineral density (BMD) further demonstrated that the minor allele of rs11614913 is asso-
ciated with lumbar spine and femoral neck BMD [40]. In these chapters we highlighted
a number of target genes of miR-4513 and miR-196a2 that are involved in different
pathways belonging to the associated phenotypes and that may be dysregulated as a
consequence of the identified variants. By their nature, miRNAs can bind to multiple
target genes and are potentially involved in different biological pathways. Thus, the
pleiotropic effect of miRNAs can be explained by regulating distinct target mRNAs that
have cell type and even cell developmental stage-specific expression profiles. Several
miRNAs have been reported previously to function as pleiotropic modulators of physi-
ological and pathological processes, such as miR-206 in cell proliferation, miR-221 in
acute liver failure and miR-26a in metabolic regulations [41-43].
Figure 2. Venn diagram shows miRNAs and target genes found to be associated with age-related disor-
ders using the GWAS data (bold) which the effect of their variants on the miRNA-mediated gene regulation 
experimentally validated in this study.
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genetic variants in miRNA-binding sites
The untranslated regions at the 3’ end of mRNA transcripts (3’UTRs) are involved in 
multiple levels of regulation [44, 45]. Although increasing evidence indicate that 3’UTRs 
contain regulatory elements that play important roles in gene expression [7, 8], they are 
not extensively mined for genetic variant discovery so far. The importance of variants 
in these regions for human diseases can be exemplified by the range of phenotypes 
affected by these variants [16, 46, 47]. In this thesis our data support the notion that 
3’UTR variants can both positively and negatively influence gene expression by affecting 
miRNA-mediated gene regulation. In chapter 2.3 we showed that approximately 1% 
of common variants are expected to be located in miRNA-binding sites. Moreover, we 
demonstrated that GWAS findings for cardiometabolic disorders are enriched in miRNA-
binding sites, suggesting the importance of such variants in genetic associations to 
disease. Likewise in chapters 3 and 4 we showed a number of potentially functional 
3’UTR variants associated with neurodegenerative or ophthalmic diseases that are likely 
to influence the interaction between miRNAs and their target genes, resulting in altred 
gene expression. To provide direct evidence that genetic variants in miRNA-binding sites 
and deregulated gene expression in disease are linked, detailed functional validation is 
required. Performing functional experiments for all disease-associated variants in puta-
tive miRNA binding sites is costly and labor-intensive. Furthermore, 3’UTR variants in 
miRNA-binding sites in many cases have high LD proxy variants in the coding regions of 
genes, which are more likely to drive the observed associations. To gain insight into loci 
harboring the associated variants in GWAS, researchers usually employ bioinformatics 
strategies to prioritize the variants based on their potential function [24, 48, 49]. These 
in silico approaches are focused mainly on coding sequence variants and include only 
a limited number of functional annotations to non-coding regions. In chapter 2.3 we 
used a prioritization method to determine miRNA-binding site variants that are more 
likely to be functional in their loci. This approach incorporates diverse biological features 
and functional annotations to conclude whether a miRNA-binding site variant has the 
potential to be functional [16]. In chapter 2.3 we found 192 cardiovascular-associated 
SNPs that are located in miRNA-binding sites. Our prioritization approach enabled us to 
rank these SNPs and select ten of them as the most likely functional variants for experi-
mental studies. Our in vitro experiments then confirmed that 7 of the variants decrease 
miRNA-mediated regulation of the genes and two of them enhance the binding of miR-
NAs to the host genes (Table 1), may indicating our approach is a valid strategy to detect 
the functional 3’UTR variants in miRNA-binding sites. In chapters 3 and 4 we success-
fully used this approach and highlighted a number of likely functional miRNA-binding 
site variants associated with neurodegenerative and ophthalmic diseases. Thesehigh-
lighted miRNA-binding site variants may be of clinical importance and warrant further 
investigations. For instance, in chapter 3.3 we found that rs4151672 associated with 
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age-related macular degeneration (AMD) is located in miR-210-5p binding site within 
the 3’UTR of CFB. We experimentally showed that, while miR-210-5p downregulates CFB 
expression, the rs4151672 minor allele decreases miR-210-5p-mediated repression of 
CFB. CFB is a key factor involved in activation of the complement cascade and higher lev-
els of the gene is associated with increased risk of AMD [50]. Our findings suggest that 
miR-210-5p may contribute to reduced risk of AMD through decreasing CFB expression. 
We demonstrated that miR-210-5p down-regulates CFB protein levels. In addition, both 
miR-210-5p and CFB are expressed in the eye [51, 52]. These data suggest miR-210-5p as 
a promising therapeutic target for AMD that warrant further investigations. Moreover, 
a number of complement-based therapeutics (e.g. antibodies against CFB protein) 
are currently tested in clinical trials to prevent and treat AMD development [53]. The 
easy accessibility of the eye by injection also makes the eye a suitable organ for miRNA 
therapeutics. In this context, local delivery of miRNA inhibitors and mimics for treating 
vascular disorders of the retina has been shown recently as a potentially clinical ap-
proach [54]. Thus, future studies (e.g. testing the role of miR-210-5p in vivo in knockout 
mice) are warranted to dissect the mechanisms that miR-210-5p may contribute to AMD 
risk and its potential in therapeutics.
genetic variants in long non-coding RNAs
lncRNAs are a heterogeneous group of transcripts with over 200 nt in length that ex-
hibit no coding potential [55, 56]. Over the past few years, it has become increasingly 
evident that lncRNAs act as important players in the epigenetic, post-transcriptional, 
Table 1. A summary of 10 experimentally validated variants in miRNA-binding sites associated with age-
related disorders 
variant ID host gene Associated
Phenotypes
miRNA ID score change effect on
miRNA-mRNA
rs3217992 CDKN2B CAD, AMD, VCDR miR-138-2-3p -0.19 Decrease
rs174545 FADS1 Lipids, FG miR-181a-2 -0.13 Decrease
rs1059611 LPL HDL,TG miR-136 -0.17 Decrease
rs13702 LPL HDL,TG miR-410 NA Decrease
rs11735092 HSD17B13 TG miR-375 -0.2 Decrease
rs7956 MKRN2 TC miR-154-5p -0.06 Decrease
rs1046875 FN3KRP HbA1C miR-34a -0.13 Decrease
rs4151672 CFB AMD miR-210-5p -0.27 Decrease
rs6857 PVRL2 Lipids, Alzheimer miR-320e -0.19 Increase
rs907091 IKZF3 HDL miR-326 NA Increase
Score change, change in the minimum free energy for the miRNA-target interaction; NA, Not available; 
CAD, Coronary artery disease; AMD, Age-related macular degeneration; VCDR, Vertical cup to disk ratio; FG, 
Fasting glucose; HDL, High Density Lipoprotein; TG, Triglyceride; TC, Total cholesterol.
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and translational coordination of gene expression [57-59]. Nevertheless, except some 
well-characterized lncRNAs, such as ANRIL and Xist, little is known about the general fea-
tures of most lncRNAs and their possible molecular mechanisms in human diseases [57, 
60-62]. In recent years, GWAS have enabled the discovery of a large number of genetic 
variants at multiple loci associated with age-related disorders. However, the majority 
of the identified variants map to non-coding genomic regions, including lncRNAs, that 
their biological relevance to the diseases remain poorly understood. In chapter 2.4 
we investigated the association of genetic variants in lncRNAs with cardiovascular risk 
factors and disease. We found 55 cardiovascular-associated SNPs, either the lead SNP 
or in strong LD with the lead SNP in their loci, that are located in lncRNAs. Our in silico 
predictions and functional annotations for these SNPs as well as DNA methylation and 
expression analyses for their lncRNAs highlighted the a number of SNPs that fulfill our 
predefined criteria for being functional and act through lncRNAs. It has been shown that 
lncRNAs can post-transcriptionally regulate gene expression by binding to miRNAs and 
preventing specific miRNAs from binding to their target mRNAs. We found that some 
of the highlighted SNPs are associated with the expression levels of (nearby or distant) 
coding genes and have the potential to affect the interaction between lncRNAs and 
miRNAs. Further, we highlighted a number of loci harboring the associated lncRNA SNPs 
for which the role of lncRNA in the association have been overlooked in the current 
literature. For instance, we found several pieces of evidence suggesting LOC157273 to 
be involved in regulating serum lipid-cholesterol, while the GWAS association has been 
annotated to PPP1R3B [12]. In particular, we found that rs4841132 in the second exon 
and cg17371580 in the promoter region of LOC157273 are associated with lipids, the 
lncRNA is exclusively expressed in liver and regulates expression of PPP1R3B, a coding 
gene which is 175 kb away from the lead variant. We posited that LOC157273 may be the 
key regulator that links the identified variant with PPP1R3B activity and with lipid profile.
In chapter 3.3 we investigated the association of lncRNA variants with Alzheimer’s 
disease and revealed a new susceptibility locus at chromosome 17q22 for AD. The 
lead variant in this locus is rs2632516 which overlaps the intron of anti-sense lncRNA 
BZRAP1-AS1 and the promoter region of miR-142 host gene in the opposite strand. Our 
in silico analysis posited that the SNP is more likely to act through affecting the promoter 
activity of miR-142. The impact of variants in promoter regions on miRNA expression 
have been shown before, for example rs57095329 in the miR-146a promoter region as-
sociated with systemic lupus erythematosus [63] and rs4938723 in the miR-34 promoter 
region associated with hepatocellular carcinoma [64]. Given the potential impact of 
variants in miRNA promoter regions on altering transcription rate, it is not surprising 
that such variants can be casual for or associated with human diseases. Moreover, we 
found evidence showing that both miR-142-3p and miR-142-5p are upregulated in hip-
pocampus and blood of AD patients [65]. A large number of putative target genes of 
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miR-142 are also expressed in the brain and they are enriched in neuronal pathways. The 
regulatory interaction between miR-142 and a number of these AD-associated target 
genes, such as SIRTL1, have been validated previously in vitro [66]. Together, these data 
strongly suggest miR-142 as a promising biomarker or even therapeutic target for AD 
that warrant further investigations.
MeThoDologIcAl coNsIDeRATIoNs
Previous studies have suggested two strategies to study if and which miRNAs are in-
volved in human diseases, including miRNA expression profiling and genetic approach. 
In the first approach, affected tissue of patients is subjected to miRNA expression 
profiling and compared to expression profiles of the same tissue of healthy individu-
als. In the genetic approach, the starting point is a linkage or an association analysis 
of miRNA-related variants between patients and controls. In this thesis we used an 
integrative approach to identify miRNAs involved in age-related disorders using genetic 
data followed by various in silico and in vitro validation studies (Figures 3 and 4). In this 
approach, we examine the association of miRNA-related genetic variants with the trait 
of interest using publicly available GWAS data. Subsequently, we perform different in 
silico analyses (e.g. RNA structure analysis, LD evaluation, pathway analysis, and miRNA-
target interaction analysis) and biological studies (e.g. miRNA and gene expression 
profiles, eQTL and methylation analysis) for the associated variants to gain some insight 
into the potential function of the associated miRNAs and their target genes in regard to 
the studied trait. Next, we perform experimental studies (e.g. transient transfection of 
the identified miRNAs and target genes, Luciferase reporter assay, and Western blot) to 
test functional consequences of the identified variants on the miRNA-mediated gene 
regulation. This approach is proven to be efficient and successful by using it for multiple 
traits. In comparison with miRNA expression profiling approach, our strategy has several 
advantages for the identification of miRNAs associated with human diseases. The main 
advantage of this approach compared to miRNA profiling is that when a miRNA variant 
is associated with disease risk, it supports the idea that the miRNA has a primary effect 
in the disease mechanisms [22]. While differential expression of miRNAs is not providing 
evidence for a causal role of the miRNAs in relation to the disease. Expression profiling 
studies are subject to confounding bias or reverse causation. For instance, differential 
expression of miRNAs can be a secondary effect of disturbed pathways due to the dis-
ease or other characteristics that are correlated to the patient group, such as lifestyle. 
The genetic approach may overcomes both challenges. Given that genetic variants are 
randomly inherited, it is unlikely that other extrinsic factors are associated with them 
(no confounding bias). In addition, as the genetic information is constant over the life 
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course, reverse causation is refuted. Another advantage of the genetic approach is that 
diseases with no accessible affected tissues (e.g. eye tissue of AMD patients or brain 
tissue of AD patients) can still be studied since genomic DNA is available from other 
tissues such as blood. Finally, in the our approach we use the summary statistics from 
GWAS which are publicly available. The secondary use of published data is very efficient 
and indicates that our strategy is implemented in the right time when large waves of 
GWAS are completed. In addition, the results are generalizable to general population 
due to using population-level data for the association studies.
Our approach, however, has some limitations that need to be addressed. First, al-
though there are 1,080 mature miRNAs that host genetic variants (n=2,347), the studies 
described in this thesis showed that the occurrence of common variants in miRNAs is 
relatively rare. Therefore, majority of the variants (~80%) are not available in GWAS data 
and cannot be tested using the genetic approach with the data available at this moment. 
Previous in silico analyses of variants in miRNAs have also shown that miRNA genes have 
lower variant densities than their flanking regions or the human genome [22-25]. To 
investigate the association of the rare miRNA variants with human disease, high density 
genotyping methods or whole-genome sequencing is needed. Second, to detect target 
genes of the associated miRNAs that mediate the downstream effects of miRNAs in the 
associated phenotypes, we tested the association of their target genes with the pheno-
type using GWAS data. Although this strategy enabled us to identify those genes that 
are associated with the phenotype, this method may overlook certain target genes of 
the miRNA and might miss some other important targets. The optimal approach would 
be to check the co-expression patterns of the miRNA and its putative targets in relevant 
cells/target tissues by RNA-sequencing and select the deregulated target genes. We can 
further filter the deregulated target genes based on their associations with the pheno-
type or pathway analysis to select the best candidates for additional in vitro or in vivo 
studies. To provide functional evidence for the binding of miRNAs to target mRNAs, and 
to show the effect of variants on the miRNA-target gene interactions, we used the well-
accepted in vitro Luciferase reporter assays. This experiment provides strong support 
for the functionality of miRNA variants, however, the chain of evidence would be more 
complete if we examine the influences of variants on the post-transcriptional regulation 
of miRNA target genes at the protein level as well in the right cellular context, though 
this may not be possible in all cases. In spite of the above-mentioned limitations, we be-
lieve that our approach is valid and helps for both identification of miRNAs for complex 
disorders and annotation of GWAS findings located in miRNAs and miRNA-binding sites 
within gene 3’UTRs.
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Figure 3. Identification and functional analyses of variants in miRNAs associated with complex disorders.
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FuTuRe DIRecTIoNs
In this thesis, we identified a number of miRNAs that may contribute to the induction 
or development of age-related disorders (Figure 2). We focused our analyses on known 
genetic variants in miRNAs. As the miRNAome evolves, it is likely that new miRNAs 
and variants will emerge that their associations with age-related disorders need to be 
investigated in future studies. Moreover, miRNA variants are rare and majority of them 
are absent in the current GWAS. To investigate the association of these rare and some-
times population-specific variants, high density genotyping methods or whole-genome 
sequencing (to increase the coverage of variants) and GWAS in larger sample sizes (to 
increase the power of study) are needed.
Genetic variants within miRNA-processing machinery genes (such as Drosha, DGCR8, 
Dicer1, XPO5, TRBP, and AGO2) have the potential to globally affect processing of small 
RNAs [16, 22]. Recent studies have suggested that such variants, for example, rs3742330 
in Dicer and rs3757 in DGCR8, are linked to complex diseases [16, 67, 68]. Since the 
global repression of miRNA maturation affect cells at several points, most of variants in 
miRNA-processing machinery genes may have deleterious effects on the miRNAome. 
Therefore, they are expected to be very rare and not available in the current GWAS. 
Accordingly, genetic variants can occur in promoter regions of miRNAs and result in 
an altered transcription rate. In silico approaches have been used to predict the effect 
of variants in miRNA gene promoters [69, 70]. Nevertheless, experimental investigation 
of this type of variants can be complicated by the presence of an independent miRNA 
promoter in addition to the host gene promoter (for intronic miRNAs). In chapter 3.3 
we showed one example of such variants which is located in the promoter region of 
miR-142 and is significantly associated with AD. We found several pieces of evidence 
showing that the variant may affect miR-142 expression and consequently alter AD risk. 
In addition, genetic variants in splice site of miRNA host genes (for intronic miRNAs) or 
of the polycistron (for clustered miRNAs) could also result in aberrant miRNA expression 
patterns [71]. Future studies are needed to systematically investigate the association 
of variants in miRNA machinery genes and miRNA regulatory regions with age-related 
disorders and uncover how these variants may influence the function of miRNAs and 
alter the expression of genes involved in age-related disorders..
Another point of attention is the complexity of miRNA-mediated gene regulation [72]. 
miRNAs can regulate multiple target genes in the same or different biological pathways. 
Further, several miRNAs can target the same gene and interact with each other creating 
miRNA-miRNA co-targeting networks. Oversimplification of miRNA functions, based 
on the traditional view of linear signaling pathways, led to ignorance the reality of 
biological complexity. The complexity of the miRNA network is further intensified by 
recognition of the presence of isomiRs (sequences that have variations with respect to 
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the reference miRNA, which may not be found yet) and alternative miRNA processing, 
which bypasses Drosha and instead uses a splicing technique to generate pre-miRNAs 
from short intronic sequences [16]. These sequences are not mapped to the genome 
and are lost in the analysis of RNA-seq data. How genetic variants affect these alternative 
pathways and miRNA forms need to be investigated in future studies.
clINIcAl IMPlIcATIoNs
MiRNA as therapeutic targets. Age-related disorders are the most common health 
threats in developed countries. Despite the success of broadly prescribed drugs for 
these complex disorders, they continue to increase in prevalence worldwide, indicating 
the need for deeper insights into the disease mechanisms and innovative therapeutic 
strategies. In recent years, miRNAs have become a source of great excitement as regula-
tors of complex disorders because they provide new insights into disease mechanisms 
and can be therapeutically targeted. However, much remains to be learned about the 
precise mechanisms of miRNA action within human disease pathways and whether such 
modest regulators can, indeed, be modulated in the setting of disease. In this thesis we 
identified a number of miRNAs associated with age-related disorders that may be of 
clinical importance (Figure 2). The potential therapeutic role of miRNAs has extensively 
studied in cardiovascular disease, such as ongoing phase II clinical trials of miRNA in-
hibitory molecules for miR-208a and miR-33 [73]. The administration of miRNA-targeted 
therapies for long-term risk modification warrants the consideration of several poten-
tial adverse effects [73]. While we are making important steps forward in developing 
inhibitory and mimic miRNA chemistries as a novel therapy, numerous obstacles and 
questions remain on the path towards the development of miRNA-based therapeutics in 
general [73]. For instance, only a few miRNAs have a very cell or tissue-specific expression 
pattern (e.g. miR-122 in liver), but many miRNAs are broadly expressed and may have 
multiple effects in different tissues. One undesirable side effect of chronically admin-
istered miRNA therapeutics could be diminished by modulation of miRNA expression 
in a specific tissue. This could be achieved by targeted delivery of miRNA therapeutics 
or specifically targeting miRNAs that show limited expression in a tissue of interest or 
specific regulation of a biochemical process. These therapeutic strategies may minimize 
adverse off-tissue effects but does not address the potential adverse on-target effects 
of chronic miRNA antagonism in the cell type of interest. Further optimization of the 
inhibitors or mimics for the identified miRNAs, as well as the search for techniques for 
efficient and safe delivery in vivo, will trigger advancement of miRNA therapeutics.
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MiRNA as diagnostic biomarkers. miRNAs have been detected in a range of biological 
fluids such as blood plasma and serum, urine, saliva and cerebrospinal fluid (CSF) [74-76]. 
Many studies have reported that miRNAs are stable in body fluids and their expression 
profiles can change under different physiological and pathological conditions [74, 77]. 
An increasing number of studies have also suggested miRNAs as putative noninvasive 
biomarkers in diagnosis, prognosis and response to treatment [74, 77]. Circulating cell-
free miRNAs can be usually packaged in micro-vesicles, exosomes or apoptotic bodies, as 
well be associated with Argonaut protein family or lipoprotein complexes, and thereby 
are resistant to RNases present in extracellular environments [78, 79]. Although serum 
miRNAs remain stable after being exposed to severe conditions, their low enrichment in 
fluids, such as plasma and CSF, make isolation and quantification of circulating cell-free 
miRNAs difficult [77, 80]. There are different methods available to detect the circulat-
ing cell-free miRNAs [81]. Currently, the most frequently adopted methods have been 
the reverse transcription real-time quantitative PCR (RT-qPCR) and the next generation 
sequencing (NGS). In order to consider the identified miRNAs in this thesis as diagnostic 
biomarkers for age-related disorders, the miRNAs have to be validated, for instance by 
individual RT-qPCR assays, in body fluids of patients from large epidemiologic studies 
with validated clinical data.
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eNglIsh suMMARy
MiRNAs are small non-coding RNA regulators of gene expression that play important 
roles in diverse biological processes and are frequently shown to be implicated in human 
diseases. In this thesis we performed genome-wide scans to identify miRNAs involved 
in age-related disorders (including cardiovascular, neurodegenerative and ophthalmic 
disorders) using genetic evidence followed by various in silico and in vitro validation 
studies.
In chapter 2.1 we examined the association of genetic variants in miRNA seed se-
quences with different cardiovascular risk factors and disease. We found a variant in the 
seed sequence of miR-4513 which is significantly associated with multiple cardiometa-
bolic traits. Performing in silico and experimental studies, we showed that the variant 
affects both miR-4513 expression and function. Our results further indicated that miR-
4513 may play a pleiotropic role in cardiovascular disease. In chapter 2.2 we examined 
the association between genetic variants in miRNA genes, beyond the seed sequence, 
and cardiometabolic disorders. We identified two associated polymorphisms including 
a variant in pre-miR-196a2 associated with waist to hip ratio (WHR) and a variant in 
pre-miR-1908 associated with serum lipid and glucose. The variant in miR-196a2 has 
been shown to reduce the mature miRNA expression. We experimentally showed that 
miR-196a2 regulates the expression of SFMBT1 and HOXC8, which are two known genes 
involved in WHR. In chapter 2.3 we extracted genetic variants in miRNA-binding sites 
within gene 3’UTRs and investigated their associations with cardiovascular risk factors 
and disease. We identified 195 associated miRNA-binding site variants. We prioritized 
the associated variants based on a defined set of criteria for being functional and ap-
pointed 10 of them for validation studies. We experimentally demostrated the functional 
impact of the appointed variants on miRNA-mediated gene regulation. In chapter 2.4 
we investigated the association of variants in lncRNAs with ten cardiovascular risk fac-
tors and disease. We identified 179 cardiovascular-associated variants that are located 
in lncRNAs. Of these, we selected 55 SNPs, either the sentinel SNP or in strong LD with 
the sentinel SNP, for further investigations. We found a number of lncRNA SNPs that are 
likely to be functional variants in their loci. Our results in this chapter further showed a 
number of loci (hosting the identified functional variants) for which the role of lncRNA 
may have been overlooked in the literature.
In chapter 3.1 we sought to identify miRNA-related variants associated Alzheimer’s 
disease (AD). We found a variant in miR-1229 associated with AD that increase the miRNA 
expression. Our results highlighted four miR-1229-3p putative targets that are associ-
ated with AD and might mediate the downstream effect of miR-1229-3p in relation to 
AD. Of these, we experimentally demonstrated miR-1229-3p-mediated regulation of 
SORL1, which is a known gene involved in the pathogenesis of AD. Further, we found 
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multiple 3’UTR variants in miRNA-binding sites that are associated with AD and could 
potentially affect miRNA-mediated gene regulation in AD. In chapter 3.2 we identified 
two variants in miR-4519 and miR-548at significantly associated with Parkinson’s disease 
(PD). Our analyses showed that these variants affect expression levels of the miRNAs. We 
then highlighted target genes that may mediate the function of these miRNAs in PD. 
Of which, we experimentally showed that NSF is a direct target of miR-4519. Moreover, 
we found a number of 3’UTR variants associated with PD that are likely to act through 
affecting miRNA-mediated regulation of their genes involved in PD. In chapter 3.3 
our systematic investigation of ncRNA variants associated with Alzheimer’s disease 
determined a new susceptibility locus (17q22) for AD. The lead variant overlaps BZRAP1-
AS1 and miR-142 host gene. Our subsequent in silico and in vitro studies showed that 
upregulation of miR-142 is implicated in increased risk of AD.
In chapter 4.1 we performed a genome-wide scan for miRNAs contributing to Age-
related macular degeneration (AMD). We identified three miRNA-variants associated 
with AMD that decrease expression levels of four miRNAs (miR-4513, miR-122/miR-3591 
and miR-3135b). We highlighted the target genes of these miRNAs that are associated 
with AMD and have  the potential to mediate the miRNA functions in AMD. Moreover, we 
found a number of variants associated with AMD in miRNA-binding sites. We prioritized 
the associated variants based on their functional potential to affect miRNA-mediated 
regulation of the host genes. Among them, we experimentally showed a CFB 3’UTR vari-
ant in the binding site of miR-210-5p decreases the miRNA-mediated regulation and re-
sults in increased CFB expression. Finally, in chapter 4.2 we examined the association of 
miRNA-related variants with four glaucoma endophenotypes, aiming to identify miRNAs 
that are involved in developing Primary Open-Angle Glaucoma (POAG). We found two 
variants in miR-612 and miR-4707 to be significantly associated with POAG endophe-
notypes. The first variant has been shown to increase the expression level of miR-612. 
We showed that, while miR-4707 down-regulates the expression of CARD10, the second 
variant decreases the miRNA-mRNA interaction, resulting in increased CARD10 expres-
sion. In addition, we found several miRNA-binding site variants associated with POAG 
endophenotypes that have the potential to affect miRNA-mediated regulation of their 
genes involved in associated phenotypes.
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NeDeRlANDse sAMeNvATTINg
MiRNAs zijn kleine niet-coderende RNA regulatoren van genexpressie die een belangrijke 
rol spelen in diverse biologische processen. Gezien de brede klinische en therapeutische 
mogelijkheden van miRNAs is het van belang om te onderzoeken of en welke miRNAs 
een rol spelen in leeftijdsgerelateerde aandoeningen. In dit proefschrift hebben we 
genoom-brede scans uitgevoerd om miRNAs te identificeren die betrokken zijn bij hart 
en vaatziekten, neurodegeneratieve en oogheelkundige aandoeningen met behulp van 
genetische gegevens, gevolgd door verschillende in silico en in vitro validatie studies.
In hoofdstuk 2.1 hebben we een dataset gemaakt van genetische variaties in 
miRNA-coderende sequenties. We hebben gekeken naar de associatie van variaties in 
miRNA seed sequenties met cardiovasculaire risicofactoren en ziekte. We vonden een 
variantie in de seed sequentie van miR-4513 die significant geassocieerd is met meer-
dere cardiometabole eigenschappen. Met het uitvoeren van in silico en experimentele 
analyses toonden we aan dat de variatie zowel de expressie als de functie van miR-4513 
beïnvloed. Onze resultaten suggereren dat miR-4513 een pleiotrope rol speelt in hart 
en vaatziekten. In hoofdstuk 2.2 onderzochten we de associatie tussen genetische 
varianties in miRNA genen, verder dan alleen de seed sequentie, en cardiometabole 
eigenschappen en ziekten. We identificeerden twee geassocieerde polymorfieën , waar-
onder een variant in de pre-miR-196a2 geassocieerd met een taille tot heup ratio (WHR) 
en een andere variate in de pre-miR-1908 geassocieerd de serum lipiden en glucose. 
Het is aangetoond dat de variatie in miR-196a2 de expressie van mature miRNA vermin-
derd. We hebben experimenteel aangetoond dat miR-196a2 de expressie van SFMBT1 
en HOXC8, twee genen betrokken bij WHR, reguleert. In hoofdstuk 2.3 hebben we 
een omvangrijke dataset gemaakt van 3’UTR variaties die zich vermoedelijk bevinden 
in miRNA bindingsplaatsen en hun associatie onderzocht met cardiovasculaire risi-
cofactoren en ziekte. We identificeerden 195 variaties in miRNA-bindingsplaatsen die 
geassocieerd zijn met de onderzochte factoren . We gaven prioriteit aan varianties op 
basis van een gedefinieerde set van criteria voor functionaliteit en benoemde tien van 
hen voor de validatie studies. We hebben de impact van deze 10 geselecteerde variaties 
op de miRNA-gemedieerde regulatie van hun gastheer genen experimenteel bevestigd. 
In hoofdstuk 2.4 onderzochten we de associatie tussen variaties in lncRNAs met tien 
cardiovasculaire risicofactoren en ziekte. We identificeerden 179 cardiovasculair geas-
socieerde variaties in lncRNAs. Hiervan selecteerden we 55 SNPs, ofwel de sentinel SNP 
of in sterke LD met de sentinel SNP, voor verder onderzoek. We toonden aan dat veel van 
deze geselecteerde lncRNA SNPs waarschijnlijk functioneel zijn in hun loci. Onze resulta-
ten in dit hoofdstuk betwisten het conventionele model voor de aanwijzing van de met 
het kenmerk geassocieerde variatie, waarbij niet-coderende variaties omstanders zijn in 
de verwijzing naar LD blokken van coderende variaties.
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In hoofdstuk 3.1 zochten we naar nieuwe miRNA-gerelateerde variaties die geasso-
cieerd zijn met de ziekte van Alzheimer (AD) . We identificeerde een functionele variatie 
in miR-1229 dat de miRNA expressie verhoogd. We selecteerde vier mogelijke doelwit-
ten van miR-1229-3p die geassocieerd zijn met AD en mogelijk een downstream effect 
kunnen hebben voor miR-1229-3p in AD. We hebben de miR-1229-3p gemedieerde 
regulering van SORL1, een bekend gen betrokken bij de pathogenese van AD, experi-
menteel bevestigd. Verder vonden we meerdere variaties in miRNA bindingsplaatsen 
geassocieerd met AD die mogelijk van invloed kunnen zijn op de miRNA-gemedieerde 
regulatie van hun genen geassocieerd met AD. In hoofdstuk 3.2 identificeerden we 
twee variaties in miR-4519 en miR-548at die significant geassocieerd zijn met de ziekte 
van Parkinson (PD). Het uitvoeren van in silico en in vitro analyses toonden aan dat 
de variaties invloed hebben op expressieniveaus van de miRNAs. Vervolgens hebben 
we targetgenen geselecteerd die de functie van de miRNAs kan bemiddelen bij PD. 
We stelde experimenteel vast dat NSF een direct doelwit is van miR-4519. Bovendien 
vonden we een aantal 3’UTR variaties geassocieerd met PD die waarschijnlijk werken via 
miRNA gemedieerde regulatie van hun genen. In hoofdstuk 3.3 in ons systematisch on-
derzoek naar ncRNA variaties geassocieerd met de ziekte van Alzheimer is mogelijk een 
nieuwe locus (17q22) voor AD geïdentificeerd. De lead variant overlapt met BZRAP1-AS1 
en miR-142 host-gen. Onze in silico en in vitro studies toonden vervolgens dat miR-142 
betrokken is bij AD.
In hoofdstuk 4.1 voerde we een genoomwijde scan uit voor miRNAs die bijdragen 
aan leeftijdsgebonden maculadegeneratie (AMD). We identificeerden drie miRNA-
variaties geassocieerd met AMD die invloed hebben op de expressie niveaus van vier 
miRNAs (miR-4513, miR-122 / miR-3591 en miR-3135b). We selecteerde de target genen 
van deze miRNAs die geassocieerd zijn met AMD met de potentie om de miRNA func-
tie te medieren in AMD. Bovendien vonden we een aantal variaties geassocieerd met 
AMD in miRNA bindingsplaatsen. We selecteerde geassocieerde variaties op basis van 
hun functionele mogelijkheden om miRNA-gemedieerde regulering van de gastheer 
genen te beïnvloeden. We toonde experimenteel aan dat een CFB 3’UTR variatie in 
de bindingsplaats van miR-210-5p de miRNA-gemedieerde regulering vermindert en 
resulteert in verhoogde expressie van CFB. Tenslotte wordt in hoofdstuk 4.2 de associ-
atie onderzocht van miRNA-gerelateerde variaties met vier glaucoom endofenotypes, 
met als doel miRNAs en genen te identificeren die betrokken zijn bij de ontwikkeling 
van primair open-hoek glaucoom (POAG). We vonden twee variaties in miR-612 en 
miR-4707 die significant geassocieerd zijn met POAG. We selecteerde targetgenen die 
kunnen worden gedereguleerd als gevolg van deze variaties, waaronder CARD10 voor 
miR-4707. We toonden aan dat miR-4707 de expressie van CARD10 down-reguleert. 
Daarnaast hebben we verschillende 3’UTR variaties geassocieerd met POAG in miRNA-
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bindingsplaatsen met de potentie om miRNA-gemedieerde regulering van hun genen 
die geassocieerd zijn met POAG.
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